Articles

Here’s a story we see all the time. You’ve been using finasteride, saw some initial improvement or stabilization, but now your hair regrowth is plateauing, you’re still noticing miniaturization, and wondering whether it’s time to switch to dutasteride. 

On the surface, the logic is simple. Dutasteride suppresses DHT more than finasteride, and in head-to-head studies, it usually improves hair counts and thickness more. But switching doesn’t just change potential results. It changes how long the drug continues to suppress DHT after discontinuation, how quickly you can evaluate whether it’s helping (or causing side effects), and how easily you can adjust or exit the treatment if needed.

Many people think of this switch as changing one variable. In reality, switching from finasteride to dutasteride can involve changing multiple variables at once: oral versus topical delivery, dose equivalence, absorption variability, drug persistence (half-life), transition strategy, and expectations for timelines. Each of these can alter both outcomes and tolerability.

This article breaks down the real-world trade-offs of switching from finasteride to dutasteride, compares the most common transition scenarios (oral-to-oral, topical-to-topical, and cross-route switches), explains what to expect, and offers our perspective on which decisions are evidence-based and which require a little more skepticism.

Interested in Oral Dutasteride?

Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Biology of Finasteride and Dutasteride

DHT is the key androgen driving follicular miniaturization in androgenic alopecia (AGA). An enzyme called 5α‑reductase (5AR) in the hair follicle converts testosterone to DHT. Because DHT is known to drive hair loss progression, many treatments for AGA target 5AR to reduce scalp DHT levels.^[1]Asfour, L., Cranwell, W., & Sinclair, R. (2023). Male androgenetic alopecia. *Endotext [Internet].* Available at: https://www.ncbi.nlm.nih.gov/books/NBK278957/ Dutasteride blocks both Type I and Type II 5AR, leading to more DHT suppression than finasteride, which only targets Type II.

Oral finasteride is most commonly prescribed at 1 mg daily for AGA, while oral dutasteride is typically taken at 0.5 mg daily. Topical formulations were developed later to change the risk profile without affecting the mechanism. Instead of lowering DHT systemically by default, topical finasteride was designed to concentrate drug activity in the scalp while limiting how much reaches the bloodstream. Topical dutasteride represents the newest and least mature category, but evidence is promising. Because dutasteride is more potent than finasteride, even very low topical concentrations (around 0.01-0.05%) can meaningfully suppress scalp DHT.

Switching Scenarios

There are many treatment options for both dutasteride and finasteride, each with different trade-offs. We’ll compare the available clinical evidence across formulations and break down the most common switching scenarios, highlighting four core considerations: expected efficacy, side-effect profile, commitment and washout dynamics, and strength of evidence.

Key Takeaways:

• Oral finasteride to oral dutasteride: the most evidence-backed upgrade.
• Oral finasteride to topical dutasteride: one study suggests improvement, but we’re skeptical about the data.
• Topical finasteride to topical dutasteride: largely guesswork, with no direct comparative trials.
• Topical finasteride to oral dutasteride: no comparative studies, but surrogate evidence suggests a gain in efficacy.
• Oral dutasteride to topical finasteride: no direct studies, but surrogate data suggests a likely loss in efficacy.

These answers can all change when you account not just for drug switches or formulation switches, but also the dose. 

Oral Finasteride to Oral Dutasteride

This is the cleanest and most evidence-supported switch. Four major comparative randomized controlled trials (RCTs) provide direct comparisons between oral finasteride and oral dutasteride at commonly used doses.

Efficacy

Here is a summary of the clinical trials that compare oral finasteride and dutasteride treatment directly: 

Study	Study Design and Population	Treatments
Study #1[3]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading	Randomized, placebo-controlled, double-blinded trial. 415 men with male pattern hair loss aged 21-45 years old; 24 weeks.	5 mg oral finasteride; 0.05, 0.1, 0.5, or 2.5 mg oral dutasteride; placebo.
Study #2[4]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading	Randomized, placebo-controlled, double-blinded trial. 917 men with AGA aged 20-50; 24 weeks.	1 mg  oral finasteride; 0.02, 0.1, or 0.5 mg oral dutasteride; placebo
Study #3[5]Shanshanwal, S. J., & Dhurat, R. S. (2017). Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled … Continue reading	Open-label, randomized study; no placebo control. 90 men with AGA aged 18-40; 24 weeks.	1 mg oral finasteride; 0.5 mg oral dutasteride.
Study #4[6]Choi, G.-S., Sim, W.-Y., Kang, H., Huh, C. H., Lee, Y. W., Shantakumar, S., Ho, Y.-F., et al. (2022). Long-term effectiveness and safety of dutasteride versus finasteride in patients with male … Continue reading	Retrospective chart review. 600 men over 18 with AGA.	1 mg oral finasteride; 0.5 mg oral dutasteride.

Across these studies, dutasteride consistently outperformed finasteride on hair parameters:

• Target-area hair counts: In Study #1 the proportion of participants with at least a 10% increase in hair counts was 41% for finasteride (5 mg), 48% for dutasteride (0.5 mg) and 56% for dutasteride (2.5 mg).^[7]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading In Study #3, dutasteride (0.5 mg) significantly increased total hair count and decreased thin hair count per cm2  compared to finasteride (1 mg).^[8]Shanshanwal, S. J., & Dhurat, R. S. (2017). Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled … Continue reading Notably, Study #2 showed that dutasteride (0.5 mg) significantly increased terminal hair count compared to finasteride (1 mg).^[9]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading
• Hair shaft diameter: Study #2 demonstrated that dutasteride (0.5 mg) was statistically superior to finasteride (1 mg) in increasing hair width.^[10]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading
• Global photographic assessment: Across studies, investigators were more likely to rate dutasteride (0.5 mg) users as “improved” or “markedly improved” compared to those receiving finasteride (1 mg).^[11]Choi, G.-S., Sim, W.-Y., Kang, H., Huh, C. H., Lee, Y. W., Shantakumar, S., Ho, Y.-F., et al. (2022). Long-term effectiveness and safety of dutasteride versus finasteride in patients with male … Continue reading
• DHT suppression: In Study #1, serum DHT levels were significantly lower with dutasteride (0.5 mg and 2.5 mg) than with finasteride (5 mg). Additionally, finasteride (5mg) decreased scalp DHT by 41%, while dutasteride (0.5 mg) decreased it by 51%, and dutasteride (2.5 mg) decreased it by 79%.^[12]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading

Important caveat: Most RCTs lasted only 24 weeks. Finasteride continues to produce gains for up to 48 months in longer studies, so some of dutasteride’s apparent advantage may reflect faster onset rather than an infinite ceiling of benefit. However, longer-term observational data suggest that dutasteride maintains superiority on global classification scales.

Side-Effects

The most frequently discussed side effects of finasteride and dutasteride include:

• Sexual side effects – These include decreased libido, erectile dysfunction, and ejaculation disorders. Across randomized trials, these effects occur in a minority of users (generally in the single-digit percentages), appear most often early in treatment, and frequently resolve spontaneously, even while continuing therapy.^[13]Hirshburg, J. M., Kelsey, P. A., Therrien, C. A., Gavino, A. C., & Reichenberg, J. S. (2016). Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic … Continue reading
• Breast-related effects – Breast tenderness or enlargement has been reported, but rates are low across both drugs and typically comparable between finasteride and dutasteride.
• Other reported effects: Fatigue, mood changes, or nonspecific symptoms are occasionally reported, but these occur inconsistently, lack clear dose–response relationships, and are difficult to separate from background rates and expectation effects.

Across clinical trials, overall side-effect rates were similar for finasteride and dutasteride, averaging approximately 8-9% for both drugs. Notably, a 2019 systematic review and meta-analysis found no significant difference in adverse event rates between the two treatments, including for sexual side effects such as altered libido, erectile dysfunction, and ejaculation disorders.^[14]Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., Cui, Y. (2019). The Efficacy And Safety Of Dutasteride Compared With Finasteride In Treating Men With Androgenetic Alopecia: A Systematic Review And … Continue reading 

The key difference may not be how often side effects occur, but how long drug-induced hormonal changes persist after stopping treatment. Because dutasteride remains biologically active far longer than finasteride, any changes may take longer to unwind after stopping.

Commitment & Washout Dynamics

In this article, when we discuss commitment or washout dynamics, we are referring to how long a drug continues to suppress DHT after it is stopped, not how long hair regrowth or side effects persist. This reflects how quickly the body can clear the medication and return toward baseline hormone activity once therapy is discontinued.

Dutasteride involves a higher level of commitment than finasteride because it remains biologically active for far longer. Oral dutasteride (0.5 mg daily) has a half-life of around 4-5 weeks, meaning drug activity can persist for months after discontinuation, whereas oral finasteride has a half-life of roughly 6-8 hours.

This means that dose changes or discontinuation of dutasteride lead to much slower changes in systemic DHT suppression compared with finasteride. Dutasteride is not a “try it and see how you feel in two weeks” medication. Its pharmacologic effects unwind gradually, requiring a substantially higher level of decision commitment.

Evidence Strength: Strong

Overall, the oral finasteride to oral dutasteride switch is the most evidence-supported pathway in terms of both efficacy and safety. This consistent superiority in hair outcomes is why oral dutasteride is often considered when finasteride results plateau.

If you’re a member and would like to learn more about oral dutasteride, read our ultimate guide here.

Oral Finasteride to Topical Dutasteride

At the end of 2025, the first RCT involving 135 men with AGA comparing oral finasteride (1 mg) to topical dutasteride (0.01-0.05%) over 24 weeks was published.^[15]Panuganti, V.K., Kumar Madala, P., Ramalingayya Grandhi, V., Varma Alluri, C., Mohammad, J., Rao, K.S.S.V.V., Reddy Dundigalla, M., (2025). A Randomized, Double-Blind, Placebo and Active Controlled … Continue reading   

The study suggested that topical dutasteride (0.05%) outperformed oral finasteride, which would represent a major shift in how we think about treatment escalation. 

But, after we took a closer look at the paper, we think the findings should be interpreted with caution due to multiple concerns with their methodology. 

Efficacy

In the study, several hair parameters appeared to improve more in the topical dutasteride (0.05%) group than in those receiving oral finasteride (1 mg). The authors reported an average increase of +75 hairs per cm² with topical dutasteride compared to +41 hairs per cm² with oral finasteride. Additionally, 69% of participants using topical dutasteride were rated as “improved” on global photographic assessment, compared with 21% in the oral finasteride group.

However, we think these results are likely inflated. Here are two of the major problems with this study:

#1 Baseline hair counts defy biology

The study reports baseline densities of 300+ hairs per cm² in balding men. For context, healthy, non-balding scalps have around 100-250 hairs per cm², whereas men with Norwood III-V AGA typically have around 25-100 hairs per cm² in the vertex.

This suggests they likely counted vellus hairs, mis-measured the sampling area, or used unreliable manual counting methods. This could significantly inflate improvements. 

#2 The measurement circle moves

In the published images, the target circles change location, size, and shape, they appear hand-drawn, and they clearly do not track the same exact scalp area over time.

A 1-2 mm shift can change hair counts by 50%+. The study’s reported gains (10-30%) fall well within the error range of sloppy circle placement, meaning the entire efficacy signal could be measurement noise.

Side-Effects

Despite large hair-growth claims, systemic hormone changes were minimal. Serum DHT change for oral finasteride was between -11% to -27%, and -9% to -11% for topical dutasteride (0.05%). Plasma dutasteride levels were mostly near the quantification limit, but some samples spiked to 2,555 pg/mL, and dutasteride remained detectable at day 168 while participants were still receiving treatment. This suggests that average exposure was low, but absorption may be unpredictable in some users.

Commitment & Washout Dynamics

While participants were actively using topical dutasteride, most had very low drug levels in the blood, but a small number showed noticeable absorption. This means that applying dutasteride to the scalp does not completely prevent it from entering the bloodstream, and individual responses can vary.

Because the study did not measure drug levels after treatment was stopped, it does not tell us how long topical dutasteride continues to have effects once discontinued. So although average exposure appears lower than with oral finasteride, the length of time its effects persist after stopping remains uncertain.

Evidence Strength: Moderate (but controversial) 

This is the first RCT that compared oral finasteride directly with topical dutasteride alone, but it had major pitfalls, including implausible baseline hair counts, unreliable target area placement, and results that contradict years of real-world outcomes. These flaws reduce our confidence in this study’s efficacy claims

If you’d like to read more about our interpretation of the 2025 study comparing oral finasteride to topical dutasteride, read our article here.

Topical Finasteride to Topical Dutasteride

Currently, there are no head-to-head studies comparing topical finasteride with topical dutasteride. That means outcomes are highly dependent on formulation choices, and most conclusions in this switch category are informed speculation rather than solid evidence.

Efficacy

Because there are no comparative trials, we cannot say with confidence that topical dutasteride is more effective than topical finasteride. Any perceived improvement would depend on:

• Drug concentration
• Vehicle (alcohol, liposomal, foam, etc.)
• Volume applied per use
• Application frequency
• Individual scalp absorption

In other words, this switch should be viewed as an experiment, not an upgrade supported by clinical data.

Side-Effects

Topical application does not guarantee that finasteride or dutasteride will remain confined to the scalp. Both agents can suppress serum DHT depending on formulation, dose, vehicle, and application frequency. As a result, systemic effects are still possible, particularly when higher concentrations or larger application volumes are used.^[17]Caserini, M., Radicioni, M., Leuratti, C., Annoni, O., & Palmieri, R. (2014). A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen … Continue reading

Commitment & Washout Dynamics

Topical finasteride generally leads to lower overall drug exposure than oral finasteride, with smaller reductions in serum DHT, suggesting a shorter washout window and greater flexibility with dose adjustments.^[19]Piraccini, B. M., Blume-Peytavi, U., Scarci, F., Jansat, J. M., Falqués, M., Otero, R., Tamarit, M. L., et al. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic … Continue reading 

Topical dutasteride still uses a drug with a long half-life and strong binding to 5AR. However, in the trial comparing oral finasteride (1 mg) to topical dutasteride (0.05%), systemic exposure and serum DHT suppression were modest, suggesting that at these doses most of its effect is likely occurring in the scalp rather than through prolonged whole-body exposure.^[20]Panuganti, V.K., Kumar Madala, P., Ramalingayya Grandhi, V., Varma Alluri, C., Mohammad, J., Rao, K.S.S.V.V., Reddy Dundigalla, M., (2025). A Randomized, Double-Blind, Placebo and Active Controlled … Continue reading 

This implies that topical dutasteride (0.05%) is less committing than oral dutasteride (0.5 mg daily), but may still be more committing than low-dose topical finasteride, especially at higher concentrations or with frequent application, because of dutasteride’s pharmacology. That said, this remains an inference rather than a proven conclusion.

Evidence Strength: Weak

Due to the lack of clinical studies comparing topical finasteride with topical dutasteride, the evidence base for making the switch between these two topical therapies is limited. Any decision to make the switch should be treated as a dose-dependent experiment rather than an evidence-backed upgrade. 

Topical Finasteride to Oral Dutasteride

There are no direct comparative studies for this switch. Still, using surrogate data from Study #1-4 comparing oral finasteride to oral dutasteride, we can reasonably expect a gain in efficacy for many users. This transition moves from a variable, dose-dependent topical regimen to a potent and consistently studied systemic DHT-suppression strategy. 

While this switch is likely to improve hair outcomes, it also represents a meaningful change in drug exposure. It involves moving from a formulation that often limits systemic absorption to one that produces sustained, whole-body DHT suppression with a drug that remains biologically active for weeks. As a result, dose adjustments and discontinuation lead to slower changes in hormone suppression, and any unwanted effects may take longer to resolve after stopping.

Oral Dutasteride to Topical Finasteride

There are also no head-to-head studies for changing from oral dutasteride to topical finasteride. But we can infer that switching from oral dutasteride to topical finasteride will have the opposite effect to what was seen in Study #1-4 comparing oral finasteride to oral dutasteride. 

Switching from oral dutasteride to topical finasteride will likely result in a loss of efficacy for many people, as there will be both a reduction in pharmacologic potency and a move from systemic exposure to a less predictable topical delivery system. 

From an exposure standpoint, this switch may generally reduce overall systemic drug levels and shorten the washout window. Topical finasteride typically lowers serum DHT less than oral dutasteride and clears the body more quickly, meaning that changes in dosing or discontinuation tend to result in faster shifts in biological activity.

How To Make the Decision to Switch

Step 1: Are you stable and satisfied using finasteride?

Yes: Don’t fix what isn’t broken. If your hair is stable or slowly improving, the safest move is often staying the course and reassessing with standardized photos every 3-6 months.

No: Go to Step 2.

Step 2: Is the priority more efficacy, or minimizing downside risk?

Efficacy priority: The most evidence-backed switch is oral finasteride to oral dutasteride. This switch is best suited for those with aggressive or rapidly progressing AGA, extensive miniaturization, or those who have clearly plateaued after a consistent finasteride trial.

Risk priority: Consider optimizing finasteride (dose/frequency) or adding adjuncts (minoxidil/microneedling). Finasteride remains the more forgiving option due to its shorter half-life and easier dose adjustment.

Step 3: Do you tolerate oral 5AR inhibitors?

Yes: Oral dutasteride is the cleaner evidence path for improved efficacy.

No: Topical options can work, but treat them as dose-dependent experiments rather than guaranteed upgrades.

If you’d like more information on oral versus topical dutasteride, take a look at our article here. 

Step 4: Set the evaluation window before you switch.

Don’t judge a switch in 6-8 weeks. Commit to 6-12 months and take standardized photographs to track your progress.

Avoid switching (or be extra cautious) if:

• You’re trying to conceive soon.
• You’ve previously experienced severe side effects when using 5AR inhibitors.
• You prefer treatments that leave your system quickly if something goes wrong.

Our Final Thoughts

Both finasteride and dutasteride offer real benefits, but each comes with distinct trade-offs. If you’re considering switching, it’s critical to focus on what the evidence actually supports. Currently, the only switch backed by high-quality comparative data is oral finasteride to oral dutasteride, making it the most evidence-based upgrade.

That said, this path comes with a higher level of commitment. Because dutasteride persists in the body for weeks, drug-induced hormonal changes unwind more slowly, which may delay how quickly unwanted effects fade after stopping. Other switching scenarios currently don’t have robust clinical evidence, so they should be approached with caution and treated as informed experiments rather than proven upgrades.

If you’d like a deeper breakdown of finasteride versus dutasteride, read our ultimate guide here. 

Oral minoxidil has become a widely used off-label option for androgenic alopecia (AGA) in men and women, despite initially being approved only as an antihypertensive medication decades ago.

Oral minoxidil is increasingly offered to address specific unmet needs in AGA treatment: 

• Topical non-responders: Some people don’t see satisfactory results with topical minoxidil, possibly due to inadequate absorption, variations in scalp skin properties, or genetic factors affecting drug metabolism.
• Scalp sensitivity/irritation: Topical minoxidil can cause local side effects such as itching, flaking, or dermatitis due to the vehicle (especially propylene glycol) or the active ingredient itself. Switching to oral minoxidil bypasses these local reactions.
• Simpler routines/adherence: Oral dosing eliminates the need for daily topical application, which can be messy, time-consuming, or interfere with hair styling. For some, this leads to better long-term adherence and quality of life.

Regrowth with oral minoxidil can be variable, however. This variability mainly stems from biological differences between patients. Because minoxidil is a prodrug that requires conversion by the enzyme sulfotransferase (SULT1A1) into its active form, individual variation in enzyme activity strongly influences response.^[1]Ramos, P.M., Goren, A., Sinclair, R., Miot, H.A. (2020). Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern … Continue reading  

Interested in Oral Minoxidil?

Low-dose oral minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Unfortunately, what most people see online are extremely successful oral minoxidil before and after photos (which you’ll see below), which can lead people to believe that they will experience more regrowth than they actually might.

In this article, we will explore what the likely (not just possible) results are and what the clinical trials show.

But first, let’s have a quick refresher on what oral minoxidil is.

What is Oral Minoxidil?

Oral minoxidil is a tablet medication originally developed as a vasodilator for severe hypertension, but now increasingly used off-label at low doses to treat AGA and other hair loss conditions. It enhances scalp flow and prolongs the growth phase (anagen) of hair follicles, primarily by increasing prostaglandin E2 and vascular endothelial growth factor (VEGF). 

Oral minoxidil acts by opening ATP-sensitive potassium channels in vascular smooth muscle, which increases perifollicular blood flow. It also prolongs the anagen phase of the hair cycle. Unlike topical minoxidil, which requires local sulfotransferase enzyme activity in the scalp for conversion to its active form, oral minoxidil is metabolized systemically via hepatic sulfotransferase, potentially bypassing poor scalp enzyme activity in some individuals.^[2]Kaiser, M., Abdin, R., Gaumond, S.I., Issa, N.T., Jiminez, J.J. (2023). Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clinical, Cosmetic and Investigational Dermatology. 16. … Continue reading 

For hair loss, oral minoxidil is prescribed at significantly reduced dosages compared to antihypertensive therapy – typically:

• 0.25 mg – 1.25 mg for women
• 2.5 mg – 5 mg for men
• Adverse effects are much less frequent at these low doses but may include hypertrichosis (excess unwanted body hair), fluid retention, and, rarely, cardiovascular effects.^[3]Bloch, L.D., Carlos, R.M.D. (2024). Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients. Skin Appendage Disorders. 11(1). 14-18. Available at: … Continue reading 

While oral minoxidil is not FDA-approved for hair loss, a number of studies show its efficacy. 

The Evidence

You can see a complete table of oral minoxidil studies here, but we have picked a few to show.

Study One – AGA (Female)

Vahabi-Amlashi et al (2021) conducted a triple-blind, randomized clinical trial in 72 women with female pattern hair loss, comparing oral minoxidil 0.25 mg daily to 2% topical minoxidil twice daily over 36 weeks.^[4]Vahabi-Amlashi, S., Layegh, P., Kiafar, B., Hoseininezhad, M., Abbaspour, M., Khaniki, S.H., Forouzanfar, M., Sabeti, V. (2021). A randomized clinical trial on the therapeutic effects of 0.25 mg oral … Continue reading 

• Measured outcomes included hair shedding, Sinclair scores by three independent evaluators, trichoscopy assessments of hair density and diameter, and safety labs (liver, kidney, electrolytes).
• Both groups showed significant improvement in hair diameter and density:
  • Group 1 (oral): 13% improvement in hair density.
  • Group 2 (topical): 6% improvement in hair density.
• Sinclair and shedding scores decreased significantly in both groups by the end of the study.
• There was no significant difference between groups in any measured endpoint. 
• Oral minoxidil showed slightly better improvement in hair density; topical minoxidil showed slightly better improvement in hair diameter.
• Adverse events:
  • Group 1 (oral): hirsutism (7.7%), gastrointestinal intolerance (7.7%), weight gain (3.8%), hypotension (3.8%), leading to withdrawal.
  • Group 2 (topical): hirsutism (8%).

Study Two – AGA (Male)

Panchaprateep and Lueangarun (2020) conducted an open-label, prospective single-arm study in 30 men with AGA, treated with 5 mg oral minoxidil once daily for 24 weeks.^[5]Panchaprateep, R., Lueangarun, S. (2020). Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic … Continue reading

• Statistically significant increase in total hair count at 24 weeks (+35.1±18.9 hairs/cm2; p=0.003).
• Hair diameter improved by 15.2% from baseline (p<0.001).
• Global photographic assessment: 43% of patients achieved an “excellent improvement” score by study end.
• High rate of hypertrichosis (93.3% at 24 weeks); pedal edema was reported in 3 patients, resolving after 2-3 months in all cases.
• No serious cardiovascular side effects were observed.

Study Three – AGA and TE (Male and Female)

Feaster et al. (2023) performed a multicenter retrospective study in 210 patients (50 men, 160 women) with AGA and/or telogen effluvium (TE), comparing low-dose oral minoxidil (0.625 – 2.5 mg daily) to a control (no minoxidil or other non-minoxidil treatments) over 52 weeks.^[6]Feaster, B., Onamusi, T., Cooley, J.E., McMichael, A.J. (2023). Oral minoxidil use in androgenetic alopecia and telogen effluvium. Archives of Dermatological Research. 315(2). 201-205. Available at: … Continue reading 

• Group 1 (oral minoxidil): 52.4% of patients showed clinical improvement in hair growth; 41.9% had hair loss stabilization; 5.7% experienced worsening.
• These results were significantly better than the control group (p=0.001). 
• The mean duration of oral minoxidil use was 25.1 months (range 12-54); the most common dose was 1.25 mg daily.
• Adverse effects were uncommon (9.5% of patients), generally mild, and included:
  • Hypertrichosis (4.8%)
  • Edema (1.9%)
  • Hair shedding (1%)
  • Lower extremity cramping (1%)
  • Palpitations (1%)
  • Scalp dysesthesia (1%)
• There were no serious side effects or study withdrawals due to adverse events in the analyzed population.

Overall, these studies demonstrate that oral minoxidil is an effective and generally well-tolerated treatment option for both AGA and TE in men and women. Across the studies, clinical improvements were observed, with similar efficacy to topical minoxidil.

However, the results that people show online are usually more dramatic than what is seen in clinical studies. 

What’s Possible ≠ What’s Probable

When reviewing outcomes, such as oral minoxidil before and after photos, it’s essential to distinguish what can happen from what is likely to happen. Take a look at the example we have created below. The scattered data points represent the full spectrum of possible individual results, while the central trendline shows the average, reflecting the most common or expected response.

These anecdotes (arrows on the graphs) often highlight “hyper-responders”. These are individuals who experience notably dramatic hair regrowth. They may have higher SULT1A1 activity, leading to higher levels of minoxidil activation.

These accounts, although genuine, illustrate results that surpass what most people can achieve. Problems can then arise when people fixate on these exceptional outcomes and assume that their experience will be similar. If their own hair growth is slower or less impressive, they might discontinue treatment early, or wrongly conclude that it isn’t working.

Impressive results are more frequently shared than modest improvements as a result of survivorship bias. This bias happens when only the most impressive successes receive attention, while the many cases with typical or less remarkable outcomes are overlooked or not reported.

Survivorship bias can distort our understanding of how hair loss treatments perform. Online narratives often draw attention to the most extreme cases, either astonishing successes or clear failures, while the more typical moderate outcomes that most people experience are rarely seen or discussed.

Now that we have covered the clinical evidence, strategies, and reasonable expectations for oral minoxidil, let’s now look into 10 firsthand accounts of oral minoxidil before and after photos shared by real users on Reddit.

Oral Minoxidil Success Stories

Keep in mind that the experiences below are purely anecdotal in nature and are not subject to any independent verification. They strictly reflect the individual journeys of each poster and should not be construed as reliable clinical evidence or medical advice.

Case 1: Male (29), Oral minoxidil monotherapy (11 months, 5 mg nightly)

This Redditor began oral minoxidil monotherapy at a dose of 2.5 mg before increasing to 5 mg once nightly. He had switched from topical minoxidil after a year of subpar results. He experienced shedding in the early months of therapy, with visible regrowth by month 3, and a major improvement in hair density by 11 months. Overall, the patient was satisfied with thicker scalp coverage, a fuller beard and brows, and did not report any significant side effects.

Case 2: Male (26), finasteride and oral minoxidil (2 years total; 1 mg finasteride and 2.5 mg oral minoxidil daily)

This 26-year-old used a combination of 1 mg finasteride and 2.5 mg oral minoxidil once daily, having switched from topical to oral minoxidil one year into treatment. He reported notable improvement one year into therapy, with visible regrowth by the 4-month mark. He did not report any shedding or other side effects after switching from topical to oral formulations. After two years of treatment, the patient reported marked hair thickening and cosmetic improvement.

Case 3: Female, oral minoxidil monotherapy (2 years; 2.5 mg daily, titrated up from 1.25 mg)

This user reported one her progress with oral minoxidil monotherapy over 2 years. She started at a daily dose of 1.25 mg, before increasing to 2.5 mg. She had tried vitamins, spironolactone, oils, and Nioxin/Nizoral without benefit for one year prior. Shedding started shortly after beginning the protocol and normalized by the fourth month. She reported visible improvement within one year, and by the end of the second year, she had notable improvement in ponytail thickness and part density. She also reported that her hair looked and felt close to pre-loss baseline. The user did not report any significant side effects.

Case 4: Female (24), Oral and topical minoxidil (9 months topical 5% foam; 6 months oral 0.625 – 1.25 mg nightly)

This 24-year-old began minoxidil monotherapy with 5% foam nightly, before adding oral minoxidil 0.625 mg three months later, and titrating to 1.25 mg nightly the following month. She continued both nightly for six months. She did not note any noticeable shedding on the foam, nor after incorporating 0.625 mg orally. She reported steady baby hairs and a reduction in hair loss at ~6-9 months alongside thickening compared to the baseline, and mentioned that her hair felt and looked much closer to its pre-loss condition overall. She also reported faster growth of facial/body hair (hypertrichosis), water retention, and bloating after salt meals, and occasional stronger heartbeat at night, after incorporating oral minoxidil, though this last symptom did resolve.

Case 5: Male, oral minoxidil (6 weeks shown; 5 mg daily) and weekly microneedling

This male Redditor used oral minoxidil 5 mg once daily in addition to microneedling once weekly with a pen device. The poster also noted no side effects from finasteride, implying that they might have used it alongside the other treatments. He reported an initial shedding phase at around week 3 and rapid visible coverage by week 6 into treatment. In commenting on the progress to date, he noted fuller coverage compared to baseline and said his beard was slightly thicker without any apparent increase in body hair. He did not report any side effects.

Case 6: Female, oral minoxidil + spironolactone (1 year; 1.25 mg oral minoxidil daily, 50 mg spironolactone daily)

The poster took oral minoxidil 1.25 mg once daily, in addition to spironolactone 50 mg once daily (started at 100 mg but reduced the dose due to drowsiness). She noted visible improvement after about 5 months of consistent use, with shedding slowing markedly around weeks 7-8. At the one-year mark, she reported noticeably fuller hair at the part and temples, with ongoing gradual thickening, and “good hair days”. She reported increased body and facial hair from oral minoxidil, which she managed by waxing, and did not report any noticeable weight gain or low-blood-pressure symptoms. 

Case 7: Female, oral minoxidil monotherapy (6 months; 1.25 mg daily, titrated from 0.625 mg)

This female Redditor took oral minoxidil 1.25 mg once daily for six months, having started from the initial dose of 0.625 mg. She supplemented with vitamin B12 injections every two weeks for pernicious anemia, daily shampooing, higher protein intake, and therapy/stress management. She reported steady improvement in hair through month 6, despite a brief “dread shed” in the initial month. Unfortunately, the images don’t show the same hair pulled back, so we can’t see exactly how much improvement was gained. She did report increased facial hair, which she has been managing by shaving/dermaplaning.

Case 8: Female, oral minoxidil monotherapy (1 year; 1.25 mg daily)

This user took oral minoxidil 1.25 mg once daily for one year. She also used Nizoral shampoo on the same timeline. Her hair loss was first diagnosed as telogen effluvium that did not resolve, and she now suspects AGA. She reported modest shedding in the first 2 months, then gradual thickening over the year. The photos showed some improvement, but the patient stated that she is not fully back to baseline. Regarding side effects, she noted increased body hair growth and mild dizziness in the first month that resolved.

Case 9: Male, self-made oral minoxidil (3 months; ingested diluted topical solution)

This male Redditor switched from applying topical minoxidil to drinking a diluted solution mixed with water. He reported taking “a few drops” per dose, having discontinued application of the topical preparation to the scalp. At the three-month mark, the Redditor reported clearly greater overall density and said results were still improving. He did not report any side effects, except for some extra body hair. 

We should mention that we do not recommend ingesting topical minoxidil – if oral therapy is pursued, it is advised to use a prescribed oral dose under medical supervision to control dosing and avoid health risks.

Case 10: Female, oral minoxidil monotherapy (12 months; dose not reported)

This user reported taking oral minoxidil at an unspecified dose for about one year. The photos show modest improvements around the parting. The poster did not report any side effects. Notwithstanding the sparse information provided by this Redditor, multiple commenters observed hair thickening and density gains in the before-and-after photos.

Strategies to Optimize Oral Minoxidil Response

To maximize the benefits of oral minoxidil, consistent use and patience are essential as optimal regrowth often takes 6-8 months to fully manifest. Combining oral minoxidil with other treatments like finasteride or dutasteride, platelet-rich plasma (PRP), or low-level laser therapy (LLLT) can improve results for those who do not respond sufficiently to minoxidil alone. Recent studies support the efficacy of combination regimens, particularly oral minoxidil plus finasteride, with one retrospective study finding significant and clinically meaningful improvements.^[7]Johnson, H., Huang, D., Clift, A.K., Bersch-Ferreira, A., Guimaraes, G.A. (2025). Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service … Continue reading 

People using oral minoxidil, especially at 2.5 mg or more and in combination with other treatments, should keep an eye on potential side effects. This can help catch rare but potentially serious side effects like edema or changes in blood pressure. Regular follow-ups can ensure that any adverse effects are detected early and that the regimen can be safely adjusted to maintain a balance between safety and efficacy. This patient-tailored management increases the likelihood of achieving the best possible outcomes while minimizing health risks.

Probable Regrowth Timeline

Based on the available evidence, the expected regrowth timeline for oral minoxidil is around 8 months.

Months 0-3: Possible increased shedding; no visible gains

• Temporary shedding can occur as follicles transition into a new growth cycle.
• This process often resolves within the first 4-8 weeks and is seen as an early sign that the treatment is starting to take effect.

Months 3-6: First positive density changes for many

• Early visible improvements, such as reduced shedding and appearance of fine new hairs, can be expected.
• Thicker, darker regrowth starts to become apparent for most users during this period.

Months 6-8: Maximal visible benefits

• Cosmetic changes peak, with stronger hair, increased density, and the greatest coverage observed. 
• This is the period of maximum regrowth for most individuals. 

Months 8-12+

• Further gains plateau.
• Continued daily use is needed to maintain improvements.
• Some might consider combination treatment at this point to increase growth outcomes.

Safety and Side Effects

While oral minoxidil can avoid local irritation occurring with the topical formulation, some safety concerns do remain.

Oral minoxidil use does carry a risk of cardiovascular issues like pericardial effusion, especially at the high doses used for blood pressure control. At hair loss doses (0.25 – 5 mg), such events are rare and tend to be individual rather than predictable. 

The majority of side effects, such as excess body hair, mild ankle swelling, lightheadedness, or palpitations, are mild and usually resolve with dose adjustments or stopping the medication. 

Large safety studies have shown that serious side effects are exceedingly rare in otherwise healthy individuals taking low-dose oral minoxidil, with only a small percentage discontinuing treatment due to adverse effects. 

A gradual dose escalation is recommended to minimize side effects with oral minoxidil. Recent studies have shown that a 2.5 mg daily dose is as effective as 5 mg for treating male pattern hair loss, but with a better safety profile, and this supports 2.5 mg as a preferred starting dose for men.^[9]Fonseca, L.P.C., Miot, H.A., Chaves, C.R.P., Ramos, P.M. (2025). Oral Minoxidil 2.5 mg vs 5 mg for Male Androgenetic Alopecia: A Double-Blind Randomized Clinical Trial. Journal of the American … Continue reading 

If you want to use a higher dose, sublingual minoxidil may be beneficial for reducing the risk of cardiovascular side effects.^[10]Gupta, A.K., Bamimore, M.A., Williams, G., Talukder, M. (2025). Comparative Efficacy of Minoxidil and 5-Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta-Analysis Study … Continue reading 

Practical Takeaways

• Oral minoxidil is an effective and generally well-tolerated alternative for people who cannot use topical minoxidil or do not respond to it.
• Clinical trial results typically show stabilization or modest regrowth. Hyper-responder cases seen online are possible but not common. 
• Careful dose selection (0.25 – 2.5 mg daily) minimizes side effects while maintaining efficacy.
• Consistent, long-term use is key; optimal results generally take 6-8 months to appear and require ongoing treatment to maintain gains.
• Combining oral minoxidil with other therapies such as finasteride, dutasteride, PRP, or LLLT may improve outcomes for partial responders.

Final Thoughts

Oral minoxidil use is growing, but should be recognized as an off-label option (albeit backed by a solid body of emerging evidence.. Most users can expect stabilization or noticeable yet modest regrowth rather than dramatic transformation. The best outcomes come with realistic expectations, consistent use over several months, and regular medical supervision to ensure safety. By focusing on average, evidence-based results rather than rare hyper-responder anecdotes, patients can make balanced decisions and maintain long-term adherence to their treatment plan.

Oral finasteride remains the most clinically validated medication for androgenic alopecia (AGA). Over 20 years of trials and follow-up data show consistent, predictable outcomes in slowing miniaturization and restoring density, particularly in the vertex and mid-scalp.

Yet, despite this wealth of data, online forums and “miracle” before-and-after photos often distort expectations. These transformations represent the upper end of the response curve, while most users experience more moderate, steady results that unfold over months to years.

This article explores what realistic regrowth looks like with oral finasteride, how to interpret finasteride before and after photos critically, and what to expect when used correctly and consistently. 

Interested in Oral Finasteride?

Oral finasteride & minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

What is Oral Finasteride?

Oral finasteride is a type II 5ɑ-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT), the key androgen responsible for hair follicle miniaturization in AGA. 

Originally approved by the FDA at a dose of 1 mg for male pattern hair loss, oral finasteride has since become widely known as the gold-standard treatment for hair loss. Its primary mechanism is systemic DHT suppression, lowering circulating levels by roughly 60-70% and scalp DHT by up to 65%.^[1]Caserini, M., Radicioni, M., Leuratti, C., Terragni, E., Iorizzo, M., Palmieri, R. (2016). Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men … Continue reading

Mechanism of Action

As mentioned above, finasteride is a competitive inhibitor of the 5ɑ-reductase enzyme, specifically targeting the type II (and to a lesser extent, type III) isoenzymes.^[2]Zito, P.M., Bistas, K.G., Patel, P., Syed, K. (2024). Finasteride. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513329/

Treatment with finasteride leads to a significant decrease in both scalp and serum DHT concentrations. This effect is dose-dependent and has been observed as early as 28 days after starting treatment.^[3]Dallob, A.L., Sadick, N.S., Unger, W., Lipert, S., Geissler, L.A., Gregoire, S.L., Nguyen, H.H., Moore, E.C., Tanaka, W.K. (1994). The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp … Continue reading Lower DHT levels in the scalp prevent androgen-dependent miniaturization of hair follicles, promoting the maintenance and improvement of hair follicle size and number in the anagen (growth) phase.

Unlike topical formulations, oral finasteride exerts a systemic effect. More comprehensive, but also more likely to cause side effects in sensitive individuals.

Adverse Effects

The most commonly reported adverse effects of oral finasteride are sexual in nature, including decreased libido, erectile dysfunction, and reduced ejaculatory volume. These occur in a range of users depending on the study and determination of what a side effect is (<1% to 25%).^[4]Traish, A.M., Hassani, J., Guay, A.T., Zitzmann, M., Hansen, M.L. (2011). Adverse side effects of 5ɑ-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and … Continue reading 

Other potential side effects include psychological and neuropsychiatric effects and post-finasteride syndrome (PFS). PFS refers to persistent sexual, neurological, and physical symptoms that continue after stopping finasteride. However, the existence and prevalence of PFS are debated, with some studies suggesting a possible genetic predisposition.^[5]Gupta, A.K., Talukder, M., Keene, S.A., Bamimore, M.A. (2025). Is the safety of finasteride correlated with its route of administration: topical versus oral? A pharmacovigilance study with data from … Continue reading 

You can read in more depth about the potential side effects in our oral finasteride ultimate guide.

Why Expectation Setting Matters

Finasteride is powerful and predictable, but even the best data can get lost when you see incredible results online. Online before-and-after posts tend to showcase outliers, individuals who happen to respond at the extreme high end of the efficacy curve. 

Meanwhile, clinical averages show that:

• Most men stop or reverse their hair loss progression.
• Around 65-80% experience visible thickening after 12-24 months.
• Only a small subset achieves “complete restoration”.

Unrealistic expectations can lead to disappointment, early discontinuation, or cycling through treatments unnecessarily. Grounding expectations in clinical probabilities rather than forum anecdotes helps users stay consistent long enough to see results. 

What’s Possible ≠ What’s Probable

While oral finasteride can produce impressive regrowth, most users experience gradual thickening and stabilization rather than dramatic restoration. 

Treatment outcomes typically follow a distribution pattern:

• A minority are “hyper responders”, achieving rapid and substantial visible improvement.
• The majority notice moderate, progressive gains, such as fuller density or slowed shedding.
• A smaller subset experience arrest of hair loss but remain unsatisfied with new hair growth.^[6]Dhurat, R., Mathapati, S. (2015). Response to Microneedling Treatment in Men with Androgenetic Alopecia Who Failed to Respond to Conventional Therapy. Indian Journal of Dermatology. 60(3). 260-263. … Continue reading 

Factors influencing response:

• Age and duration of hair loss: Finasteride efficacy is higher in younger patients and those with less advanced disease at treatment initiation.^[7]Camacho, F.M., Garcia-Hernandez, M.J., Fernandez-Crehuet, J.L. (2008). Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under … Continue reading Starting treatment at age 40 or higher is an independent risk factor for insufficient efficacy.^[8]Yoshitake, T., Takeda, A., Ohki, K., Inoue, Y., Yamawaki, T., Otsuka, S., Akimoto, M., Nemoto, M., Shimakura, Y., Sato, A. (2015). Five-year efficacy of finasteride in 801 Japanese men with … Continue reading 

• Consistency: Missing doses or cycling off can interrupt the stabilization of hair loss.

• Adjunct therapies: Combining finasteride with other therapies like topical minoxidil can improve results.^[9]Hu, R., Xu, F., Sheng, Y., Qi, S., Han, Y., Miao, Y., Rui, W., Yang, Q. (2015). Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and … Continue reading 
• Genetics: Variations in the androgen receptor (AR) gene sensitivity affect responsiveness.^[10]Keene, S., Goren A. (2011). Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic … Continue reading 

Strong Evidence = Predictable Results

Unlike many newer (and even potentially stronger acting treatments), oral finasteride benefits from decades of standardized data, making outcomes highly predictable. A good example of this is comparing finasteride to dutasteride. Finasteride is extremely well-studied; therefore, we can usually predict the type of results we will see. Dutasteride, on the other hand, has studies showing it can outperform even the likes of finasteride in terms of hair regrowth. But the number of clinical studies is lacking, meaning that it is more difficult to predict a consistent outcome.

This predictability helps clinicians set clear, realistic expectations and provides users with confidence that consistency will lead to steady results.

Real Case Studies: Oral Finasteride Before and After

The examples below help see what’s possible and do not represent what every user should expect. They are purely anecdotal and not independently verified by us or any qualified third party.

Case Summary #1: Male (23), 3 Months on Oral Finasteride 1 mg (then every other day) + Topical Minoxidil Foam (twice daily)

This 23-year-old male took oral finasteride 1 mg daily for 2 months before titrating down to 1 mg every other day due to side effects. He also applied topical minoxidil foam twice daily, initially to the whole scalp but later exclusively to the hairline. He noted an initial shedding phase and early side effects on finasteride in the first month of treatment. In the second month, he described visible thickening while still on 1 mg daily. By month 3, he reduced finasteride to every other day and continued with minoxidil to maintain the progress. He reported marked improvement in hairline and density over the 3 months. 

The user also described early transient effects, including testicular ache (first week), watery semen, heightened libido, and less intense orgasm, which resolved after dialing the finasteride down to every other day. 

Case Summary #2: Male (25), 1-Year Course of Finasteride (1 mg) + Topical Minoxidil (1–2x Daily) + Monthly Dermarolling

This male Redditor started treatment at age 24 after severe crown thinning since he was about 18. His one-year course consisted of finasteride 1 mg daily (generic), topical liquid minoxidil 1–2/day, and dermarolling roughly monthly (post-shower, before nightly minoxidil). He supplemented with vitamin D and occasional biotin, and he regularly used argan oil after showers to limit flaking.

The patient noted a strong early response, but felt his results peaked roughly halfway into treatment. He stopped minoxidil for 1 month and missed some doses in the months leading up to the post. His photos indicated a significant improvement in density compared to baseline, particularly at the hairline and the top. He noted more coverage at the crown but felt it was still noticeably weaker than desired. The patient reported no sexual side effects or skin issues.

Case Summary #3: Male (24), 6 Months on Oral Finasteride 1 mg Daily + Oral Minoxidil 2.5 mg Daily

This 24-year-old male’s intervention consisted of oral finasteride 1 mg once daily and oral minoxidil 2.5 mg once daily. The user noted the emergence of small baby hairs at the hairline and temples at month 2 of treatment. By months 4-5, he reported noticeable thickening, with longer eyelashes and denser eyebrows. By month 6, the user showed clear improvement, as evidenced by his wet-hair photos and day-to-day density. He reported visible density gains at the hairline with better coverage under bright light, with his crown improved from baseline, though not fully closed. He reported no side effects, apart from brief mild erectile difficulty early on that resolved. 

Case Summary #4: Male (25), 3 Months on Oral Finasteride 1 mg Daily + Oral Minoxidil 2.5 mg Daily (added at month 2) + Ketoconazole Shampoo 3x/week + Microneedling 1.5 mm Weekly 

This 24-year-old male’s intervention was oral finasteride 1 mg daily for 3 months, oral minoxidil 2.5 mg daily (added 2 weeks before the 3-month update), ketoconazole shampoo (Nizoral) about three times weekly, and dermaroller 1.5 mm once weekly over the whole scalp.

The user described gradual thickening over the 3-month finasteride course, with minoxidil introduced at month 2.5. He reported a noticeable improvement in density at the hairline and mid-scalp compared with baseline. He described a possible mild libido reduction on finasteride and thinning of the eyebrows thinned on finasteride, which appeared fuller after starting minoxidil. He reported no other significant effects. 

Case Summary #5: Male (38), 7 Months on Oral Finasteride + Topical Finasteride + Topical Minoxidil + Weekly Microneedling

This 38-year-old male started the current treatment with oral finasteride 1 mg daily and topical minoxidil (strength/frequency not specified). He added topical finasteride (concentration not specified) and weekly microneedling at 0.25 mm in month 5. The patient reported a slight but noticeable improvement vs. baseline at month 5 and, at month 7, likewise described his progress as modest. In the 7 months, he achieved stabilization with modest density improvement, most visible anteriorly, with the crown remaining limited. He reported no side effects from finasteride and minoxidil. 

Case Summary #6: Male (28), 10 Years on Oral Finasteride + 4–5 Months on Oral Minoxidil 

This 28-year-old male reported on his 10-year treatment progress on oral finasteride 1 mg daily, before adding oral minoxidil 2.5 mg twice daily 4-5 months before the progress report. He confirmed no dermarolling or topical agent application. The patient reported that, between the ages of 18 and 27, he was on finasteride monotherapy, achieving significant regrowth and strong maintenance. Towards the end of that period, he reported subtle renewed thinning, prompting him to add oral minoxidil. Within 4 months thereafter, his hair density and thickness nearly doubled. 

He reported good tolerance to finasteride with no noticeable side effects. He added that oral minoxidil caused mild generalized hypertrichosis (slightly darker chest/back hair, fuller beard, higher cheek/temple hairs), but was otherwise tolerated. 

Case Summary #7: Male (28), 2–3 Months on Oral Finasteride 1 mg Monotherapy

This 28-year-old male’s intervention included oral finasteride 1 mg daily, weekly microneedling with dermastamp 1.0–1.5 mm, and supplementation with vitamin D3 + K2, zinc, folate, magnesium glycinate, and ketoconazole 2% shampoo. Additionally, he made lifestyle adjustments, including going to the gym 2x/week and starting a higher-protein diet.

He noted a mild shedding phase in the first month of treatment. By month 2, he described the first visible tiny regrowth after a buzz cut, by which point the shedding had reduced. Overall, the patient described early regrowth at the hairline and thinning zones. He reported no side effects on finasteride 1 mg daily, stating that libido and energy have remained unchanged or improved.

Case Summary #8: Male (unspecified age), 3 Years on Oral Finasteride 1 mg Daily + Topical Minoxidil

This male Redditor’s intervention over 3 years was oral finasteride 1 mg daily and topical minoxidil (strength not specified).

In the first year, he noted steady cosmetic improvement, followed by continued thickening and maintenance of gains over years 2-3. Overall, the user reported substantial density gain, with perceived improvement in the hairline and temples over time. He mentioned no significant side effects and confirmed his sex drive had remained unchanged throughout treatment. He noted that the minoxidil sometimes caused dandruff and that on finasteride, he required greater mental focus to push weight-lifting sets to failure. 

Case Summary #9: Male (early 30s), 3.5 Months on Oral Finasteride 1.25 mg Daily

This male, in his early 30s, opted for a treatment consisting of oral finasteride monotherapy at 1.25 mg daily (5 mg tablets quartered). He described a mild daily shedding phase within the first month of treatment. By month 2.5, he reported his first visible thickening. At the 3.5-month progress report, the user achieved a fuller crown with reduced scalp show-through. He reported no side effects. 

Case Summary #10: Male (25), 5.5 Months on Oral Finasteride 1.25 mg Daily + Oral Minoxidil 5 mg Daily

This 25-year-old South Asian male’s intervention was oral finasteride 1.25 mg daily (5 mg tablets quartered) and oral minoxidil, starting at 2.5 mg daily, titrated to 5 mg after 3 months. He described a substantial shedding phase, particularly in the first 3 weeks of month 3. The following month, he reported progressive thickening and density gains with improved coverage. As of month 5.5, he is still improving and continuing both agents unchanged. Overall, he reported a marked increase in density, with a thicker texture, and the crown and hairline both looked fuller than baseline. He reported no side effects on either dose level for finasteride or oral minoxidil. 

Probable Regrowth Timeline

Based on the available research (which you can take a look at with our research tables here), we have created a probable hair regrowth timeline.

Months 0-3: Adjustment Phase

In the first three months, most users experience minimal visible change. Finasteride actively lowers scalp and serum DHT levels, initiating follicle recovery. Some users notice a temporary increase in shedding as older hairs are shed to make way for new growth, while others observe subtle stabilization of hair loss.

Months 3-6: Reduction in Shedding

By this stage, a clear reduction in hair shedding often becomes noticeable. Although visible thickening remains limited for many, the treatment is beginning to normalize hair cycling. Early responders may report small areas of improved density, particularly in the crown or vertex.

Months 6-12: Early Cosmetic Improvements

Between 6 and 12 months, most responders start to see visible regrowth. Hair density gradually improves, strands appear thicker, and areas of thinning begin to fill in. The crown region typically shows improvement sooner than the frontal hairline, which tends to respond more slowly. Continued adherence is essential during this phase to sustain progress.

Months 12-24: Peak Response Period

During the second year, responders generally achieve their maximum results. Hair density, coverage, and stabilization reach their highest levels, with further visible gains possible in some individuals. Those starting with more advanced thinning usually experience consolidation rather than full growth.

Months 24+: Maintenance and Long-Term Stability

After two years, most users reach a plateau in visible improvement. Continued daily use of finasteride is needed to preserve these gains, as stopping the medication often results in gradual hair loss returning to baseline within 6-12 months. Some people combine treatments at this point to achieve further outcomes.

For most users, oral finasteride provides progressive, steady improvements over time, with long-term commitment being the key to maintaining results.

Setting Realistic Expectations

It’s important to set realistic expectations when starting any treatment. Finasteride primarily stabilizes hair loss during the early months, with noticeable growth typically developing later in the treatment course. True cosmetic improvement usually unfolds gradually over 12 to 24 months rather than weeks, reflecting the natural pace of the hair growth cycle. 

Clinical trials suggest that most men experience visible thickening and halting of progression rather than full restoration, effectively “turning back the clock” by two to five years in terms of density and coverage.^[11]Kaufman, K.D., Olson, E.A., Whiting, D., Savin, R., DeVillez, R., Bergfeld, W., Price, V.H., Van Neste, D., Roberts, J.L., Hordinsky, M., Shapiro, J., Binkowitz, B., Gormley, G.J. (1998). Finasteride … Continue reading,^[12]Price, V.H., Roberts, J.L., Hordinsky, M., Olsen, E.A., Savin, R., Bergfeld, W., Fiedler, V., Lucky, A., Whiting, D.A., Pappas, F., Culbertson, J., Kotey, P., Meehan, A., Waldstreicher, J. (2000). … Continue reading,^[13]Rossi, A., Mari, E., Scarno, M., Garelli, V., Maxia, C., Scali, E., Iorio, A., Carlesimo, M. (2012). Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a … Continue reading 

Consistent photographic tracking using identical lighting and angles can help visualize these incremental gains. Long-term adherence is crucial, as discontinuation typically leads to renewed miniaturization and hair loss within several months of stopping treatment.

Practical Takeaways

• Oral finasteride remains the most effective DHT blocker for male AGA
• Decades of clinical data make results highly predictable and durable
• The safety profile is well-established, with sexual side effects uncommon and often reversible
• Combining treatments can improve outcomes, especially for advanced loss.

Final Thoughts

Oral finasteride remains the most extensively studied and clinically validated treatment for androgenic alopecia, offering predictable outcomes for most users through gradual thickening, stabilization of shedding, and preservation of existing hair rather than dramatic restoration. While newer options like oral minoxidil are gaining popularity, they remain off-label despite growing supportive evidence and should be used under medical supervision. 

The key to achieving and maintaining meaningful results lies in consistency, patience, and realistic expectations, recognizing that hair regrowth is a slow, cumulative process measured over months and years. By grounding expectations in clinical evidence rather than anecdotal extremes, patients can make informed, balanced decisions and stay committed to a long-term plan that maximizes both safety and effectiveness.

Finasteride is a prescription medication originally created to treat benign prostatic hyperplasia (BPH), and now commonly used to treat androgenic alopecia (AGA). It achieves this through targeting 5α‑reductase (5AR), an enzyme that converts testosterone to dihydrotestosterone (DHT), lowering levels of DHT in the scalp. DHT is the key androgen driving follicular miniaturization and is known to drive hair loss. Therefore, the finasteride-induced reduction of DHT results in increased hair growth.^[1]Asfour L, Cranwell W, Sinclair R, (2023), Male Androgenetic Alopecia. In: Feingold KR, Adler RA, Ahmed SF, et al., editors, Endotext [Internet], South Dartmouth (MA): MDText.com, Inc.; Available at: … Continue reading 

Despite the high amount of evidence supporting finasteride use, many users are concerned about starting due to its potential side effects, including a loss of libido and erectile dysfunction.^[2]Diviccaro, S., Melcangi, R.C., Giatti, S. (2019). Post-finasteride syndrome: an emerging clinical problem. Neurobiology of Stress. 12. 100209. Available at: https://doi.org/10.1016/j.ynstr.2019.100209 Many people presume that these side effects, to some extent, are caused by finasteride’s effects on male hormones. In fact, many people presume that these side effects are caused by finasteride lowering testosterone.

The potential for the finasteride mechanism to lower testosterone levels is a common fear; however, the sexual side effects observed in a minority of finasteride users do not occur due to a finasteride-induced reduction in testosterone. Paradoxically, finasteride causes a rise in testosterone, yet occasional sexual side effects are still seen.

In this article, we will discuss whether finasteride lowers testosterone and what the mechanisms are behind sexual side effects in finasteride users.

Interested in Oral Finasteride?

Oral finasteride & minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

How Does Finasteride Work?

AGA is one of the most common hair loss disorders in the world, and is most often characterized as the progressive miniaturization of hair follicles – induced by androgen sensitivity. Activation of the androgen receptor shortens the growth phase of the hair cycle, increases rates of hair shedding, and upon reentry into anagen, affected hairs are often thinner than in the previous cycle. This eventually leads to visible hair loss that is chronic and progressive; without treatment, it worsens over months, years, and decades.^[3]Ho, C.H., Sood, T., Zito, P.M., (2024), Androgenetic Alopecia. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430924/ (Accessed: 07 January 2026)

DHT is the key androgen driving follicular miniaturization. When free testosterone comes into contact with an enzyme called 5AR, that free testosterone is converted into another hormone – DHT – which then binds to hair follicle sites and initiates a cascade that results in hair shedding and hair follicle miniaturization. Both 5AR and DHT have been shown to be elevated in balding areas of the scalp compared to the hair-containing scalp.^[4]Dallob, A.L., Sadick, N.S., Unger, W., Lipert, S., Geissler, L.A., Gregoire, S.L., Nguyen, H.H., Moore, E.C. and Tanaka, W.K. (1994). The Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on … Continue reading

Effect of Finasteride on DHT Suppression

Finasteride suppression of DHT can be fit to a non-linear (logarithmic) dose-response curve, i.e., even very low levels of finasteride (≤0.2 mg/day) can produce near-maximal suppression of DHT in both the serum and the scalp.^[5]Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W.P., Cotterill, P.C., Thiboutot, D.M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S.J., Griffin, E.I., Weiss, D., … Continue reading The majority of its inhibitory action is achieved at low doses, with higher dosing only providing marginal additional effects.

Clinical trials have demonstrated that finasteride treatment decreases levels of DHT in the serum by 71-72% and in the scalp by 64-69%.^[6]Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W.P., Cotterill, P.C., Thiboutot, D.M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S.J., Griffin, E.I., Weiss, D., … Continue reading

Clinical Effectiveness

The clinical effectiveness of finasteride in improving hair growth has been demonstrated in multiple clinical trials. It has been shown to improve hair growth and slow further hair loss across 1-year, 2-year, and 5-year clinical trials, with 65% of finasteride-treated men demonstrating increased hair count at 5 years compared to 0% of the placebo-treated (sugar pill group) men.^[7]Finasteride Male Pattern Hair Loss Study Group. (2002). Long-Term (5-Year) Multinational Experience With Finasteride 1 mg in the Treatment of Men With Androgenetic Alopecia. Eur J Dermatol. 12:38-49. … Continue reading,^[8]Shapiro, J., Kaufman, K.D. (2003). Use of Finasteride in the Treatment of Men With Androgenetic Alopecia (Male Pattern Hair Loss). J Investig Dermatol Symp Proc. 8(1):20-23. Available at: … Continue reading

Does Finasteride Lower Testosterone?

The belief that finasteride lowers testosterone is common. However, there is no evidence supporting this. In fact, research has actually shown that finasteride treatment increases levels of testosterone.

A four-year clinical trial investigating the safety and efficacy of finasteride in patients with BPH demonstrated a ~15% rise in testosterone in the serum compared to the placebo group.^[9]Roehrborn, C., Lee, M., Meehan, A., Waldstreicher, J. (2003). Effects Of Finasteride On Serum Testosterone And Body Mass Index In Men With Benign Prostatic Hyperplasia. Urology. 62(5). 894–899. … Continue reading Additional trials have also reported a moderate rise in testosterone (5-33%; not dose-dependent).^[10]Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W.P., Cotterill, P.C., Thiboutot, D.M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S.J., Griffin, E.I., Weiss, D., … Continue reading,^[11]Uygur, M.C., Arık, A.İ., Altuğ, U., Erol, D., (1998). Effects Of The 5α-Reductase Inhibitor Finasteride On Serum Levels Of Gonadal, Adrenal, And Hypophyseal Hormones And Its Clinical … Continue reading,^[12]Amory, J.K., Wang, C., Swerdloff, R.S., Anawalt, B.D., Matsumoto, A.M., Bremner, W.J., Walker, S.E., Haberer, L.J. and Clark, R.V. (2007). The Effect Of 5α-Reductase Inhibition With Dutasteride And … Continue reading

Although the rise in testosterone was significantly different between finasteride- and placebo-treated individuals, levels of testosterone consistently remained within the normal physiological range. The increase in testosterone was identified in women as well as men, and was found to be more pronounced in men with low baseline testosterone.^[13]Albasher, G., Bin-Jumah, M., Alfarraj, S., Al-Otibi, F., Al-Sultan, N.K., Alarifi, S., Alkahtani, S. and Al-Qahtani, W.S. (2020). Prolonged Use Of Finasteride-Induced Gonadal Sex Steroids … Continue reading,^[14]Roehrborn, C., Lee, M., Meehan, A., Waldstreicher, J. (2003). Effects Of Finasteride On Serum Testosterone And Body Mass Index In Men With Benign Prostatic Hyperplasia. Urology. 62(5). 894–899. … Continue reading However, not all patients tested experienced this rise in testosterone.

The evidence therefore supports a short-term rise in testosterone on finasteride treatment, while remaining within the physiological range. Many of these studies were carried out in relation to BPH, where the finasteride doses are higher (generally 5 mg vs 1 mg), so the impact of finasteride for AGA treatment is likely to be even lower.

Why Does Testosterone Increase When DHT Falls?

The inhibition of the 5AR enzyme results in the blocking of the DHT production pathway, resulting in the testosterone that would otherwise have been converted to DHT remaining as testosterone. No large increases in testosterone are seen, as not only do negative feedback adjustments occur, but free testosterone is also thought to be redistributed within the androgen pathway, where it is converted into estradiol. 

Can the Rise in Testosterone Have Sexual Side Effects?

The moderate rise in testosterone identified in individuals taking finasteride does not result in a rise above the physiological range, making sexual side effects directly as a result of the rise in testosterone unlikely. In general, a moderate rise in testosterone levels improves sexual function. This appears to contradict the well-characterized (though uncommon) sexual side effects of finasteride treatment. Therefore, another mechanism must be at work to induce these sexual side effects.

Finasteride Sexual Side Effects

What are the Sexual Side Effects of Finasteride?

Sexual side effects have been reported in a small minority of users. These include:

• Erectile dysfunction
• Ejaculatory dysfunction
• Loss of libido

While these symptoms often improve or resolve on their own, persistent sexual dysfunction has been reported in a very small number of finasteride users, in a condition known as post-finasteride syndrome.^[15]Hirshburg, J.M., Kelsey, P.A., Therrien, C.A., Gavino, A.C. and Reichenberg, J.S. (2016). Adverse Effects And Safety Of 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. … Continue reading However, reports of this condition are controversial, and conflicting results are seen in different studies. If you are interested in learning more, see our article exploring post-finasteride syndrome.

What is the Prevalence of Sexual Side Effects?

In controlled clinical trials, sexual side effects of taking finasteride are uncommon, but exact estimates vary depending on the dose, study design, and population receiving treatment.

• In a 4-year, randomized, placebo-controlled clinical trial assessing the prevalence of sexual adverse experiences (AEs) on the treatment of BPH with 5 mg of finasteride, 15% of finasteride-treated and 7% of placebo-treated men had sexual AEs within the first year, indicating an increase in AEs in the finasteride group. However, no differences between placebo- and finasteride-treated AEs were seen in years 2-4.^[16]Wessells, H., Roy, J., Bannow, J., Grayhack, J., Matsumoto, A.M., Tenover, L., Herlihy, R., Fitch, W., Labasky, R., Auerbach, S., Parra, R., Rajfer, J., Culbertson, J., Lee, M., Bach, M.A. and … Continue reading
• A meta-analysis (a study where data from multiple independent studies are analyzed) of 15 clinical trials where AGA was treated with 1 mg of finasteride found that only 5.31% of users had adverse sexual effects compared to 3.05% of those taking a placebo.^[17]Lee, S., Lee, Y.B., Choe, S.J. and Lee, W. (2019). Adverse Sexual Effects Of Treatment With Finasteride Or Dutasteride For Male Androgenetic Alopecia: A Systematic Review And Meta-Analysis. Acta … Continue reading
• A different meta-analysis of 17 clinical trials found that men taking finasteride had a 1.29 times higher risk of underactive sexual desire or a 1.47 times higher risk of erectile dysfunction.^[18]Corona, G., Tirabassi, G., Santi, D., Maseroli, E., Gacci, M., Dicuio, M., Sforza, A., Mannucci, E. and Maggi, M. (2017). Sexual Dysfunction In Subjects Treated With Inhibitors Of 5α-Reductase For … Continue reading

Meta-analyses and studies with a high number of participants are the gold standard for assessing the risk of sexual side effects. Smaller studies have put the incidence of sexual side effects higher; however, these results should be interpreted with caution due to the limitations of the clinical trials.

Further caution should be taken due to the “nocebo” phenomenon, where a patient may experience negative symptoms or worse outcomes due to their being informed that the product may cause them harm. 

A small study investigating this phenomenon in patients treated for BPH with 5 mg finasteride found that the group who received counseling on the sexual side effects (i.e., were informed of these side effects) demonstrated a significantly higher proportion of sexual side effects than the group who did not receive counseling (43.6% vs. 15.3%).^[19]Mondaini, N., Gontero, P., Giubilei, G., Lombardi, G., Cai, T., Gavazzi, A. and Bartoletti, R. (2007). Finasteride 5 mg And Sexual Side Effects: How Many Of These Are Related To A Nocebo Phenomenon? … Continue reading

Care should also be taken when interpreting information on natural health websites and online forums, as the perceived prevalence of sexual side effects may seem incredibly high on these. This may occur due to multiple reasons, including:

• Fearmongering due to the desire to sell natural remedies claiming to be sexual side-effect-free (which often isn’t true).
• Users are more likely to post in anger about issues with the product, whereas those content with the product are less likely to post (the “Yelp Effect”).

Why do Sexual Side Effects Occur Despite Higher Testosterone?

As discussed above, increased testosterone (within the physiological range) enhances sexual function. However, despite the slightly raised testosterone seen in men taking finasteride, sexual side effects still occur. Below are three main pathways through which these side effects have been suggested to occur. Please consider that none of these mechanisms have been conclusively proven, and are only suggestions as to how sexual side effects may be occurring.

DHT Depletion

DHT is a potent androgen, binding the androgen receptor with greater strength than testosterone. DHT and testosterone can bind to androgen receptors in the corpora cavernosa (erectile tissue in the penis), causing an upregulation in nitric oxide production and resulting in increased blood flow into the penis and an erection.

It has been suggested that susceptible individuals experiencing decreased levels of DHT on finasteride treatment experience a reduction in nitric oxide production, limiting blood flow into the penis, and, consequently, in erectile dysfunction.^[20]Clapauch, R. (2011). Finasteride and Erectile Dysfunction: Fact or Fiction? Brasília Medical (Medical Experience). 48(4), pp.422–427. Available at: … Continue reading,^[21]Erdemir, F., Harbin, A. and Hellstrom, W.J.G. (2008). 5-Alpha Reductase Inhibitors And Erectile Dysfunction: The Connection. The Journal Of Sexual Medicine. 5(12), pp.2917–2924. Available at: … Continue reading

DHT is also an important contributor to secretory function and semen volume, as controlled by two glands – the prostate and seminal vesicles. These glands are androgen-dependent. DHT is the primary androgen involved, but testosterone can compensate for reduced DHT.^[22]Anitha, B., Inamadar, A.C., Ragunatha, S. (2009). Finasteride-Its Impact on Sexual Function and Prostate Cancer. J Cutan Aesthet Surg. 2(1):12–16. Available at: … Continue reading,^[23]Cai, L.Q., Fratianni, C.M., Gautier, T., Imperato-McGinley, J. (1994). Dihydrotestosterone Regulation of Semen in Male Pseudohermaphrodites with 5 Alpha-Reductase-2 Deficiency. Journal of Clinical … Continue reading

Finasteride treatment does not cause low semen or ejaculatory volume in all users, but this does appear in rare cases. This ejaculatory dysfunction could occur as a result of testosterone not sufficiently compensating for DHT’s role in secretory function.

Neurosteroids in the Central Nervous System

In addition to its ability to convert testosterone to DHT, 5AR is also important in the conversion of other molecules into neurosteroids. Neurosteroids are steroids synthesized within the central nervous system (CNS; formed of the brain and spinal cord) that play a key role in controlling activity within the CNS, including anxiety, stress, and depression. 

Treatment with 5AR inhibitors, such as finasteride, can cause a decrease in active neurosteroids within the CNS and altered transmission of certain signals within the brain. This disrupted neurosteroid signaling has been suggested as a potential cause of the decreased libido side effect that is occasionally seen in users of finasteride.^[24]Irwig, M.S. (2014), Persistent Sexual and Nonsexual Adverse Effects of Finasteride in Younger Men. Sex Med Rev. 2(1):24–35. Available at: https://doi.org/10.1002/smrj.19,^[25]Traish, A.M., Hassani, J., Guay, A.T., Zitzmann, M., Hansen, M.L. (2011). Adverse Side Effects of 5 Alpha-Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and … Continue reading

Androgen Redistribution

As discussed above, the inhibition of 5AR results in less testosterone being converted into DHT and a mild rise in testosterone. It has been suggested that the increase in free testosterone may be compensated for through androgen redistribution via conversion to estradiol (an estrogen).

Estradiol levels show a minor rise in finasteride users of approximately 15% (while remaining within physiological reference ranges).^[26]U.S. Food and Drug Administration, (2022), Propecia (Finasteride) Tablets Label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf (Accessed: 07 January 2026) For those with a genetic predisposition to high estrogen or whose diets, lifestyles, and environments have elevated their estrogen levels, a finasteride-induced further rise in estrogen may be sufficient for the development of gynecomastia (the development of male breast tissue).

How Can We Reduce the Risk of Sexual Side Effects?

The first step if side effects occur is to speak to your primary care physician to ensure that side effects are recorded and appropriate management steps are taken. If side effects are severe or rapidly worsening, you should immediately see your physician. The strategies discussed below are only applicable if mild to moderate side effects are experienced, and should only be carried out under clinical supervision. More information on finasteride-associated side effects can be found in our articles on topical finasteride and reducing side effects.

• Lowering your daily dose of finasteride

Finasteride produces the majority of its DHT-lowering effects at relatively low doses. The standard finasteride daily dose is 1 mg. Due to its non-linear dose-response curve, lower doses can still have significant effects on lowering serum and scalp DHT and enhancing hair growth.

Finasteride side effects are often dose-sensitive, meaning that lowering the daily dose could be a first step to reducing side effects, without a significant loss in benefits.

• Lowering the frequency of dosing

Mild flexibility in finasteride dosing also allows for carefully controlled alterations in dosing frequency. Finasteride has a relatively short half-life (time taken for the amount of drug in the body to halve), but does accumulate with repeated doses.^[27]Steiner, J.F. (1996). Clinical Pharmacokinetics and Pharmacodynamics of Finasteride. Clinical Pharmacokinetics. 30(1):16–27. Available at: https://doi.org/10.2165/00003088-199630010-00002

As a result, the frequency of finasteride dosing can be reduced to 1 mg three times per week or 0.5 mg every other day (once steady-state suppression has been achieved) while maintaining sufficient DHT inhibition for significant hair growth effects.

This has the potential to reduce finasteride-associated side effects, particularly sexual side effects associated with hormonal changes.

• Switching to a topical finasteride

Topical, as opposed to oral, formulations deliver the drug directly to the scalp without extensive systemic circulation and therefore reduce overall drug exposure.

Randomized clinical trials have been carried out to assess the effectiveness of oral vs topical finasteride. These have demonstrated comparable clinical benefits, including hair count, hair thickness, and size of bald area.^[28]Hajheydari, Z., Akbari, J., Saeedi, M., Shokoohi, L. (2009). Comparing the Therapeutic Effects of Finasteride Gel and Tablet in Treatment of the Androgenetic Alopecia. Indian Journal of Dermatology, … Continue reading,^[29]Bhura, M. (2013). Comparative Analysis of Topical and Oral Finasteride in Androgenetic Alopecia: Impact on Hair Growth, Systemic Absorption, and Adverse Effects. Indian Journal of Basic and Applied … Continue reading

Topical application lowers the amount of systemic drug, resulting in reduced side effects. Studies have shown that sexual side effects, in particular, are improved when using finasteride topically instead of orally.^[30]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falqués, M., Otero, R., Tamarit, M.L., Galván, J., Tebbs, V., Massana, E., Topical Finasteride Study Group. (2022). Efficacy and Safety … Continue reading

Interested in Topical Finasteride?

Low-dose & full-strength finasteride available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

The beneficial effects of topical finasteride require consistent, measured application and strong adherence to the prescribed application regimen. As such, users who are not experiencing side effects may find it easier to use oral finasteride instead.

• Using PDE5 inhibitors to manage sexual side-effects

PDE5 inhibitors can be used to treat erectile dysfunction by relaxing the blood vessels so as to allow increased blood flow into the penis. The effectiveness of these drugs is well studied, and they have also been shown to improve erectile function specifically in men taking finasteride.^[31]Casabé, A., Roehrborn, C.G., Da Pozzo, L.F., Zepeda, S., Henderson, R.J., Sorsaburu, S., Henneges, C., Wong, D.G. & Viktrup, L. (2014). Efficacy and Safety of the Coadministration of Tadalafil … Continue reading

While PDE5 inhibitors improve erectile performance and sexual confidence, they do not address other sexual side effects of finasteride, such as libido or ejaculatory volume. In addition, as prescription medications, they should only be used under clinical supervision to reduce the risk of drug interactions.

Final Thoughts

Finasteride does not lower testosterone. In fact, clinical evidence consistently demonstrates that the reduced conversion of testosterone into DHT causes a modest increase in serum testosterone, which remains within the normal physiological ranges. Concerns about finasteride causing testosterone deficiency are therefore not supported by the scientific literature.

Sexual side effects, while real, occur only in a small minority of users and are unlikely to be caused by changes in testosterone. Instead, they are more likely linked to DHT depletion in androgen-sensitive tissues, altered neurosteroid signaling, androgen distribution, or the “nocebo” effect. 

For most users, finasteride is effective and well-tolerated. For those who do experience side effects, strategies like dose adjustment or switching to topical use under the guidance of your physician may improve tolerability while maintaining benefits.

Minoxidil has been a cornerstone of hair-loss treatment for decades, and the options have expanded well beyond over-the-counter 2% and 5% topicals. Low-dose oral minoxidil has become increasingly common off-label, especially for people who struggle with topical routines or don’t respond well to them. 

As a result, many people find themselves re-evaluating their approach and thinking about switching to oral minoxidil. We’ll break down how the oral and topical formulations compare and outline when a switch is likely to help.

Interested in Oral Minoxidil?

Low-dose oral minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

How Does Minoxidil Work?

Topical and oral minoxidil both work through the same basic mechanisms. At a biological level, minoxidil alters the hair cycle by shortening the resting (telogen) phase and promoting earlier entry into the growth (anagen) phase. This increases the proportion of follicles actively producing hair at any given time. Minoxidil also enlarges miniaturized hair follicles, resulting in thicker, longer hair shafts.^[1]Messenger, A. G., & Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 150(2). 186–194. Available at: … Continue reading

Beyond hair-cycle effects, minoxidil influences several signaling and support pathways within the follicle. It increases local blood flow, activates the Wnt/β-catenin signaling pathway involved in follicular cell proliferation and differentiation, and appears to have cytoprotective and anti-inflammatory effects, in part by increasing prostaglandin E2 production.

What is the Difference Between Topical and Oral Minoxidil?

Where topical and oral minoxidil meaningfully diverge is not in what the drug does once active, but in how it becomes active and reaches the follicle.

Topical minoxidil must first penetrate the scalp barrier and then be converted into its active form within the hair follicle itself. This conversion depends on local sulfotransferase enzyme activity, which varies between individuals and even between scalp regions. As a result, exposure to active minoxidil can be highly variable, even when application is consistent.

Oral minoxidil, by contrast, is absorbed through the gastrointestinal tract and converted to its active form primarily in the liver, where sulfotransferase activity is abundant and consistent. The active drug is then delivered to hair follicles via the bloodstream, largely bypassing both the scalp barrier and variability in local enzymatic activation.

These differences in activation and delivery are what make switching between topical and oral formulations clinically meaningful.

Why Do People Switch Between Minoxidil Forms?

Switching is rarely about chasing a small theoretical advantage. Most switches happen for one of three reasons:

1. Convenience and Adherence

Topical minoxidil can work well in trials, but adherence is hard in real life. Many people struggle with twice-daily application for months, and discontinuation rates in real-world settings are high, with the most commonly cited reason being a lack of compliance (i.e., people couldn’t maintain their treatment regimen).^[2]Shadi, Z. (2023). Compliance to topical minoxidil and reasons for discontinuation among patients with androgenetic alopecia. Dermatology and Therapy. 13(5). 1157–1169. Available at: … Continue reading

Topical minoxidil can also present cosmetic challenges that influence long-term adherence. Liquid solutions may leave the hair feeling greasy or stiff, create visible residue or flaking that can resemble dandruff, and interfere with hairstyling, particularly in people with longer hair or finer textures. 

Oral minoxidil is simpler, usually a once-daily pill, and for many people, that alone changes outcomes.

2. Inconsistent Response to Topical Therapy

Some people use topical minoxidil correctly for long enough and still see little benefit. This can happen even when everything “looks right” on paper. The second most cited reason for discontinuing topical minoxidil was unsatisfactory results, and clinical data have shown that response rates are high in the first 3-6 months, but drop after a year or longer of use.^[3]Olsen, E. A., Weiner, M. S., Amara, I. A., & DeLong, E. R. (1990). Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. *Journal of the American Academy of … Continue reading

3. Side Effects

The side effects most commonly associated with topical minoxidil are local rather than systemic, reflecting the fact that only a small fraction of the applied drug enters the bloodstream. The most frequently reported issues include scalp irritation, dryness, flaking, itching, and contact dermatitis. In many cases, these reactions are driven less by minoxidil itself and more by the vehicle used to deliver it, particularly formulations containing propylene glycol.^[4]Olsen, E. A., DeLong, E. R., & Weiner, M. S. (1987). Long-term follow-up of men with male pattern baldness treated with topical minoxidil. Journal of the American Academy of Dermatology. 16(3). … Continue reading

Minoxidil is also toxic to pets, and even small exposures to topical or oral products can cause severe, sometimes fatal cardiovascular events. Because topical formulations can be harder to control, and need to be handled with care, some users may switch to oral formulations to decrease the risk of accidental exposure.^[5]Tater, K. C., Gwaltney-Brant, S., & Wismer, T. (2021). Topical minoxidil exposures and toxicoses in dogs and cats: 211 cases (2001–2019). *Journal of the American Animal Hospital Association.* … Continue reading

Propylene glycol is included in many liquid formulations to enhance solubility and penetration, but it is a well-known irritant and contact sensitizer. In susceptible individuals, this can lead to erythema, scaling, burning, or eczematous dermatitis, particularly with twice-daily use.

Oral minoxidil produces a different side-effect profile because it is systemically absorbed and pharmacologically active throughout the body. At the low doses used for hair loss, it is generally well tolerated, but adverse effects occur more frequently than with topical formulations and tend to be dose-dependent.

The most common side effect is hypertrichosis, or unwanted hair growth outside the scalp, including on the face. This was reported in 15% of 1404 users in a follow-up study.^[6]Vañó-Galván, S., Pirmez, R., Hermosa-Gelbard, A., Moreno-Arrones, Ó. M., Saceda-Corralo, D., Rodrigues-Barata, R., Jimenez-Cauhe, J., et al. (2021). Safety of low-dose oral minoxidil for hair … Continue reading

Hypertrichosis is typically more of an issue for women taking minoxidil, for whom hair on the face and body may be off-putting.

Other common side effects reported in the follow-up study included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (elevated heart rate, 0.9%), and headache (0.4%). Serious cardiovascular complications are rare at the low doses used for hair loss and have been reported primarily in higher-dose antihypertensive use or in individuals with pre-existing cardiovascular disease.

If you’re concerned about minoxidil side effects, check out our article on 10 ways to reduce them.

Why Oral Minoxidil Might Work Better for Some

Topical minoxidil relies heavily on follicular sulfotransferase activity (notably SULT1A1). Lower activity is associated with weaker response.^[8]Pietrauszka, K., & Bergler-Czop, B. (2022). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: … Continue reading

As such, minoxidil’s “ceiling” isn’t the same for everyone: people with lower SULT1A1 activity will generally not respond as well.

Similarly, the penetration of topical minoxidil through the scalp is essential for it to function. This can depend on a range of factors, including the type of formulation, scalp health, contact time, and application technique.

Oral minoxidil bypasses these barriers to absorption. It is absorbed through the gastrointestinal tract and converted into its active form primarily in the liver, where sulfotransferase activity is abundant. Systemic activation makes exposure more uniform across the scalp and less dependent on follicular enzyme variability.

Oral Minoxidil vs Topical Minoxidil

So what does the clinical evidence tell us about the efficacy of the two approaches? 

Both topical and oral minoxidil are supported by robust clinical evidence demonstrating their effectiveness in treating hair loss, including androgenic alopecia (AGA).^[9]Jaén, P., & Arias-Santiago, S. (n.d.). Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. Available at: … Continue reading,^[10]Panchaprateep, R., & Lueangarun, S. (2020). Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global … Continue reading,^[11]Silva, M. N. E., Ramos, P. M., Silva, M. R., Silva, R. N. E., & Raposo, N. R. B. (2022). Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 … Continue reading,^[12]Sinclair, R. D. (2018). Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. *International Journal of Dermatology.* 57(1). … Continue reading,^[13]Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical … Continue reading,^[14]Adil, A., & Godwin, M. (2017). The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. *Journal of the American Academy of Dermatology.* 77(1). … Continue reading

Direct head-to-head comparisons, however, are less common. 

Direct Comparisons in Men

A 2024 randomized clinical trial compared 5 mg oral minoxidil once daily vs 5% topical minoxidil twice daily for 24 weeks in men with AGA. They found no significant difference in hair outcomes overall, but oral trended higher for density and showed significantly greater improvement in photographic assessment at the crown.^[15]Penha, M. A., Miot, H. A., Kasprzak, M., & Ramos, P. M. (2024). Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatology. 160(6). … Continue reading

This matches the broader trend seen across male oral minoxidil studies at 2.5-5 mg daily: more consistent, dose-dependent results with cosmetic relevance.^[16]Panchaprateep, R., & Lueangarun, S. (2020). Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global … Continue reading

Direct Comparisons in Women

As we’ve already noted, doses for women tend to be lower than for men, typically 1 mg daily versus 5 mg daily, so as to avoid hypertrichosis.

The first direct comparison in women comes from a 24-week randomized, open comparative study conducted in Brazil, which evaluated oral minoxidil 1 mg once daily versus topical minoxidil 5% solution applied once daily in women aged 18–65 with pattern hair loss.^[17]Ramos, P. M., Melo, D. F., Radwanski, H., Cortez de Almeida, R. F., & Miot, H. A. (2023). Female-pattern hair loss: therapeutic update. Anais Brasileiros de Dermatologia. 98. 506–519. Available … Continue reading

After 24 weeks, terminal hair density increased by 12% in the oral minoxidil group and 7.2% in the topical group. While this improvement favored oral therapy, the difference was not statistically significant.

Side-effect patterns differed in expected ways. Hypertrichosis was reported in 27% of women taking oral minoxidil, compared with 4% in the topical group. 

A similar trial comparing 1mg oral minoxidil to 5% topical minoxidil also found no statistically significant differences between the two groups in hair diameter. They did, however, report improvement in photographic assessment in the topical group.^[18]Asilian, A., Farmani, A., & Saber, M. (2024). Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled … Continue reading

Lower doses of oral minoxidil for women may reduce its efficacy compared to topical treatments, which are typically applied at similar concentrations to men (5%).

What About Higher Concentrations of Topical Minoxidil?

As we’ve seen, most clinical research focuses on 5% topical minoxidil. However, in practice, many people use higher concentrations of minoxidil, with 7-8% being common, and sometimes concentrations as high as 10-15% are employed as a more aggressive treatment.

What’s more, minoxidil is often paired with tretinoin/retinoic acid, which enhances activation and penetration of the drug. While there is limited clinical data on such pairings, anecdotal evidence from our members suggests that this combination could help to optimize topical minoxidil’s efficacy.

We see that 7-8% minoxidil paired with 0.005-0.02% retinoic acid appears to outperform 5 mg oral minoxidil, even in cases of diffuse thinning.

For comprehensive information about using retinoic acid for hair loss, check out our ultimate guide.

Anecdotal evidence from our members also suggests that higher concentrations of topical minoxidil (10-15%) can generate similar results to 5 mg oral minoxidil.

Is there a clear winner?

In short, no. A 2025 meta-analysis comparing topical and oral minoxidil found no significant difference between approaches overall, which reflects how much outcomes depend on dose, population, and study design.^[20]Fazal, F., Malik, B. H., Malik, H. M., Sabir, B., Mustafa, H., Ahmed, M., Abid, A., Adil, M. L., Shafi, U., & Saad, M. (2025). Can oral minoxidil be the game changer in androgenetic alopecia? A … Continue reading

It is important to note that adherence to a strict routine in trials is typically well enforced, and topical treatments are applied with consistent volumes at consistent times. This doesn’t necessarily reflect how people use topical minoxidil in the real world.

On the other hand, many users find that they can optimize a topical approach by increasing the strength or frequency of application, or by adding enhancer ingredients like tretinoin/retinoic acid. If you’re using such a combination therapy, you might, in fact, see worse results when switching to oral.

When Switching From Topical to Oral Makes the Most Sense

Switching to oral minoxidil is most rational when the limiting factor is activation or adherence, or when topical treatment isn’t delivering the results you expect.

Good Candidates for Switching to Oral Minoxidil

If systemic exposure is acceptable from a safety and tolerability standpoint, there are circumstances in which switching from an oral to a topical formulation makes sense.

Poor topical responders – If you’ve used topical minoxidil consistently for 6-12 months and can reasonably say adherence wasn’t the problem, oral is a logical next step because it bypasses follicular enzyme variability.^[21]Pietrauszka, K., & Bergler-Czop, B. (2022). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: … Continue reading

Diffuse or Advanced Thinning – As larger areas of the scalp are affected, ensuring even coverage requires more time, higher product volumes, and careful technique, which many people struggle to sustain long term. Missed areas and uneven delivery are common and can limit results even when follicles remain responsive. 

Oral minoxidil avoids these practical constraints by delivering the drug systemically, allowing uniform exposure across the entire scalp and making treatment easier to scale as hair loss progresses.

Convenience-driven adherence problems – When adherence is the primary issue, oral minoxidil often has a practical advantage. Topical therapy requires regular scalp application, drying time, and styling time, all of which can erode consistency over months or years of use. Missed applications are common and can reduce effectiveness. Oral minoxidil makes consistent long-term use more achievable for many people.

Scalp Inflammation – Inflammation of the scalp occurs in a high proportion of individuals with AGA, with seborrheic dermatitis being common. If you’re pairing minoxidil with inflammatory treatments like retinoic acid, this can exacerbate underlying chronic inflammation and prevent regrowth.

Scalp inflammation decreases the efficacy of topical minoxidil.^[22]Whiting, D. A. (1993). Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. *Journal of the American Academy of Dermatology.* 28(5). … Continue reading Switching to oral minoxidil, or even removing the inflammatory component from your treatment, can help improve underlying inflammation.

People Who Should Be Cautious Switching

Anyone with cardiovascular disease, kidney issues, fluid retention tendencies, low blood pressure, or unexplained palpitations should be conservative and involve a clinician before starting or escalating oral minoxidil.^[23]Gupta, A. K., Bamimore, M. A., Abdel-Qadir, H., Williams, G., Tosti, A., Piguet, V., & Talukder, M. (2025). Low-dose oral minoxidil and associated adverse events: analyses of the FDA Adverse … Continue reading

When Switching From Oral to Topical Makes the Most Sense

There are also times when switching from topical oral minoxidil might be a sensible decision. These will most commonly occur when side effects have made use difficult or intolerable. 

You might also consider an optimized topical approach, incorporating enhancers such as tretinoin/retinoic acid or increasing topical dosage. Anecdotal experiences of our members suggest these topical combinations can outperform low-dose oral minoxidil. 

If you’’re interested in topical minoxidil for, check out our articles for men and women on the best products currently available.

Hair Shedding: Should You Be Concerned?

When people start a new hair loss treatment, shedding events are common. This includes treatments that are working! ‘Treatment-induced telogen effluvium shedding’ is the term used to describe this phenomenon, and can actually be a good predictor of whether minoxidil treatment will work down the line.^[24]Bi, L., Kan, H., Wang, J., Ding, Y., Huang, Y., Wang, C., & Fan, W. (2025). Whether the transient hair shedding phase exist after minoxidil treatment and does it predict treatment efficacy? A … Continue reading

However, it’s hard to tell if shedding when you switch treatments is a positive sign, or if it’s a indicator of decreased efficacy. These cases are referred to as a ‘treatment withdrawal telogen effluvium shed’, and won’t lead to improvement in the future.

Information from our members indicates that shedding after switching from topical to oral minoxodil tends to fall into the latter camp: shedding is a result of the treatment working less well.

Be aware of shedding after switching treatments, as it could be an indicator that your new treatment isn’t working as well.

You can read more about minoxidil shedding in our comprehensive article.

How to Switch

There’s no universally validated switching protocol supported by large controlled trials. But there are sensible principles that reduce avoidable problems.

1. Avoid Abrupt Stop and Start Changes

Minoxidil works by keeping follicles in a growth-supportive environment. Abrupt discontinuation can allow hairs that were being prolonged in anagen to shed as cycles normalize. 

1. Expect a Transition Period

Whether switching to oral or topical, you’re changing local concentrations and the consistency of follicular exposure. That can mean a temporary shed or plateau before stabilization, so don’t judge too early. 

1. Be Patient and Track Longterm Changes

As with all hair loss treatments, consistency is key. Because minoxidil primarily influences hair-cycle timing rather than creating new follicles, benefits accrue gradually and are best assessed over 6–12 months of consistent use. Tracking progress with standardized photographs, consistent lighting, and fixed time intervals can help distinguish true treatment effects from normal cycle-related variation.

If you experience severe adverse effects, you should discontinue treatment and speak to a clinician.

Final Thoughts

Switching between topical and oral minoxidil should be a deliberate and strategic decision guided by potential reasons your current approach isn’t working. The evidence consistently shows that both topical and oral minoxidil can be effective, but their real-world performance is shaped by adherence, activation, dose, side effects, and how well the treatment fits into your life.

For people with limited topical response, inconsistent application, or large areas of thinning, oral minoxidil can provide more uniform exposure and better long-term consistency. However, real-world experience and member data suggest that higher-strength topical formulations (7–8%), especially when paired with penetration or activation enhancers like retinoic acid, often produce stronger results. 

In some cases, these optimized topical approaches appear to match or even outperform low-dose oral minoxidil. For people who tolerate topical therapy well and can maintain consistency, increasing topical strength may be a more effective next step than switching to oral treatment.

Ultimately, switching treatments always carries trade-offs and some risk. The safest path forward is deliberate, not reactive: avoid abrupt changes, allow sufficient time to assess outcomes, and monitor both hair and systemic responses carefully.

Spironolactone is a potassium-sparing diuretic with anti-androgen properties that has become increasingly popular for treating hair loss, particularly female pattern hair loss. By blocking androgen receptors, spironolactone can slow hair shedding and promote regrowth in hormonally driven alopecia. 

Despite its benefits, many patients worry about potential side effects, especially whether spironolactone leads to weight gain. Anecdotally, several patients have reported weight gain when they begin taking spironolactone. In this article, we examine that concern by reviewing typical dosing for hair loss, summarizing clinical evidence on weight changes, explaining possible biological mechanisms, and outlining practical strategies to minimize unwanted weight or fluid-related effects during treatment.

What is Spironolactone?

Spironolactone is a prescription medication classified as a potassium-sparing diuretic. In other words, it is a pill that helps the body get rid of excess fluid like water and salt by increasing urination, but it prevents excessive loss of the vital mineral potassium.

It mediates this function by acting as an aldosterone antagonist. Spironolactone blocks the binding of the hormone aldosterone to its receptors, an action that regulates the body’s sodium and potassium levels.

This is why spironolactone is commonly prescribed for hypertension (high blood pressure), heart failure, and edema (swelling). By blocking aldosterone, spironolactone reduces water and salt retention and helps lower blood pressure, strain on the heart, and swelling.^[1]Carone, L., Oxberry, S.G., Twycross, R., Charlesworth, S., Mihalyo, M., Wilcock, A. (2017). Spironolactone. Journal of Pain and Symptom Management. 53(2). 288–292. Available at: … Continue reading

How Does Spironolactone Work For Hair Loss? 

Aside from blocking aldosterone receptors, spironolactone is also capable of binding to androgen receptors. These receptors typically bind to male androgen hormones like testosterone and dihydrotestosterone (DHT).^[2]Vargas-Mora, P., Morgado-Carrasco, D. (2020). Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Hair Loss, and Hirsutism. Actas Dermo-Sifiliográficas (English … Continue reading

Levels of DHT above average are a common symptom in those with androgenic alopecia. In the body, the binding of DHT to androgen receptors stimulates a range of effects, including hair follicle miniaturization. That is, hairs become thinner, shorter, and weaker. This is because DHT reduces the length of the growth phase (the anagen phase) of hair follicles, while also increasing the length of the non-growing phase (the telogen phase).^[3]Ustuner, E. T. (2013). Cause of Androgenic Alopecia: Crux of the Matter. Plast Reconstr Surg Glob Open. 1(7). e64. Available at: https://doi.org/10.1097/GOX.0000000000000005,^[4]Sekhavat, H., Bar Yehuda, S., Asotra, S. (2025). Using the Mechanisms of Action Involved in the Pathogenesis of Androgenetic Alopecia to Treat Hair Loss. Int J Mol Sci. 26(21). 10712. Available at: … Continue reading

Thus, by binding androgen receptors, spironolactone can prevent the binding of DHT and, in this way, effectively “blocks” DHT to prevent hair loss.^[5]Vargas-Mora, P., Morgado-Carrasco, D. (2020). Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Hair Loss, and Hirsutism. Actas Dermo-Sifiliográficas (English … Continue reading

Side effects

Because spironolactone blocks male hormones, it can lead to unwanted feminization in men, such as gynecomastia (enlarged breasts), reduced facial or body hair, and redistribution of body fat. It may also lead to a loss of libido and other sexual dysfunctions.^[6]Carone, L., Oxberry, S.G., Twycross, R., Charlesworth, S., Mihalyo, M., Wilcock, A. (2017). Spironolactone. Journal of Pain and Symptom Management. 53(2). 288–292. Available at: … Continue reading,^[7]Haynes, B.A., Mookadam, F. (2009). Male Gynecomastia. Mayo Clinic Proceedings. 84(8). 672. Available at: https://doi.org/10.4065/84.8.672

For this reason, it is usually prescribed to women but not to men for the purpose of treating non-life-threatening conditions, such as androgenic alopecia. 

Women prescribed spironolactone may experience some other side effects. For example, 15-30% of women report irregular menstruation, while fewer than 5% report breast tenderness, reduced libido, nausea, headache, and fatigue.^[8]Vargas-Mora, P., Morgado-Carrasco, D. (2020). Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Hair Loss, and Hirsutism. Actas Dermo-Sifiliográficas (English … Continue reading

The Science: Hair Growth Benefits 

Oral spironolactone as a hair loss treatment has been studied across concentrations from 25 mg to 200 mg per day. Collectively, these trials demonstrate that spironolactone can provide meaningful improvements in hair growth in those with androgenic alopecia; however, not all trials have the scientific robustness to make clear conclusions on its efficacy.

Low doses (25-50 mg/day)

A pilot study of 100 women taking 25 mg spironolactone with 0.25 mg minoxidil for 12 months nearly halved hair shedding and substantially improved hair loss severity. However, the absence of a placebo control group limits interpretation, meaning the true effectiveness of low-dose spironolactone within this combination remains uncertain.^[9]Sinclair, R.D. (2018). Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. International Journal of Dermatology. 57(1). … Continue reading 

Medium doses (75-100 mg/day)

A 2025 randomized, placebo-controlled pilot study over 24 weeks evaluated 100 mg daily spironolactone plus 3% topical minoxidil versus placebo plus minoxidil in women with androgenic alopecia. Both groups experienced significant increases in hair density and diameter from baseline. The spironolactone group showed greater increases in terminal hairs and hair diameter than placebo, though this difference was not statistically significant.^[10]Werachattawatchai, P., Khunkhet, S., Harnchoowong, S., Lertphanichkul, C. (2025). Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, … Continue reading

Earlier research from 1991 found that women treated with 75–100 mg spironolactone did not have a significant change in hair density after 12 months, while untreated women experienced decreases, suggesting spironolactone may prevent further loss rather than promote regrowth.^[12]Rushton, D., Futterweit, W., Kingsley, D., Kingsley, P., Norris, M.J. (1990). Quantitative assessment of spironolactone treatment in women with diffuse androgen-dependent alopecia. Journal of the … Continue reading

Combination therapies appear promising. A larger study comparing 5% minoxidil alone, minoxidil with 100 mg spironolactone, and minoxidil with microneedling found all groups had increased hair density at 24 weeks. The minoxidil plus spironolactone group had greater gains than minoxidil alone, though less than the microneedling group, indicating that adding spironolactone may enhance treatment effects.^[13]Liang, X., Chang, Y., Wu, H., et al. (2022). Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A … Continue reading

High doses (150-200 mg/day)

Early studies suggested high doses of spironolactone might benefit people with androgenic alopecia, but the supporting evidence is limited and inconsistent. 

A very small trial reported large improvements in hair growth and reductions in hair loss after six months of 200 mg daily treatment; however, this study involved only four patients and lacked a control group, severely limiting its reliability.^[15]Adamopoulos, D.A., Karamertzanis, M., Nicopoulou, S., Gregoriou, A. (1997). Beneficial effect of spironolactone on androgenic alopecia. Clinical Endocrinology. 47(6). 759–760. Available at: … Continue reading 

Larger research has failed to confirm such strong effects. In a study of 80 women comparing spironolactone with another anti-androgen, no significant difference was found between treatments. Overall, only 44% of participants experienced regrowth, while the same proportion saw no clear change and 12% continued to lose hair.^[16]Sinclair, R., Wewerinke, M., Jolley, D. (2005). Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology. 152(3). 466–473. Available at: … Continue reading  

Indeed, case evidence suggests that spironolactone alone may not provide long-term benefits. A 53-year old woman with androgenic alopecia was treated with 200 mg spironolactone daily. Hair regrowth was evident after 12 months, but regrowth was not sustained after 24 months. Adding topical minoxidil alongside oral spironolactone to a treatment routine appeared to restore and maintain regrowth, indicating that combination therapy may be more effective than spironolactone on its own.^[17]Hoedemaker, C., Van Egmond, S., Sinclair, R. (2007). Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australasian Journal of Dermatology. 48(1). 43–45. … Continue reading 

Is Spironolactone Effective for Hair Loss?

Evidence does not support spironolactone alone as an effective hair-loss treatment, especially at higher doses. Medium doses around 100 mg/day may slow further loss, but regrowth is poorly supported. Across all doses, spironolactone works best in combination therapies, particularly with minoxidil, where sustained regrowth is more consistently observed.

Does Spironolactone Have Any Mechanism That Could Cause Weight Gain? 

There is no plausible biological mechanism by which spironolactone would cause true weight gain (i.e., fat accumulation). Typically, drugs that cause weight gain will cause one or more specific effects that can lead to fat-gain.^[18]Verhaegen, A.A., Van Gaal, L.F. (2000). Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. Endotext. MDText.com, Inc. Available at: http://www.ncbi.nlm.nih.gov/books/NBK537590/ These include:

 

• Increased appetite
• Changed insulin resistance
• Slowdown of metabolism
• Increased cortisol

However, spironolactone has no known interactions that would lead to these effects. In fact, because spironolactone blocks aldosterone, it reduces sodium and water retention in the blood and can cause mild weight loss due to its diuretic effect. 

Spironolactone and Weight Gain: What Do We See from Clinical Evidence?

Many clinical studies assessing the effectiveness of spironolactone for hair loss or other medical conditions also report side effects. As doses increase, more side effects are likely to occur, but is weight gain one of them? 

Low doses (25-50 mg/day)

In the pilot study by Sinclair in 2018, side effects were reported in eight women, but they were not related to weight gain.^[19]Sinclair, R.D. (2018). Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. International Journal of Dermatology. 57(1). … Continue reading

Medium doses (75-100 mg/day)

The trial by Werachattawatchai and colleagues in 2025 reported menstrual irregularities in 37.5% of women but no mention of weight gain.^[20]Werachattawatchai, P., Khunkhet, S., Harnchoowong, S., Lertphanichkul, C. (2025). Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, … Continue reading Similarly, in the study by Rushton and colleagues in 1991, some women reported changes to their menstrual cycles, but there was again no mention of weight gain.^[21]Rushton, D., Futterweit, W., Kingsley, D., Kingsley, P., Norris, M.J. (1990). Quantitative assessment of spironolactone treatment in women with diffuse androgen-dependent alopecia. Journal of the … Continue reading 

The trial by Liang and colleagues in 2022 also had no reports of weight gain, but the spironolactone group had the most adverse effects reported. Menstrual disorder, hyperkalemia, and edema of the limbs occurred only within groups receiving spironolactone treatment. While it may appear paradoxical as spironolactone is designed to treat edema, spironolactone can also cause edema because it promotes shifts in fluids from the bloodstream to the tissues. ^[22]Liang, X., Chang, Y., Wu, H., et al. (2022). Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A … Continue reading 

When used to treat hormonal disorders, a prospective clinical trial with women with polycystic ovary syndrome showed that intake of 100 mg spironolactone per day was not associated with weight gain.^[24]Zulian, E., Sartorato, P., Benedini, S., et al. (2005). Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile. Journal of … Continue reading

High doses (150-200 mg/day)

Adamopoulos and colleagues reported that participants experienced no adverse side effects from taking 200 mg spironolactone per day.^[25]Adamopoulos, D.A., Karamertzanis, M., Nicopoulou, S., Gregoriou, A. (1997). Beneficial effect of spironolactone on androgenic alopecia. Clinical Endocrinology. 47(6). 759–760. Available at: … Continue reading In the study by Sinclair in 2005 and case study by Hoedemaker and colleagues, adverse reactions, including weight gain, were not noted in the report, which suggests side effects were not measured.^[26]Sinclair, R., Wewerinke, M., Jolley, D. (2005). Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology. 152(3). 466–473. Available at: … Continue reading,^[27]Hoedemaker, C., Van Egmond, S., Sinclair, R. (2007). Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australasian Journal of Dermatology. 48(1). 43–45. … Continue reading

In applications outside of hair loss, spironolactone has shown to actually cause weight loss. Administration of up to 200 mg spironolactone to patients with mineralocorticoid-induced hypertension resulted in a reversal of mineralocorticoid-induced abnormalities, including increased body weight.^[28]Nicholls, M.G., Ramsay, L.E., Boddy, K., Fraser, R., Morton, J.J., Robertson, J.I.S. (1979). Mineralocorticoid-induced blood pressure, electrolyte, and hormone changes, and reversal with … Continue reading

Why Some People Think Spironolactone Causes Weight Gain

Even though spironolactone has no known mechanism that could cause weight gain, and has actually been shown to induce weight loss, some individuals taking spironolactone have reported weight gain anecdotally. Why could this be?

1. Water Retention

Spironolactone helps your body get rid of salt and water. It works by making the kidneys remove sodium and water from the bloodstream, which lowers the amount of fluid circulating in the vessels. That helps when edema is caused by too much circulating volume, like in heart failure or certain hormone disorders.

However, spironolactone can also relax veins and lower blood pressure. Edema can be caused by these exact symptoms. Thus, spironolactone can sometimes make fluid move into your tissues instead of staying in your bloodstream, causing swelling. This is why some studies report edema as a side effect. 

Those in spironolactone may experience this water retention and swelling, causing them to feel that they have gained weight as a result of taking this medication. 

1. Multiple Medications

It is likely that the individual is taking multiple medications. Spironolactone is best used in combination with other medications, and is safe to use with anti-depressants or birth control, both of which have clinically shown to cause weight gain.^[29]Gafoor, R., Booth, H.P., Gulliford, M.C. (2018). Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. k1951. Available at: … Continue reading,^[30]Lopez, L.M., Ramesh, S., Chen, M., et al. (2016). Progestin-only contraceptives: effects on weight. Cochrane Database of Systematic Reviews. 2016(8). CD008815. Available at: … Continue reading. Research summarising population characteristics of those prescribed spironolactone found that 22% had been using hormonal contraceptives, suggesting an alternative reason than spironolactone for reported weight gain.^[31]Burns, L.J., Souza, B.D., Flynn, E., Hagigeorges, D., Senna, M.M. (2020). Spironolactone for treatment of female pattern hair loss. Journal of the American Academy of Dermatology. 83(1). 276–278. … Continue reading

1. Menopause

Weight gain is also one of the most common side effects of perimenopause, menopause, and postmenopause, affecting over 40% of women.^[32]Knight, M.G., Anekwe, C., Washington, K., Akam, E.Y., Wang, E., Stanford, F.C. (2021). Weight Regulation in Menopause. Menopause. 28(8). 960–965. Available at: … Continue reading,^[33]Davis, S.R., Castelo-Branco, C., Chedraui, P., et al. (2012). Understanding weight gain at menopause. Climacteric. 15(5). 419–429. Available at: https://doi.org/10.3109/13697137.2012.707385 Population characteristics of those prescribed spironolactone found that 51% were postmenopausal.^[34]Burns, L.J., Souza, B.D., Flynn, E., Hagigeorges, D., Senna, M.M. (2020). Spironolactone for treatment of female pattern hair loss. Journal of the American Academy of Dermatology. 83(1). 276–278. … Continue reading Weight gain may therefore be related to life stage rather than spironolactone itself.

1. Other Side Effects

Many medications including spironolactone itself may cause symptoms such as fatigue. Those experiencing fatigue would be less inclined to stick to their active routines. Inactivity or changes to diet as a result could lead to weight gain. 

1. Stress

We must also consider that external factors like stress can cause hormonal changes that influence weight. It is reasonable to assume that those prescribed spironolactone may be experiencing hypertension, heart failure, edema, or hair loss. Ongoing conditions like these could contribute to stress and hormonal changes that ultimately lead to weight gain.^[35]Kyrou, I., Tsigos, C. (2009). Stress hormones: physiological stress and regulation of metabolism. Current Opinion in Pharmacology. 9(6). 787–793. Available at: … Continue reading

Managing Weight Fluctuations If They Occur 

Because spironolactone has a diuretic effect, you may notice some temporary weight loss due to fluid reduction. This is not fat loss, but if you wish to maintain your weight, it’s important to monitor your body closely and make gradual lifestyle changes. The same can be advised if you are also experiencing weight gain for any reason.

To manage weight fluctuations if they occur, consider the following:

• Record keeping: Keep a consistent record of your weight to track change and distinguish between fluid-related changes and true weight changes

• Diet: Maintain a balanced diet rich in whole grains, lean proteins, healthy fats, fruits, and vegetables to stabilize weight.

• Hydration: Fluid shifts from diuretics can sometimes trigger dehydration, which may influence appetite and energy levels.

• Physical activity: Support muscle maintenance and overall metabolism by engaging in regular physical activity 

• Take time: Weight changes from spironolactone are often temporary as your body gets used to the medication

If you feel your medication is causing your weight to change substantially, speak with your clinician, as it may indicate problems with your dosage, interactions with other medications, or additional health conditions.

Should I Take Spironolactone If I’m Concerned About Weight Gain?  

There are some side effects of spironolactone, but weight gain is not one of them. Clinical evidence shows that daily usage of spironolactone at any dose is not known to cause weight gain.

If you’ve been prescribed spironolactone, take it with peace of mind that it will not cause permanent changes to your weight.

Final Verdict 

Spironolactone isn’t a “fat-gain” drug, even though it can sometimes get that reputation online. Any early weight changes are usually from temporary fluid shifts, and many people actually notice weight loss over time due to the diuretic activity of this treatment.

Benefits to hair loss tend to appear at moderate doses like 50-100 mg per day and are most substantial when combined with common hair loss treatments like minoxidil. True weight gain has not been reported clinically, and anecdotal evidence from users is likely the result of other medications, age, activity level, or hormonal shifts. That being said, pairing treatment with sensible eating, hydration, and regular activity can help keep any weight changes in check, so the only thing you see growing is your hair.

Many people are interested in RU58841 after hearing anecdotes about it working well for hair regrowth. Even though RU58841 is classified as for “research purposes only,” you can find promotion of RU58841 on many YouTube channels. It is increasingly used as a preventive measure against hair loss, especially in the bodybuilding community and among individuals who cannot tolerate traditional treatments like finasteride due to side effects. Some people have demonstrated incredible results with no side effects. While others have reported no results and side effects ranging from brain fog to severe chest pain.

Despite its reputation, RU58841 is still a clinical mystery. No one knows why the human clinical trials were never published, and why the research chemical was ultimately abandoned. This article explores preclinical and clinical data on RU58841, presents our perspectives, and provides information we believe is rarely discussed about this research chemical and its potential issues. 

What Is RU58841 and How Does It Work?

RU58841 is a topical androgen receptor antagonist developed in the mid-1990’s to combat androgenic alopecia by preventing DHT from having its effects.^[1]Battmann, T., Bonfils, A., Branche, C., Humbert, J., Goubet, F., Teutsch, G., Philibert, D. (1994). RU 58841, A New Specific Topical Antiandrogen: A Candidate of Choice for the Treatment of Acne, … Continue reading 

As an androgen receptor antagonist, RU58841 blocks the “landing pads” (i.e., androgen receptors) on cell surfaces for the hormone DHT, preventing DHT from exerting its effects. If DHT cannot bind to androgen receptors in balding-prone hair follicles, it cannot induce the cascade of events that leads to hair follicle miniaturization, which is the defining characteristic of androgenic alopecia.^[2]Ho, C.H., Sood, T., Zito, P.M. (2024). Androgenetic Alopecia. In: StatPearls. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430924/

It’s important to note that androgen receptor antagonists like RU58841 work differently from drugs like finasteride or dutasteride that inhibit the enzyme that turns testosterone into DHT (reducing DHT levels overall). Androgen receptor antagonists block the “landing pads” on the cell surfaces, preventing DHT from binding. The body can still freely produce DHT, but in the presence of androgen receptor antagonists, DHT cannot bind to hair follicle sites and have its negative effects.

Interested in Topical Finasteride?

Low-dose & full-strength finasteride available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Follow this link to our article here to learn more about the side effects of finasteride.

The goal when developing RU58841 was to design a drug that blocked androgen receptors locally (i.e., in the scalp). With hopes of preventing its binding to androgen receptors everywhere else in the body (like with oral spironolactone), therefore preventing interference with androgen production in places like the testes, ovaries, or adrenal glands. In fact, one of the premises behind RU58841 was to simply avoid side effects that sometimes come with drugs like finasteride and dutasteride.

What the Evidence Actually Shows

Preclinical studies show promising results for RU58841. Yet despite tens of millions of dollars spent on RU58841’s human clinical trials, little information from those studies has been made public.^[4]ISRCTN Registry, (no date), ISRCTN49873657. Available at: https://www.isrctn.com/ISRCTN49873657 (Accessed: 02 January 2026),^[5]ISRCTN Registry, (no date), ISRCTN71083772. Available at: https://www.isrctn.com/ISRCTN71083772 (Accessed: 02 January 2026)

Soon after these clinical studies were completed, the drug’s research and development were discontinued, with financial concerns cited as the reason for halting RU58841’s progress. It was stated that with more money, development could continue. However, further development never occurred, and decades later (after the drug’s patents expired), companies began selling RU58841 for “research purposes only,” citing its initial, and small, clinical trials showing favorable results for male pattern hair loss. 

Let’s break down what we actually know about RU58841 from preclinical and clinical research. 

Evidence From Preclinical Data

Preclinical studies suggest RU58841 works as intended and may be effective for blocking androgen activity. But we must remember that they cannot confirm long-term human safety, and they do not guarantee purely local action in real-world conditions (where dose, formulation, frequency of application, and individual absorption vary).

How Strong Is RU58841 Compared to Natural Androgens?

RU58841 was designed as a nonsteroidal androgen-receptor antagonist and contains structural features (notably perfluoroalkyl and nitrile groups) that are associated with strong androgen-receptor binding.

Early receptor-binding experiments measuring equilibrium association constants (Ka) demonstrated that RU58841 binds the androgen receptor with affinity equal to or greater than testosterone in several species and skin-relevant tissues, including the hamster flank organ and the human receptor.^[6]Battmann, T., Bonfils, A., Branche, C., Humbert, J., Goubet, F., Teutsch, G., Philibert, D. (1994). RU 58841, A New Specific Topical Antiandrogen: A Candidate of Choice for the Treatment of Acne, … Continue reading This is positive as it supports the premise that RU58841 can effectively compete with natural androgens at target sites.

When compared with other nonsteroidal antiandrogens such as flutamide, RU58841 was reported to have approximately 30x higher receptor affinity, a key reason it was pursued as a best-in-class topical antiandrogen candidate.^[7]Battmann, T., Bonfils, A., Branche, C., Humbert, J., Goubet, F., Teutsch, G., Philibert, D. (1994). RU 58841, A New Specific Topical Antiandrogen: A Candidate of Choice for the Treatment of Acne, … Continue reading

But potency works both ways. Strong androgen receptor binding makes RU58841 mechanistically credible for scalp blockade. However, it also raises the stakes if any meaningful amount escapes the scalp, accumulates, or produces systemically active metabolites. 

Does RU58841 Stay Local in the Skin?

In an early study using an intact hamster flank-organ model, topical RU58841 showed strong local antiandrogen activity with minimal evidence of systemic spillover at low doses.^[8]Battmann, T., Bonfils, A., Branche, C., Humbert, J., Goubet, F., Teutsch, G., Philibert, D. (1994). RU 58841, A New Specific Topical Antiandrogen: A Candidate of Choice for the Treatment of Acne, … Continue reading When applied topically at doses up to 100 µg/animal, RU58841 reduced flank-organ area in a dose-dependent manner while showing no effect on the opposite flank organ, no meaningful change in serum testosterone, and no detectable antiandrogenic effects on sex organs (e.g., prostate/seminal vesicles).^[9]Battmann, T., Bonfils, A., Branche, C., Humbert, J., Goubet, F., Teutsch, G., Philibert, D. (1994). RU 58841, A New Specific Topical Antiandrogen: A Candidate of Choice for the Treatment of Acne, … Continue reading These findings supported the premise that RU58841 can act locally within a certain exposure window.

Are the Effects of RU58841 Reversible?

In a separate hamster ear model focused on sebaceous gland size, topical RU58841 (10 µg) reduced sebaceous gland volume by roughly 60% in the treated ear, with no measurable effect on the untreated ear.^[10]Matias, J.R., Gaillard, M. (1995). Local Inhibition Of Sebaceous Gland Growth By Topically Applied RU 58841. Annals of the New York Academy of Sciences. 761. 56-65. Available at: … Continue reading Importantly, gland size returned to its baseline size within approximately four weeks after stopping treatment, showing that RU58841’s local antiandrogenic effects were reversible in this model. Dose-response experiments in this model revealed that more is not necessarily better. Around 3 µg/day was found to be as effective as 100 µg/day in reducing sebaceous gland size, indicating a pharmacologic limit.

At What Point Does “Local” Become Systemic?

In the hamster flank-organ study, when RU58841 was given subcutaneously (to mimic complete systemic exposure), systemic antiandrogen signals emerged at higher doses.^[12]Battmann, T., Bonfils, A., Branche, C., Humbert, J., Goubet, F., Teutsch, G., Philibert, D. (1994). RU 58841, A New Specific Topical Antiandrogen: A Candidate of Choice for the Treatment of Acne, … Continue reading At 300-1000 µg/animal, researchers observed reductions in prostate weight, indicating that systemic antiandrogenic effects can appear once exposure is high enough.

In intact rats, strong androgen-dependent effects were generally absent up to 1 mg/rat regardless of route of administration, but became apparent at 10 mg/rat. Testosterone increases were noted only after subcutaneous dosing at the highest dose. This suggests endocrine feedback can occur when systemic exposure is sufficiently high.

Does RU58841 Regrow Hair in Primate Models?

The most hair-relevant preclinical data for RU58841 comes from studies conducted in stump-tailed macaques.^[14]Obana, N., Chang, C., Uno, H. (1997). Inhibition Of Hair Growth By Testosterone In The Presence Of Dermal Papilla Cells From The Frontal Bald Scalp Of The Postpubertal Stumptailed Macaque. … Continue reading These primate species can develop an androgenic alopecia-like pattern with age, making it a useful, though still not perfect, translational model. 

In these experiments, topical RU58841 was applied to alopecic scalp and produced concentration-dependent improvements in visible hair parameters. A lower concentration (around 0.5%) did not yield impressive results, while a higher concentration (around 5%) produced the strongest regrowth signal over months of treatment.

Reported benefits included increased hair density and hair length. Beyond surface-level changes, the primate work also reported findings that align with meaningful follicle biology improvements, including support for dermal papilla cell growth and evidence consistent with vellus-to-terminal hair conversion.

One particularly notable mechanistic detail from the macaque work is that RU58841 appeared to prevent testosterone-related androgen receptor effects in the dermal papilla. This suggests testosterone may also contribute to miniaturization through androgen receptor signaling, with the androgen receptor acting as a “lynchpin” for both testosterone and DHT in susceptible follicles.

Even so, the macaque evidence has clear constraints. Sample sizes were small, dosing equivalence to human scalp use is uncertain (vehicle, skin barrier, follicular penetration), and the overall pattern suggests benefits are linked to continued treatment rather than a permanent reversal of the underlying process.

Does Normal Blood Testosterone Mean It’s Truly Safe?

The primate experiments reported no meaningful change in circulating testosterone during topical RU58841 treatment. These results are often used as a surrogate for limited systemic exposure, particularly when compared with therapies designed to change systemic androgen levels.

However, unchanged serum hormones do not prove the drug is strictly confined to the scalp. Low-level systemic absorption can still occur without shifting hormone levels, and systemic androgen receptor modulation can theoretically happen even when circulating testosterone/DHT remains normal, especially if active metabolites are involved or if certain tissues are more sensitive. So while these findings are encouraging for safety, they are not definitive proof that effects are strictly confined to the application site. 

Human Evidence: The Missing Link

Two human clinical trials of RU58841 (under the name PSK‑3841) were registered and marked as completed in the early 2000’s. But the interesting thing is that the results from both of these studies have never been published, leaving a critical gap between promising preclinical work and real-world clinical decision-making. 

The unpublished PSK-3841 trials:

• Completion in 2002: A phase I study (ISRCTN49873657) tested a 5% PSK‑3841 solution twice daily for 4 weeks in about 30 men with androgenetic alopecia, with primary endpoints focused on safety, tolerability, endocrine profiles, plus pharmacokinetics.^[16]ISRCTN Registry, (no date), ISRCTN49873657. Available at: https://www.isrctn.com/ISRCTN49873657 (Accessed: 02 January 2026)
• Completion in 2003: A larger, multi‑centre, double‑blind trial (ISRCTN71083772) then treated 120 men for 6 months with 2.5% or 5% PSK‑3841 once daily versus vehicle, measuring total and anagen hair counts, safety, tolerability, and pharmacokinetics.^[17]ISRCTN Registry, (no date), ISRCTN71083772. Available at: https://www.isrctn.com/ISRCTN71083772 (Accessed: 02 January 2026)

The fact that both studies were completed, yet no peer-reviewed results or detailed reports have appeared, is a major red flag. 

For a potentially first-in-class topical antiandrogen with completed phase I and II trials, companies are usually highly motivated to publish positive data. The fact that developers walked away after finishing a 6-month, 120-subject trial, without even a basic efficacy and safety paper, strongly suggests something in the data made the program unattractive to advance. 

Why Unpublished Trials Change the Risk Calculation

Without access to the actual results from these clinical trials, it’s impossible to verify key parameters such as:

• How effective RU58841 was for human hair regrowth
• Types and frequency of any adverse events
• How many participants discontinued using RU58841, and the underlying reasons
• Changes in systemic hormones and sex organs
• Durability of any hair regrowth after stopping treatment 
• Dose-response relationships 

Missing the data from clinical studies forces a dangerous guessing game. Internet anecdotes cannot answer questions that only controlled trials can resolve, like whether rare but serious adverse events occurred, whether endocrine markers shifted subtly over months, or whether regrowth reversed after discontinuation. 

Controlled trials also reveal patterns that never appear in forums, such as subgroup vulnerabilities, time-dependent toxicity, or dose thresholds where benefits collapse into harm. Without these insights, users are effectively self-experimenting with a research chemical that already failed to make it through the regulatory system.

Why Was RU58841 Abandoned?

The short answer is that nobody outside the original development team truly knows why RU58841 was abandoned.

But what we do know is that in pharmaceutical development, it is normal for early-stage compounds to fail.^[18]Sun, D., Gao, W., Hu, H., Zhou, S. (2022). Why 90% Of Clinical Drug Development Fails And How To Improve It? Acta Pharmaceutica Sinica B. 12(7). 3049-3062. Available at: … Continue reading What is not normal is for companies to complete phase I and II trials and then allow all efficacy and safety data to vanish without any peer-reviewed publication, abstract, or regulatory disclosure. 

Once a drug has reached a completed multi-centre, double-blind phase II study, the cost of publishing the results is trivial compared to the tens of millions already spent developing, patenting, manufacturing, and running the trials. Even negative results are typically published or disclosed. 

Let’s examine the three most plausible explanations.

Hypothesis 1: Financial Reasons 

The official explanation given by the companies involved was financial difficulty.

On the surface, this does sound plausible. Drug development is expensive. But when viewed in context, this explanation collapses. RU58841 had already cleared the most expensive hurdles, such as toxicology work, formulation development, and phase I and II human trials. Writing up and submitting those results would have cost a few thousand dollars at most. 

It does not make sense for a company to invest tens of millions into patenting, testing, and completing two human trials, only to stop short of the final, cheapest step. For this reason, financial limitations are the weakest explanation. 

Hypothesis 2: Lack of Efficacy

Another possibility is that RU58841 was not effective for hair regrowth in humans. 

It is actually quite common for companies to bury disappointing studies while only publishing favorable ones. However, when it comes to RU58841, this reason is highly unlikely, mainly due to the consistent anecdotal reports across forums describing visible regrowth and stabilization with RU58841.

While anecdotes cannot replace clinical trials, the volume and consistency of regrowth reports make it unlikely that RU58841 was completely ineffective in humans. If efficacy were truly absent, the enthusiasm around this research chemical would almost certainly not have persisted throughout the past two decades. 

Hypothesis 3: Safety Concerns

This leaves the most plausible explanation, something in the human data made RU58841 commercially or medically unattractive to advance. 

While this hypothesis is speculative, it is supported by several warning signals. Follow-up research on RU58841 reported that at least one of its metabolites possessed strong antiandrogenic activity, undermining the original premise that the drug would only act locally in the scalp.^[19]Cousty-Berlin, D., Bergaud, B., Bruyant, M.C., Battmann, T., Branche, C., Philibert, D. (1994). Preliminary Pharmacokinetics And Metabolism Of Novel Non-Steroidal Antiandrogens In The Rat: Relation … Continue reading If systemically active metabolites were forming in humans, this would fundamentally change the drug’s risk profile. 

Preclinical work also raised more subtle molecular concerns that are rarely discussed online. Some androgen-receptor antagonists can exhibit something called antagonistic-agonism, where compounds designed to block the receptor can, under certain conditions, partially activate it as well.^[20]Miyamoto, H., Yeh, S., Wilding, G., Chang, C. (1998). Promotion Of Agonist Activity Of Antiandrogens By The Androgen Receptor Coactivator, ARA70, In Human Prostate Cancer DU145 Cells. Proceedings of … Continue reading 

This appears to involve androgen-receptor co-activators such as ARA70, which amplify androgen signaling once the receptor complex is transported into the nucleus. In experimental systems, RU58841 showed a mild but measurable ability to enhance androgen-receptor co-activation in wild-type receptors in a dose-dependent manner. ^[21]Miyamoto, H., Yeh, S., Wilding, G., Chang, C. (1998). Promotion Of Agonist Activity Of Antiandrogens By The Androgen Receptor Coactivator, ARA70, In Human Prostate Cancer DU145 Cells. Proceedings of … Continue reading While it remains unknown whether this effect occurs in humans or is clinically meaningful, it represents exactly the type of risk that would make long-term use of a topical antiandrogen far less predictable than originally hoped.

Additionally, it’s worth noting that some people trying RU58841 online have reported chest pain, brain fog, and other issues, such as sexual dysfunction. We have not found credible evidence that these effects are permanent, but their nature is consistent with unintended endocrine or cardiovascular involvement. 

Together, the evidence is quite difficult to ignore. RU58841 may well have been effective for hair regrowth, but a combination of systemically active metabolites, loss of localization in the scalp, and early molecular signals suggesting complex androgen-receptor behavior may have made the drug too risky to advance.

If you’re a member and would like to find out more about these molecular safety mechanisms, click the link here for more details in our RU58841 Ultimate Guide

Final Thoughts

So is RU58841 legit for efficacy? Plausibly yes. Given the preclinical data and sheer volume of regrowth anecdotes, RU58841 does likely block androgen signaling in the scalp.

But is RU58841 legit as a recommended treatment? No. Its safety profile is still a clinical mystery. Its human trials were never published, and the drug was abandoned at a stage where most drugs either move forward or fail. The gap in clinical information changes the entire risk calculation. 

In our opinion, evidence quality and long-term safety hold more weight than exciting anecdotes. 

For individuals who cannot tolerate finasteride, there are topical antiandrogen options with more transparent development histories and human data, including topical fluridil, topical CB-03-03, topical spironolactone, and newer molecules like pyrilutamide that are currently progressing through regulated clinical trials. While none are perfect, they at least exist within a framework of published safety monitoring.

If you’d like to learn more about pyrilutamide, read our article here, which covers all of the publicly available data on pyrilutamide and evaluates its mechanisms of action, efficacy, and safety.

We recommend proceeding with extreme caution when using RU58841, and only use it if you understand and are willing to accept the absence of human safety and efficacy data.

The best practice is to prioritize therapies with published human trials and regulatory oversight. Ultimately, given the lack of safety information and regulatory oversight for RU58841, we recommend erring on the side of caution. 

Minoxidil has been a cornerstone of hair-loss treatment for decades, and there are now more options than ever for users. Alongside traditional topical solutions and foams, low-dose oral minoxidil has emerged as a popular off-label alternative.

Which raises the question: which formulation is the best choice for hair loss? And which option comes with the fewest side effects? In this article, we break down how oral and topical minoxidil compare across mechanisms, evidence, side effects, and real-world use, so you can make an informed decision about which approach fits your hair loss pattern, risk tolerance, and lifestyle.

Interested in Topical Minoxidil?

High-strength topical minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

How Does Minoxidil Work?

Despite being used to treat hair loss for over 40 years, the mechanisms through which minoxidil promotes hair growth are only partially understood. We know that it alters the hair cycle, shortening the resting (telogen) phase so follicles enter the growth (anagen) phase earlier. This increases the number of growing hairs at any one time. It also increases follicle size, which translates into thicker, longer hair shafts.^[1]Messenger, A. G., & Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. *British Journal of Dermatology.* 150(2). 186–194. Available at: … Continue reading

Minoxidil can increase blood flow to hair follicles, which increases the flow of oxygen and nutrients to support growth. The drug is also known to  activate the Wnt/ꞵ-catenin signaling pathway, which supports the growth of cells in the follicle, and provides cytoprotective effects and regulates local inflammation.

In contrast to antiandrogenic drugs like finasteride and dutasteride, minoxidil doesn’t impact hormones.

Before we compare topical and oral treatments, we’ll look at the formulations separately to understand the options available for each.

Topical Minoxidil

Topical minoxidil is designed to work primarily at the scalp, not systemically. After you apply it, only a small fraction of the dose actually penetrates intact skin, and an even smaller fraction reaches the follicle structures where it matters most.

Where it does work is at (or near) the follicle, particularly around the outer root sheath and dermal papilla. That’s why topical minoxidil has a strong safety record: most of the drug never leaves the scalp in meaningful quantities.

Why Some People Respond Better to Topical Minoxidil

Minoxidil relies on activating enzymes to work, most notably sulfotransferase SULT1A1. SULT1A1 activity in the hair follicles is closely linked to how well topical minoxidil works, and people with lower levels of activity tend to see less benefit from treatment.^[3]Pietrauszka, K., & Bergler-Czop, B. (2022). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: … Continue reading

Because minoxidil needs SULT1A1 to work, people with low levels of the enzyme in the hair follicle might not see much improvement from minoxidil (“enzyme low-responders”).

The effectiveness of topical minoxidil also depends on a range of other factors, including the type of formulation, scalp health, contact time, application technique, and the use of penetration enhancers. This is one reason why topical minoxidil performs reliably in clinical trials, but users find results more variable.

Typical Dosing: How Much and How Often?

Most over-the-counter minoxidil is sold in 2% or 5% formulations. 5% generally produces stronger average results and shows higher satisfaction in many studies. It also comes with a slightly higher irritation risk, especially in solution form. As such, 2% formulations are often used when scalp irritation from higher doses is too disruptive, or for milder cases.^[4]Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical … Continue reading

Higher concentrations (7–15%) are also sometimes considered, but they offer diminishing returns for many users and a higher risk of irritation. Because of this, they’re usually reserved for people who don’t respond to standard options and can tolerate the vehicle.

Dosing frequency is about balancing efficacy with adherence: there’s no benefit to be gained from planning a treatment schedule that you can’t stick to.

Twice-daily use is the traditional standard for maximum effect, especially in people using solutions. Once-daily 5% is often good enough for many people, and can dramatically improve adherence, although studies have shown that switching to twice to once daily can slightly worsen outcomes. ^[5]Olsen, E. A., DeLong, E. R., & Weiner, M. S. (1987). Long-term follow-up of men with male pattern baldness treated with topical minoxidil. *Journal of the American Academy of Dermatology.* 16(3). … Continue reading

Similarly, in women, once-daily 5% foam can perform similarly to twice-daily 2% solution while being easier to sustain. Foam formulations are often recommended for women because foam tends to stay localized on the scalp and drip down less onto the face than solutions. This reduces the chance of unwanted facial hair growing as a result of treatment. Evidence also suggests that foam formulations have lower systemic absorption into the bloodstream.^[6]Blume-Peytavi, U., Hillmann, K., Dietz, E., Canfield, D., & Garcia Bartels, N. (2011). A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in … Continue reading,^[7]Gogtay, J. A., & Panda, M. (2009). Minoxidil topical foam: a new kid on the block. *International Journal of Trichology.* 1(2). 142. Available at: https://doi.org/10.4103/0974-7753.58560

Limitations of Topical Minoxidil

Topical minoxidil works, but it requires consistency. Results typically require months of consistent use before they become apparent, and many people struggle to maintain the routine, especially with twice-daily application. 

Absorption of topical solutions can also be inconsistent, and is impacted by scalp condition, contact time, and the type of vehicle used (propylene glycol-based solutions, foams, propylene glycol-free lotions, nanoemulsions, etc.). As such, even with consistent application, results can vary.

The main side effects associated with topical minoxidil are local rather than systemic. Common issues include itching, dryness, flaking, and contact dermatitis, which are often driven by the formulation rather than the drug itself. Many users also find the product cosmetically inconvenient due to a greasy feel, visible residue, or interference with hairstyling, particularly for those with longer hair.^[8]Olsen, E. A., DeLong, E. R., & Weiner, M. S. (1987). Long-term follow-up of men with male pattern baldness treated with topical minoxidil. *Journal of the American Academy of Dermatology.* 16(3). … Continue reading

Evidence for Topical Minoxidil

The use of topical minoxidil is backed up by substantial clinical data showing increased hair counts, density, and coverage in androgenic alopecia (AGA) and other alopecias, with response in a majority but not all patients. We’ll look at evidence from clinical trials involving men and women separately, as they are typically studied in different clinical trials.

Evidence in Men

The earliest significant clinical evidence supporting the use of minoxidil for hair loss is from a 1985 trial, which compared 2% and 3% solutions to placebo in 126 men with early male pattern baldness. They assessed changes in vellus hairs and terminal hairs, an important distinction as vellus hairs are fine, light colored hairs that don’t contribute to the overall appearance of hair thickness.^[9]Olsen, E. A., DeLong, E. R., & Weiner, M. S. (1987). Long-term follow-up of men with male pattern baldness treated with topical minoxidil. *Journal of the American Academy of Dermatology.* 16(3). … Continue reading

They found a significant increase in terminal hair counts in 2% and 3% minoxidil-treated participants, with a greater improvement in the 3% group, though this was not statistically significant. 

The study methodology switched the placebo group to 3% minoxidil after 4 months and showed that the switch increased hair counts. Unfortunately, this means that it’s not possible to assess actual changes in hair count over the 12-month study. Notably, the placebo group also showed increases in hair count during the first 4 months, which might not be expected in men with pattern baldness or AGA and could cast doubt on the hair counts.

Larger trials have been conducted since. A 48 week study compared 2% and 5% solutions to placebo and found approximately 13% and 19% increases in nonvellus hairs respectively, although hair counts did appear to start to drop after week 16.^[10]Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical … Continue reading

Similarly, a Japanese study compared 1% and 5% formulations, and found a 26.4% increase in nonvellus hair count in the 5% topical minoxidil group and 21.2% increase in the 1% group.^[11]Tsuboi, R., Arano, O., Nishikawa, T., Yamada, H., & Katsuoka, K. (2009). Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese … Continue reading

Notably, these trials tend to be relatively short, with many lasting only 16 weeks. Even in these short trials, there is a noticeable drop-off in hair counts after an initial growth boost. Data suggests that topical minoxidil response rates are high in the first 3-6 months, but drop after a year or longer of use. Real-world data show that 86–95% of users discontinue topical minoxidil within one year, most commonly because the results fall short of their expectations for visible cosmetic improvement.^[12]Olsen, E. A., Weiner, M. S., Amara, I. A., & DeLong, E. R. (1990). Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. *Journal of the American Academy of … Continue reading,^[13]Shadi, Z. (2023). Compliance to topical minoxidil and reasons for discontinuation among patients with androgenetic alopecia. *Dermatology and Therapy.* 13(5). 1157–1169. Available at: … Continue reading

If you’re interested in topical minoxidil for men, check out our article on the best products currently available.

Evidence in Women

Most clinical trials evaluating topical minoxidil in women have traditionally used a 2% solution applied twice daily. A meta-analysis, which combines the results from multiple trials found that 2% minoxidil produced an average increase of about 12 hairs per square centimeter compared with placebo after 24 weeks of treatment.^[14]Adil, A., & Godwin, M. (2017). The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. *Journal of the American Academy of Dermatology.* 77(1). … Continue reading

Data also suggest that higher-strength formulations offer similar outcomes: both 5% minoxidil solution used twice daily and 5% minoxidil foam applied once daily have shown no significant difference in efficacy compared with twice-daily 2% solution use.^[15]Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., Savin, R. C., & Tharp, M. D. (2004). A randomized, placebo-controlled trial of 5% and 2% topical minoxidil … Continue reading

As we’ve already noted, foams are often preferred by women as they can potentially limit off-target hair growth. A large, 24-week trial demonstrated that foam minoxidil formulation resulted in 9.1 hairs more per cm2 more than a placebo (foam without minoxidil), with no significant differences in irritation.^[16]Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., Savin, R. C., & Tharp, M. D. (2004). A randomized, placebo-controlled trial of 5% and 2% topical minoxidil … Continue reading

Oral Minoxidil

Unlike topical minoxidil, oral minoxidil is absorbed through the gastrointestinal tract and converted into its active form primarily in the liver, where sulfotransferase activity is abundant. This systemic activation largely bypasses one of the major limitations of topical therapy: variations in follicular enzyme activity. As a result, nearly all ingested minoxidil is activated and made bioavailable, which helps explain why oral formulations can work even in people who do not respond well to topical formulations.

Typical Dosing

Minoxidil was originally developed to treat hypertension, and it is still used for the condition today. Dosage for hair loss is much lower than that for hypertension, and most regimens fall within the low-dose range of 0.25 to 5 mg per day. 

Within this range, efficacy appears to be dose-dependent. In men, doses between 2.5 and 5 mg daily are commonly used and tend to produce the most robust regrowth.^[18]Jaén, P., & Arias-Santiago, S. (n.d.). Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. Available at: … Continue reading,^[19]Jimenez-Cauhe, J., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O. M., Fernandez-Nieto, D., & Vaño-Galvan, S. (2019). Effectiveness and safety of low-dose oral … Continue reading

However, lower doses may still be effective for slowing progression or improving density in milder cases. In women, lower doses (0.25 to 1.25 mg daily) are preferred, as they balance efficacy with a lower risk of unwanted body hair growth and fluid retention.^[20]Gupta, A. K., Bamimore, M. A., Abdel-Qadir, H., Williams, G., Tosti, A., Piguet, V., & Talukder, M. (2025). Low-dose oral minoxidil and associated adverse events: analyses of the FDA Adverse … Continue reading

To find out more about minoxidil dosing, check out our article.

Oral Minoxidil Side Effects

Because oral minoxidil is systemically active, its side effects differ from those of topical formulations. Still, at the low doses used for hair loss, oral minoxidil is generally well tolerated, and most adverse effects are reversible with adjustment or discontinuation.

The most commonly reported side effect is unwanted hair growth outside of the scalp, including on the face and arms.  While this effect is often mild and reversible, it is often more of an issue for women and becomes more likely as the dose increases.^[21]Vañó-Galván, S., Pirmez, R., Hermosa-Gelbard, A., Moreno-Arrones, Ó. M., Saceda-Corralo, D., Rodrigues-Barata, R., Jimenez-Cauhe, J., et al. (2021). Safety of low-dose oral minoxidil for hair … Continue reading

Another relatively common effect is fluid retention, which may present as mild ankle or lower-leg swelling. This occurs because minoxidil is a vasodilator and can promote sodium and water retention. Some patients also report lightheadedness or dizziness, particularly when starting treatment or increasing the dose.

Less commonly, patients may experience palpitations or changes in heart rate. These symptoms are usually short-lasting and improve with dose reduction. Importantly, serious cardiovascular complications are rare at doses of 0.25-5 mg daily and have been reported primarily in higher-dose antihypertensive use or in individuals with underlying heart disease.^[22]Gupta, A. K., Bamimore, M. A., Abdel-Qadir, H., Williams, G., Tosti, A., Piguet, V., & Talukder, M. (2025). Low-dose oral minoxidil and associated adverse events: analyses of the FDA Adverse … Continue reading

 

If you’re concerned about minoxidil side effects, check out our article on 10 ways to reduce them.

Evidence in Men

Multiple studies in men with AGA show consistent increases in total hair count and visible thickening, with reported response rates ranging from roughly 60% at very low doses (0.25 mg) to 90–100% at doses between 2.5 and 5 mg daily over 6-12 months.

The 60% response at 0.25 mg comes from a 2020 retrospective study of 25 men, looking at the effect of very-low-dose minoxidil. While there was a 60% response rate, there wasn’t any meaningful increase in terminal hair count on average.^[24]Pirmez, R., & Salas-Callo, C. I. (2020). Very-low-dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation. *Journal of the American Academy of … Continue reading

At higher doses, response rates are higher, and hair growth is more predictable. A 24-week study using 5 mg minoxidil daily found a 19% increase in hair count. An open-label study using 5 mg minoxidil, without a placebo control, found increases in hair count and improvements in photographic assessment at 12 and 24 weeks. They also found a 19% improvement in hair counts compared to baseline.^[25]Jaén, P., & Arias-Santiago, S. (n.d.). Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. Available at: … Continue reading,^[26]Panchaprateep, R., & Lueangarun, S. (2020). Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global … Continue reading

A retrospective study of only 41 men found a response rate of 90%, though changes were not well quantified.^[27]Jimenez-Cauhe, J., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O. M., Fernandez-Nieto, D., & Vaño-Galvan, S. (2019). Effectiveness and safety of low-dose oral … Continue reading

In these studies, average gains included double-digit percentage increases in hair count and noticeable improvements on global photographic assessment, indicating that oral minoxidil can produce cosmetically relevant changes rather than purely statistical ones.

Evidence in Women

In female pattern hair loss (FPHL), oral minoxidil at doses between 0.25 and 1.25 mg daily has demonstrated efficacy comparable to 5% topical minoxidil, with the added benefit of avoiding scalp irritation. Combination approaches appear particularly promising: studies pairing low-dose oral minoxidil with spironolactone report earlier reductions in shedding and greater density gains than either agent alone, although direct head-to-head comparisons remain limited.^[28]Silva, M. N. E., Ramos, P. M., Silva, M. R., Silva, R. N. E., & Raposo, N. R. B. (2022). Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 … Continue reading,^[29]Sinclair, R. D. (2018). Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. *International Journal of Dermatology.* 57(1). … Continue reading

Oral Minoxidil in Special Populations

Evidence also supports oral minoxidil’s utility in several special populations. In people with diffuse thinning, including chronic telogen effluvium, low-dose oral minoxidil has been associated with reduced shedding and gradual improvements in density over 6–12 months.^[30]Perera, E., & Sinclair, R. (2017). Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study. *F1000Research.* 6. 1650. Available at: … Continue reading

While these studies are largely retrospective and lack placebo controls, the consistency of improvement across patients suggests a real biological effect, especially given minoxidil’s known ability to shorten telogen and promote anagen entry.

In alopecia areata, oral minoxidil alone produces modest response rates, but when added to immunomodulatory agents such as tofacitinib, it appears to substantially enhance regrowth without requiring higher doses of the primary drug.^[31]Wambier, C. G., Craiglow, B. G., & King, B. A. (2021). Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. *Journal of the American Academy of Dermatology.* 85(3). … Continue reading

Oral vs. Topical Minoxidil: Direct Comparison

Due to differences in study design and the range of doses and formulations used, it is difficult to compare the results of studies on oral and topical minoxidil. Luckily, a few trials have compared the two treatment routes directly. 

Comparison Study #1

The only direct comparison of the efficacy of topical and oral minoxidil in men comes from a 2024 randomized placebo-controlled trial comparing a 5 mg oral dose (once daily) and 5% topical formulation (twice daily) for 24 weeks. They found no significant difference between the two formulations in hair, though there was a 20% increase in hair density in the oral group compared to 7% increase in the topical group. Photographic assessment indicated a significantly greater improvement in the oral group at the crown.^[32]Penha, M. A., Miot, H. A., Kasprzak, M., & Ramos, P. M. (2024). Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. *JAMA Dermatology.* 160(6). … Continue reading

There was a higher rate of adverse events in the oral treatment group, though this was largely due to increased hair growth in other parts of the body. Participants taking oral minoxidil experienced significantly more headaches, while the topical group experienced scalp irritation more frequently, as we would expect.

Comparison Study #2

There are more head-to-head comparisons of oral and topical formulations in women. The first direct comparison of oral and topical minoxidil for female-pattern hair loss comes from a 24-week randomized, open comparative study conducted in Brazil. The trial compared low-dose oral minoxidil (1 mg once daily) with topical minoxidil 5% solution applied once daily in women aged 18–65 years.^[33]Ramos, P. M., Melo, D. F., Radwanski, H., Cortez de Almeida, R. F., & Miot, H. A. (2023). Female-pattern hair loss: therapeutic update. *Anais Brasileiros de Dermatologia.* 98. 506–519. … Continue reading

After 24 weeks, terminal hair density increased by 12% in the oral minoxidil group and by 7.2% in the topical group. This difference did not reach statistical significance . Secondary outcomes, including hair density, global photographic assessment by dermatologists, quality-of-life scores, and hair shedding, were also evaluated, with no significant between-group differences reported.

Hypertrichosis (hair growth on other parts of the body) was reported in 27% of the oral group, compared to 4% in the topical group. This lower incidence of adverse events in the oral group in this trial compared to the study #1 is likely due to lower doses used.

Comparison Study #3

In a 6-month trial, both treatment groups demonstrated a statistically significant increase in hair diameter. Again, no significant differences between topical and oral minoxidil were reported. Photographic assessment showed significant improvement in hair densityn the topical minoxidil group, whereas no significant improvement was detected in the oral minoxidil group; however, between-group differences were not statistically significant.^[34]Asilian, A., Farmani, A., & Saber, M. (2024). Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled … Continue reading

Patient satisfaction exceeded 60% in both groups, with no significant difference reported. Both treatments were well tolerated, and no major safety concerns were identified, though two patients in the oral group experienced hypertrichosis on their face and extremities.

Comparison Study #4

Our final study again showed no significant difference between the two groups. This study used lower doses than previously seen: 0.25 mg daily with a topical placebo or topical minoxidil 2% solution with an oral placebo for 9 months.^[36]Vahabi-Amlashi, S., Layegh, P., Kiafar, B., Hoseininezhad, M., Abbaspour, M., Hajebi Khaniki, S., Forouzanfar, M., & Sabeti, V. (2021). A randomized clinical trial on therapeutic effects of 0.25 … Continue reading

In the oral minoxidil group, average hair density increased from 102/cm² to 115/cm² (1.12% increase), while in the topical minoxidil group, hair density increased from 107/cm² to 113/cm² (1.06%). 

These improvements are modest compared to those we have seen previously, likely due to the lower doses used. This is also reflected in the very low incidence of side effects reported.

Meta-Analysis

Meta-analyses compile numerous studies together to see if there are consistent results across different research groups and trials. A recent meta-analysis comparing topical and oral minoxidil found that there was no significant difference between the two approaches.^[37]Fazal, F., Malik, B. H., Malik, H. M., Sabir, B., Mustafa, H., Ahmed, M., Abid, A., Adil, M. L., Shafi, U., & Saad, M. (2025). Can oral minoxidil be the game changer in androgenetic alopecia? A … Continue reading

This finding is apparent in the studies we’ve looked at: there are some cases where oral treatment seems to provide better results, but this is not large or consistent enough to be significant when statistical analyses are performed. 

Given the trend towards greater improvements in oral formulations, it is possible that larger, longer-term studies might find significant differences. However, on an individual basis, these small, population-scale differences are unlikely to be large enough to influence treatment decisions.

Is Topical Minoxidil Safer?

Both formulations are well tolerated across studies, with the most common reported side effect for topical formulations being scalp irritation. We have seen a higher rate of side effects in groups taking oral minoxidil, though this is most commonly due to increased hypertrichosis, which may be more of a concern for women. 

More serious concerns around the use of oral minoxidil are related to cardiovascular events. A large-scale retrospective study assessed the safety of 1404 people taking oral minoxidil at a range of low doses appropriate for hair loss.^[38]Vañó-Galván, S., Pirmez, R., Hermosa-Gelbard, A., Moreno-Arrones, Ó. M., Saceda-Corralo, D., Rodrigues-Barata, R., Jimenez-Cauhe, J., et al. (2021). Safety of low-dose oral minoxidil for hair … Continue reading

Apart from hypertrichosis, adverse events were rare, with lightheadedness reported in 1.7% of participants and tachycardia (fast heart rate) reported in 0.9%. No life‑threatening cardiovascular events were reported.

Therefore, while there is an increased risk of more serious side effects in oral formulations, at the low doses used for hair loss, there is minimal risk of adverse events.

Adherence and Practical Considerations

One of oral minoxidil’s most compelling advantages is its performance in people who do not respond adequately to topical therapy. Because topical minoxidil requires local scalp activation by the sulfotransferase enzyme SULT1A1, and because only a small fraction of applied drug penetrates the skin, many users see limited benefit despite correct use. Oral minoxidil bypasses both of these bottlenecks by being converted to its active sulfate form in the liver and delivered systemically, ensuring uniform exposure to hair follicles across the scalp.

As well as efficacy, there are some other practical considerations that should influence your decisions when comparing oral and topical minoxidil.

Ease of Use

From a day-to-day standpoint, oral and topical minoxidil place very different demands on the user. Oral minoxidil is taken as a pill, usually once daily, or split into morning and evening doses, which makes it largely invisible in daily life. There is no impact on hairstyling, no waiting period before washing, and no concern about residue, odor, or transfer to pillows, clothing, or pets. For many people, this simplicity is the primary reason oral minoxidil feels sustainable.

Topical minoxidil, by contrast, requires direct scalp application once or twice daily, ideally to a dry scalp, with sufficient contact time before washing. Proper use often means parting hair, targeting thinning areas precisely, and tolerating cosmetic downsides such as greasiness, stiffness, or flaking. While none of these steps are difficult in isolation, the cumulative friction can become a barrier over months and years of use.

Cost and Access

Topical minoxidil has a clear accessibility advantage: it is available over the counter in standard 2% and 5% formulations, allowing immediate initiation without a prescription. For many users, this makes topical therapy an easy first-line option. Basic formulations are relatively inexpensive on a monthly basis, especially when purchased in bulk.

Oral minoxidil is prescription-only and used off-label for hair loss. This introduces an additional step and sometimes variability in access depending on region, provider comfort, and insurance coverage. That said, once prescribed, low-dose oral minoxidil is often comparable in cost and, in some cases, less expensive over time than higher-strength or specialty topical formulations.

Who Should Choose What?

Choosing between oral and topical minoxidil isn’t really about which one is “stronger” on paper. Rather, it’s important to consider which one you’re most likely to tolerate and use consistently. 

Who Topical Minoxidil Is Best For

Risk-averse individuals – Topical minoxidil remains the best first-line choice for many people because it offers meaningful benefit with minimal systemic exposure. If you want the lowest-risk long-term approach and are comfortable with scalp application, topical is usually the most conservative starting point.

Cardiovascular contraindications (or uncertainty) – Anyone with a history of cardiovascular disease, kidney issues, fluid retention, low blood pressure, or unexplained palpitations should be cautious with oral minoxidil and involve a clinician if considering it. Topical use is generally preferred in these cases because systemic absorption is far lower and systemic side effects are much less common.

Localized thinning – If hair loss is limited to smaller areas (early crown thinning, mild recession, small patches of miniaturization), topical minoxidil can be a good fit. It allows you to treat targeted regions without committing to systemic exposure, and it can work well when the application is straightforward and consistent.

Who Oral Minoxidil Is Best For

Poor topical responders – If you’ve used topical minoxidil correctly for 6-12 months and seen little to no improvement, oral minoxidil may be a logical next step. Topical therapy can fail even with perfect effort due to low follicular sulfotransferase activity or limited penetration through the scalp barrier. Oral minoxidil bypasses both issues by being activated systemically and delivered more uniformly to follicles.

Diffuse or advanced thinning – Oral minoxidil can be especially appealing when thinning is widespread across the scalp (rather than concentrated at the crown or hairline), because systemic delivery doesn’t depend on targeting specific areas. It also tends to be easier to scale for advanced loss, where topical application becomes time-consuming and difficult to do thoroughly.

Convenience-focused patients – If the routine topical treatment has been a major barrier, or if you experience issues with messiness, residue, or styling disruption, oral minoxidil is often more sustainable. 

Final Thoughts

There isn’t a universally superior option between oral and topical minoxidil; it’s just a matter of different trade-offs. Oral minoxidil tends to produce more consistent regrowth for many users because it avoids the two biggest bottlenecks of topical therapy: variable absorption and variable enzyme activation. The cost of that consistency is higher systemic exposure, which increases the likelihood of side effects like hypertrichosis, fluid retention, dizziness, or palpitations, even if serious complications remain rare at low doses.

Topical minoxidil offers a safer long-term profile, wide accessibility, and decades of clinical data, but its outcomes are more variable in real life. The same factors that make it safe, local delivery, and limited systemic absorption, also limit predictability, especially when adherence slips or the scalp barrier and follicular activation aren’t favorable.

In the end, the best outcomes come from individualized treatment plans that match the patient’s biology, preferences, and ability to stay consistent. Minoxidil can be a powerful tool either way, and the version you can tolerate and actually use is the one most likely to work.

Finasteride and dutasteride are prescription medications that treat androgenic alopecia (AGA) by targeting the hormone pathway that drives follicle miniaturization. Because they share the same core mechanism and have similar effects on hair loss, understanding which treatment is the best choice for you is not straightforward.

In this article, we tackle the questions that come up most often when choosing between finasteride and dutasteride. We’ll break down how they differ biologically, what head-to-head studies really show about regrowth and side effects, and how oral versus topical use changes the equation, so you can make a more informed decision about which option makes sense for your hair loss and your goals.

Interested in Topical Finasteride?

Low-dose & full-strength finasteride available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

What do Finasteride and Dutasteride Actually Do?

AGA is not a sudden shedding event but a slow remodeling of the hair follicle driven by androgen sensitivity. Across repeated hair cycles, susceptible follicles undergo progressive miniaturization: the growth phase (anagen) shortens with each cycle, while the rest phase (telogen) remains the same or lengthens. 

Dihydrotestosterone (DHT) is the key androgen driving follicular miniaturization. An enzyme called 5α‑reductase (5AR) in the hair follicle converts testosterone to DHT. Because DHT is known to drive hair loss progression, many treatments for AGA target 5AR to reduce scalp DHT levels.^[1]Asfour, L., Cranwell, W., & Sinclair, R. (2023). Male androgenetic alopecia. *Endotext [Internet].* Available at: https://www.ncbi.nlm.nih.gov/books/NBK278957/

Both finasteride and dutasteride can decrease levels of DHT in the body. They were originally created to treat a condition called benign prostate hyperplasia (BPH), but have been repurposed for AGA since their impact on hair growth was noticed. While finasteride is approved by the FDA for treating both BPH, dutasteride is approved only for BPH and is therefore used off-label for hair loss.

Type I vs Type II 5α-reductase

Finasteride is an inhibitor of Type II 5AR, which is highly expressed in hair follicles in androgen‑sensitive regions such as the scalp and prostate tissue. Type II is responsible for the conversion of testosterone to DHT inside miniaturizing scalp follicles, directly driving AGA‑related changes.^[2]Makridakis, N., & Reichardt, J. K. V. (2005). Pharmacogenetic analysis of human steroid 5α-reductase type II: comparison of finasteride and dutasteride. *Journal of Molecular Endocrinology.* … Continue reading

Dutasteride is a dual 5AR inhibitor, which means that it blocks Type I 5AR as well as Type II. Type I 5AR plays a more supportive role and is mainly found in sebaceous glands and skin, so it has a less direct impact on scalp follicular miniaturization.^[3]Frye, S. V. (2006). Discovery and clinical development of dutasteride, a potent dual 5α-reductase inhibitor. *Current Topics in Medicinal Chemistry.* 6(5). 405–421. Available at: … Continue reading

Because of this dual action, dutasteride may decrease levels of DHT to a greater extent than finasteride. In fact, studies have shown that dutasteride may decrease DHT by 50% more than finasteride. 

Does that mean that dutasteride is the better option? Not necessarily. Lower DHT doesn’t necessarily translate into improved hair growth. What’s more, side effects associated with decreased DHT, particularly sexual dysfunction, can affect other aspects of health and well-being.

To understand the potential benefits and side effects of finasteride and dutasteride, we’ll dive into the science and studies that can help us make choices about treatment options.

Formulations: Topical or Oral?

It’s important to recognize that there are many different ways both finasteride and dutasteride can be taken. This includes the drug’s concentration, the frequency of administration, and the formulation used.

Oral finasteride and later oral dutasteride were designed to suppress DHT throughout the body, and they remain the most thoroughly studied options for AGA. Oral finasteride is most commonly prescribed at 1mg daily for AGA, while oral dutasteride is typically taken at 0.5mg daily. Some studies have tested a wider range of concentrations to investigate if there are any changes in benefit or risk. 

Topical formulations were introduced later to change the risk profile without affecting the mechanism. Instead of lowering DHT systemically by default, topical finasteride was designed to concentrate drug activity in the scalp while limiting how much reaches the bloodstream.

Topical dutasteride represents the newest and least mature category, but evidence is promising. Because dutasteride is more potent than finasteride, even very low topical concentrations (around 0.01-0.05%) can meaningfully suppress scalp DHT. Importantly, both finasteride and dutasteride can and do enter systemic circulation when applied to the scalp, so safety concerns still need to be addressed.

Which Improves Hair Growth Most?

Because there is a range of treatment options for both finasteride and dutasteride, there is also a web of comparisons we can make when trying to compare the two. First, we’ll compare oral formulations. These are best researched, and there are a number of head-to-head comparison studies we can use to assess their effectiveness. 

Oral Finasteride vs Oral Dutasteride

Here is a summary of the clinical trials that compare oral finasteride and dutasteride treatment directly:

 

	Study Design and Population	Treatments	Impact on DHT	Hair Growth Comparison
Study #1[5]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading	Randomized, placebo-controlled, double-blinded trial. 415 men with male pattern hair loss aged 21-45 years old; 24 weeks.	5 mg finasteride; 0.05, 0.1, 0.5, or 2.5 mg dutasteride; placebo.	Serum DHT was significantly lower at 0.5 and 2.5 mg dutasteride than at 5 mg finasteride. 5mg finasteride decreased scalp DHT by 41%, while 0.5 and 2.5 mg dutasteride decreased it by 51% and 79% respectively.	The proportion of participants with at least a 10% increase in hair counts was 41% for finasteride, and  48%, and 56% for 0.5 and 2.5 mg dutasteride, respectively.
Study #2[6]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading	Randomized, placebo-controlled, double-blinded trial. 917 men with AGA aged 20-50; 24 weeks.	1 mg  finasteride; 0.02, 0.1, or 0.5 mg dutasteride; placebo	Not assessed.	0.5 mg dutasteride significantly improved hair growth compared to 1 mg finasteride.
Study #3[7]Shanshanwal, S. J., & Dhurat, R. S. (2017). Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled … Continue reading	Open-label, randomized study; no placebo control. 90 men with AGA aged 18-40; 24 weeks.	1 mg finasteride; 0.5 mg dutasteride.	Not assessed.	Increase in total hair count was significantly higher in dutasteride compared to finasteride.
Study #4[8]Choi, G.-S., Sim, W.-Y., Kang, H., Huh, C. H., Lee, Y. W., Shantakumar, S., Ho, Y.-F., et al. (2022). Long-term effectiveness and safety of dutasteride versus finasteride in patients with male … Continue reading	Retrospective chart review. 600 men over 18 with AGA.	1 mg finasteride; 0.5 mg dutasteride.	Not assessed.	Dutasteride improved BASP basic M  classification of AGA significantly better than finasteride.

 

These RCTs directly comparing finasteride and dutasteride provide the best insight into their comparative efficacy. We’ll focus on 1 mg finasteride vs. 0.5 mg as these are the most commonly used doses. While these studies differ in design and duration, their findings are consistent across several clinically meaningful outcomes.

Key Takeaways from Trials

• Across head-to-head trials lasting 24 weeks, dutasteride consistently outperforms finasteride in increasing hair counts within a predefined target scalp area.^[9]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading^[10]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading
• Dutasteride also increases average hair shaft thickness more than finasteride 1 mg over 24 weeks.
• In trials that included investigator global photo assessment (GPA) or similar global assessments, dutasteride-treated participants were more likely to be rated as “improved” or “markedly improved” compared with those receiving finasteride.^[11]Choi, G.-S., Sim, W.-Y., Kang, H., Huh, C. H., Lee, Y. W., Shantakumar, S., Ho, Y.-F., et al. (2022). Long-term effectiveness and safety of dutasteride versus finasteride in patients with male … Continue reading

An important limitation to consider when interpreting these trials is the length of the studies. Most head-to-head RCTs run for 24 weeks, which may favor dutasteride if it is faster acting. Finasteride, by contrast, is known from longer studies to continue producing gains for 48 months, with hair counts typically plateauing only after around 2 years.^[12]Price, V. H., Menefee, E., Sanchez, M., & Kaufman, K. D. (2006). Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. … Continue reading

However, long-term data, though mostly retrospective rather than randomized, still suggest sustained superiority of dutasteride on global classification scales.^[13]Choi, G.-S., Sim, W.-Y., Kang, H., Huh, C. H., Lee, Y. W., Shantakumar, S., Ho, Y.-F., et al. (2022). Long-term effectiveness and safety of dutasteride versus finasteride in patients with male … Continue reading

How Big is the Difference in Reality?

On paper, dutasteride often looks clearly superior to finasteride. But translating statistical superiority from randomized trials into real-world expectations requires more nuance. The practical difference between these drugs depends less on averages and more on what kind of hair loss someone has, how fast it’s progressing, and how much regrowth is biologically possible.

Safety & Side Effects: Is Dutasteride Actually Riskier?

Blocking 5AR interferes with hormone activity and is known to cause some side effects. The most frequently discussed effects include:

• Sexual side effects – These include decreased libido, erectile dysfunction, and ejaculation disorders. Across randomized trials, these effects occur in a minority of users (generally in the single-digit percentages), appear most often early in treatment, and frequently resolve spontaneously, even while continuing therapy.^[14]Hirshburg, J. M., Kelsey, P. A., Therrien, C. A., Gavino, A. C., & Reichenberg, J. S. (2016). Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic … Continue reading
• Breast-related effects – Breast tenderness or enlargement has been reported, but rates are low across both drugs and typically comparable between finasteride and dutasteride.
• Other reported effects: Fatigue, mood changes, or nonspecific symptoms are occasionally reported, but these occur inconsistently, lack clear dose–response relationships, and are difficult to separate from background rates and expectation effects.

As we’ve already noted, the dual action of dutasteride could mean that it poses an increased risk of side effects. To see whether the evidence backs this up, we’ll take a look at what randomized trials and retrospective studies tell us about the comparative risks of each treatment. Below is a summary of the head-to-head studies to date.

 

	Average incidence of side effects	Decreased libido	Ejaculation disorders	Erectile dysfunction	Breast enlargement and tenderness
Study #1[15]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading	Finasteride 2.6% vs dutasteride 4.6%	Finasteride – 5 mg: 4%. Dutasteride –  0.1 mg: 3%; 0.5 mg: 1%; 2.5 mg: 13%.	Dutasteride –  0.1 mg: 4%; 0.5 mg: 1%; 2.5 mg: 13%. Finasteride – 5 mg: 1%	Dutasteride –  0.1 mg: 0%; 0.5 mg: 0%; 2.5 mg: 0%. Finasteride – 5 mg: 1%	Not assessed.
Study #2[16]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading	Finasteride 10.0% vs dutasteride 10.0%	Not assessed.	Not assessed.	Not assessed.	Not assessed.
Study #3[17]Shanshanwal, S. J., & Dhurat, R. S. (2017). Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled … Continue reading	Finasteride 13.4% vs dutasteride 11.5%	Finasteride – 1 mg: 6.7%. Dutasteride –  0.02 mg: 8.1%; 0.1 mg: 6.9%; 0.5 mg: 3.3%.	Finasteride – 1 mg: 3.9%. Dutasteride –  0.02 mg: 2.2%; 0.1 mg: 4.8%; 0.5 mg: 3.9%.	Finasteride – 1 mg: 5.6%. Dutasteride –  0.02 mg: 4.3%; 0.1 mg: 3.7%; 0.5 mg: 5.6%.	Finasteride – 1 mg: 0.6%. Dutasteride –  0.02 mg: 0.5%; 0.1 mg: 0.5%; 0.5 mg: 0.6%.
Study #4[18]Choi, G.-S., Sim, W.-Y., Kang, H., Huh, C. H., Lee, Y. W., Shantakumar, S., Ho, Y.-F., et al. (2022). Long-term effectiveness and safety of dutasteride versus finasteride in patients with male … Continue reading	Finasteride 10.5% vs dutasteride 7.6%	Finasteride 0.7% vs dutasteride 1.2%	Not assessed	Finasteride 0% vs dutasteride 0.4%	Not assessed

As we can see, across randomized and controlled studies comparing dutasteride and finasteride, the overall incidence of side effects is similar between the two drugs. When averaged across trials, total reported side effects occur at nearly identical rates (approximately 8-9% for both drugs).

In some studies, finasteride shows equal or higher rates of certain sexual side effects despite producing less DHT suppression. Importantly, these findings hold even when dutasteride reduces serum DHT by an additional 19-23% beyond finasteride and scalp DHT by significantly greater margins. The most closely scrutinized adverse effects, such as reduced libido, erectile dysfunction, and ejaculation disorders, do not follow a clear dose-response pattern with dutasteride.

Why Don’t We See More Side Effects With Dutasteride?

Given that dutasteride suppresses systemic and scalp DHT substantially more than finasteride, the lack of a clear increase in side effects may seem counterintuitive.

DHT reduction alone does not appear to be a reliable predictor of side-effect risk. This suggests that once DHT is reduced beyond a certain threshold, further suppression may not meaningfully increase the likelihood of side effects, particularly if compensatory mechanisms come into play. For example, lowering of DHT below a certain level might activate hormonal mechanisms to redress the balance. Long-term studies further support this idea, showing that side-effect incidence with dutasteride tends to decrease over time rather than accumulate.

Dutasteride’s size and tissue accessibility might also play a role. It has a much higher molecular weight (around 528 daltons) than finasteride (372 daltons), which likely limits its ability to cross the blood–brain barrier. Finasteride, by contrast, is small enough to enter brain tissue more readily. Because androgen metabolism in the brain is implicated in libido and sexual function, a drug that primarily exerts its effects in peripheral tissues may suppress DHT more aggressively without proportionally increasing neurological side effects.

Why do Incidence Estimates Vary?

Reported rates of side effects with finasteride and dutasteride vary widely across studies largely because incidence is highly dependent on study design. The makeup of the participant groups can impact how likely they are to experience side effects. How side effects are defined and recorded can also influence estimates. Some studies rely on spontaneous self-reporting, while others use targeted questionnaires or direct investigator questioning. These different approaches produce different reporting rates.

Psychological and selection factors further complicate interpretation. Participants who expect problems are more likely to notice and report them, even in placebo groups (this is called the nocebo effect). This means the information that participants receive can impact side effects.

How Long-Lasting are Side Effects?

Most randomized controlled trials are short (e.g., 24 weeks), enroll relatively healthy participants, and use structured adverse-event reporting. This means they tend to capture early, transient side effects, while missing longer-term patterns such as spontaneous resolution or adaptation. In contrast, observational and retrospective studies follow broader populations over longer periods but rely on less standardized reporting, which can inflate or obscure true incidence. 

As a result, short-term trials may overestimate persistent risk, while long-term datasets may underrepresent early intolerance.

Where trials discuss the resolution of side effects, one trial reported that around half of affected participants taking dutasteride reported spontaneous resolution of symptoms while continuing treatment.^[19]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading By contrast, finasteride-associated side effects in these trials were less likely to resolve during ongoing treatment, even though many resolved after stopping the drug.

Interested in Oral Dutasteride?

Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Post-Finasteride Syndrome: What to Know

Post-Finasteride Syndrome (PFS) is a term used to describe persistent sexual, cognitive, or mood-related symptoms that continue for months after stopping finasteride. Its existence and prevalence remain highly debated among dermatologists, endocrinologists, and hair loss researchers. 

While some clinicians argue that PFS represents a real, drug-induced condition affecting a very small subset of users, others contend that the available evidence is low quality, heavily confounded by psychological factors, media influence, and the high background rates of sexual dysfunction in adult men.^[20]Traish, A. M. (2020). Post-finasteride syndrome: a surmountable challenge for clinicians. *Fertility and Sterility.* 113(1). 21–50. Available at: https://doi.org/10.1016/j.fertnstert.2019.11.030,^[21]Trüeb, R. M., Régnier, A., Rezende, H. D., & Dias, M. F. R. G. (2019). Post-finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness?. *Skin … Continue reading

Critically, high-quality clinical trials of finasteride did not report persistent side effects after discontinuation, with symptoms resolving within three months in all affected participants.^[22]Shapiro, J., & Kaufman, K. D. (2003). Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). *Journal of Investigative Dermatology Symposium Proceedings.* … Continue reading Claims of PFS largely arise from case reports, small observational studies, and self-reported data, all of which suffer from major limitations such as lack of controls and small sample sizes. 

One important exception is finasteride-induced gynecomastia (enlarged breast tissue in males), which is a well-documented side effect and can persist in a minority of cases even after stopping the drug, demonstrating that long-lasting tissue changes are possible, albeit rare.^[23]Kaplan, S. A., Chung, D. E., Lee, R. K., Scofield, S., & Te, A. E. (2012). A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has … Continue reading

If PFS is real, it is likely extremely rare, plausibly affecting fewer than 1 in 5,000 – 10,000 users. For users, the key takeaway is one of risk context: while persistent side effects cannot be ruled out entirely, their estimated risk appears very low when weighed against the well-established benefits of finasteride for AGA, especially when dosing strategies are used to minimize overall exposure.

Topical Formulations

After oral formulations, the next logical question is whether you can get the same DHT-blocking benefits where it matters most. That’s the core promise of topical finasteride and dutasteride formulations: to localize 5AR inhibition to the scalp and reduce the likelihood of systemic side effects.

The potential for using topical formulations opens up a host of new options for treating AGA. Like oral formulations, topicals can also come in a range of concentrations, but can also be delivered in a range of formulations and solutions, including:

• Solutions and Sprays – Alcohol‑ or hydroalcoholic‑based liquids applied with a dropper, spray, or pipette, sometimes combined with propylene glycol or similar penetration enhancers.
• Gels and Lotions – Semi‑solid preparations designed to increase contact time on the scalp and modulate absorption.
• Nanoparticle and Liposomal Carriers: Research formulations load finasteride or dutasteride into lipid or polymeric nanoparticles or liposomes to target follicular delivery and reduce systemic exposure.

Formulations can also be combined with physical methods, such as microneedling, or with other common pharmaceuticals, like minoxidil. This also means that the decisions we need to make when choosing the right hair loss treatment are more complicated. Again, we’ll focus on head-to-head trials that compare different topical and oral formulations, as well as what clinical studies can tell us about side effects.

Does Topical Finasteride Work?

Based on trials comparing topical dutasteride to other AGA treatments, the answer is a resounding yes. However, the challenge is that finasteride has a highly sensitive, logarithmic dose-response curve. In other words, you don’t need much finasteride in the bloodstream to create a big systemic DHT change. That’s why topical finasteride can still “leak” systemically, and why even small systemic absorption can defeat the original purpose of going topical.

To take a closer look, we’ll first see how topical formulations compare to oral.

Oral vs Topical Finasteride

Several trials directly comparing topical to oral finasteride show that topical treatment can improve target-area hair counts and other hair parameters similarly to oral dosing, while often producing less suppression of serum DHT and far lower measured systemic drug exposure. 

In one Phase III trial, topical finasteride produced hair-count improvements comparable to oral finasteride. What’s more, the oral formulation reduced mean serum DHT by 55.6%,  whereas topical finasteride reduced it by 34.5%, and sexual side effects were more associated with oral treatment.^[24]Piraccini, B. M., Blume-Peytavi, U., Scarci, F., Jansat, J. M., Falqués, M., Otero, R., Tamarit, M. L., et al. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic … Continue reading

Other randomized comparisons similarly report meaningful regrowth with topical finasteride, with most adverse events being local (irritation) and relatively few systemic complaints.^[25]Hajheydari, Z., Akbari, J., Saeedi, M., & Shokoohi, L. (2009). Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. *Indian Journal of … Continue reading

However, even at lower concentrations, topical finasteride can reduce serum DHT depending on how much you apply and how often you apply it. For example, one versus two daily applications of the same topical concentration can produce dramatically different serum DHT suppression, illustrating that frequency and volume can matter as much as concentration.^[26]Caserini, M., Radicioni, M., Leuratti, C., Annoni, O., & Palmieri, R. (2014). A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen … Continue reading

What Determines Systemic Absorption?

There are a few key factors that impact absorption:

1. Vehicle/carrier – Alcohol- and propylene glycol–based carriers tend to enhance penetration. Stronger penetration can improve scalp delivery, but it can also increase systemic leakage.
2. Amount applied per use – This is often the most overlooked variable. Two people using the same concentration can have totally different systemic exposure if one applies 0.5 mL and the other applies 2 mL.
3. Frequency of application – Twice-daily use can more than double systemic effects compared to once-daily use in certain protocols.

Does Topical Dutasteride Work?

Topical dutasteride research is newer and still developing, but early findings are encouraging. The current literature suggests that topical dutasteride can meaningfully improve hair density and shaft caliber while producing minimal changes in serum DHT. 

A randomized, placebo-controlled trial in 34 men found that microneedling plus 0.01% topical dutasteride produced significant improvements in hair thickness, density, and the vellus-to-terminal ratio, compared with microneedling plus saline.^[28]Sánchez-Meza, E., Ocampo-Candiani, J., Gómez-Flores, M., Herz-Ruelas, M. E., Ocampo-Garza, J., Orizaga-y-Quiroga, T. L., Martínez-Moreno, A., & Ocampo-Garza, S. S. (2022). Microneedling plus … Continue reading

This is only a proof-of-concept study with a small sample size. However, it does demonstrate that topical dutasteride can drive clinically meaningful changes when follicular delivery is boostedby microneedling. But it also limits generalizability: microneedling itself is an active intervention, and it may not reflect what happens with topical dutasteride alone.

A newer Phase II trial tested 0.01%, 0.02%, and 0.05% topical dutasteride and reported dose-dependent improvements in total hair count and hair width versus placebo.^[29]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., Kssvv, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo- and active-controlled phase II study … Continue reading

The authors also reported that 0.05% appeared to outperform oral finasteride in total hair count. That’s an attention-grabbing claim, but it should be interpreted cautiously. Unusually high baseline counts and possible inconsistencies in target-area placement, which could inflate apparent differences, raise concerns about the methodology used.

A common objection is that dutasteride is too large to penetrate the skin well. At around 528.5 Daltons, it sits slightly above the widely cited 500 Dalton rule, which suggests that larger molecules struggle to cross the stratum corneum. In practice, dutasteride appears capable of penetrating the scalp, as it can suppress DHT and promote hair growth. 

Combination strategies: where topical regimens often perform best

Topical regimens tend to perform best when they’re used alongside other treatments, rather than as a single agent. DHT drives miniaturization, but follicular stimulation, blood-flow signaling, and wound-healing pathways all influence whether a follicle can thicken and re-enter robust growth. 

Microneedling consistently appears in the literature as an accelerator of topical outcomes. Controlled micro-injury activates wound-healing signals that can independently improve density and shaft diameter, while also enhancing follicular penetration and local drug exposure. 

Combination with other treatments, primarily minoxidil, can also improve outcomes. The underlying logic is straightforward: minoxidil boosts growth, while dual 5AR blockade increases the probability that follicles remain protected from hormonal changes.

One study showed that adding microneedling to topical finasteride therapy alongside minoxidil can increase hair density and shaft diameter more than minoxidil alone.^[31]Chang, Y., Zhang, W., Zhou, J., Lv, L., He, Q., Chen, Y., Wang, P., & Zhai, Q. (2025). Clinical efficacy of microneedle combined with 5% minoxidil solution and finasteride in the treatment of … Continue reading

Similarly, combining dutasteride with microneedling and minoxidil has also demonstrated promising results. In a small study, all patients used topical minoxidil 5%, while adding dutasteride, either systemically or locally, significantly improved hair density and shaft caliber compared with minoxidil alone. The strongest overall results were seen with topical dutasteride 0.02% delivered via monthly microneedling, which outperformed oral dutasteride plus minoxidil on objective measures while maintaining a more favorable safety profile.^[32]Abu Obeid, M. N., Abdel Fattah, N. S., Elfangary, M. M., & Al Husseni, R. M. (2024). Comparison between topical minoxidil 5% alone versus combined with dutasteride (topical 0.02% through … Continue reading

Overall, the evidence suggests that topical regimens may be most effective when they combine anti-androgen suppression, follicular stimulation, and delivery-enhancing strategies.

Interested in Topical Dutasteride?

Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Dosing

Choosing the right dose depends on both the medication and the clinical context. Finasteride, whether oral or topical, is generally the best starting point for most men beginning pharmacologic treatment for androgenetic alopecia. Its pharmacokinetics are more forgiving, dose adjustments are easier, and when side effects occur, they are often manageable with modest reductions in dose or changes in dosing frequency.

Dutasteride, in contrast, is better suited for men with aggressive, fast-progressing AGA or for those who have not responded well to finasteride. Its greater potency comes with less flexibility, largely due to its long half-life and sustained enzyme binding. As a result, dosing with dutasteride should be conservative and deliberate, with careful consideration of long-term exposure and tolerability.

Oral Finasteride

The standard dose of oral finasteride for androgenetic alopecia is 1 mg once daily. This regimen has been used in the majority of randomized controlled trials and has consistently demonstrated improvements in key hair growth outcomes, including hair counts, hair shaft caliber, and investigator global photographic assessments.

A key pharmacologic feature of finasteride is its logarithmic dose–response curve. Most of the drug’s DHT-lowering effect occurs at relatively low doses, and by the time a daily dose of 1 mg is reached, inhibition of type II 5-alpha reductase is already close to maximal.

This explains why lower doses, such as 0.2–0.5 mg daily, can still meaningfully suppress both serum and scalp DHT, and why increasing the dose beyond 1 mg does not lead to proportionally greater hair regrowth. Instead, higher doses primarily increase systemic exposure and may raise the risk of side effects without offering additional cosmetic benefit.

From a practical standpoint, this dose–response relationship allows for flexibility in real-world use. Many individuals are able to maintain hair stabilization and regrowth with reduced dosing or alternate-day schedules, particularly after an initial period of stabilization. 

When side effects do occur, they also tend to be dose-sensitive rather than all-or-nothing, meaning that lowering the dose or adjusting the dosing schedule is often sufficient to improve tolerability while preserving therapeutic benefit.

Oral Dutasteride

The standard oral dose of dutasteride for androgenetic alopecia is 0.5 mg once daily. This is the dose most consistently studied in clinical trials and the dose used in nearly all head-to-head comparisons with finasteride. 

The reason dutasteride is prescribed at a lower milligram dose than finasteride comes down to its greater pharmacologic potency. Dutasteride’s pharmacokinetics are also different. The drug has a longer half-life (roughly 4–5 weeks), which means it accumulates in tissues over time.^[33]Arif, T., Dorjay, K., Adil, M., & Sami, M. (2017). Dutasteride in androgenetic alopecia: an update. *Current Clinical Pharmacology.* 12(1). 31–35. Available at: … Continue reading 

Because of this, missed doses tend to matter less for maintaining efficacy. However, the flip side is that if adverse effects occur, they may take weeks to months to fully resolve after discontinuation, as the drug slowly clears from the body.

These properties have important practical implications for dosing. Daily dosing is not always necessary to maintain clinical benefit, and some clinicians employ intermittent schedules, such as 0.5 mg taken two to three times per week, in an effort to balance efficacy with tolerability. 

Topical Finasteride

Topical finasteride dosing is often misunderstood because the percentage concentration listed on the label is not the most important variable. What ultimately determines both efficacy and systemic risk is total daily finasteride exposure, measured in milligrams per day. 

This total exposure is shaped by several interacting factors: the concentration of finasteride in the solution, the volume applied per use, how often it is applied (once versus twice daily), and the vehicle or carrier used, such as alcohol or propylene glycol, which influences skin penetration.

The key principle underlying topical finasteride dosing is that finasteride is extremely potent systemically. Only a very small fraction of the drug needs to enter circulation to meaningfully suppress serum DHT. As a result, topical formulations can unintentionally behave like oral finasteride if dosing is too aggressive, even when the product is intended to act locally on the scalp.

An evidence-informed dosing range is 1-2 mL of a 0.005%-0.02% topical finasteride solution applied once daily. This corresponds to roughly 0.1-0.2 mg of finasteride applied to the scalp per day, with estimated systemic exposure in common carriers of approximately 0.01-0.03 mg per day. 

Generally, high-concentration formulations (≥0.25-1%) should be avoided, especially when combined with large application volumes or twice-daily use. These regimens can suppress serum DHT to a degree similar to 1 mg of oral finasteride, effectively defeating the purpose of choosing a topical formulation in the first place.

Topical Dutasteride

Topical dutasteride dosing is less standardized than topical finasteride, largely because the evidence base is newer and consists of fewer clinical trials. That said, several consistent patterns are beginning to emerge from the available data. 

Most studies have evaluated topical dutasteride in a concentration range of 0.01% to 0.05%, typically applied once daily. In many protocols, topical dutasteride has been paired with microneedling to enhance follicular delivery, although some studies suggest that meaningful efficacy can be achieved even without microneedling.^[34]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., Kssvv, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo- and active-controlled phase II study … Continue reading

The practical takeaway is that low-concentration, low-volume topical dutasteride protocols appear to offer the best balance between efficacy and safety. Given the variability in formulations, vehicles, and individual skin permeability, optimal dosing is likely individualized, and careful titration remains essential as the clinical evidence continues to evolve.

Monitoring & Risk Management

Monitoring and risk management with finasteride or dutasteride are about using the minimum effective exposure while staying alert to tolerability over time. Ideally, treatment begins with a clear diagnosis of androgenetic alopecia, baseline photos, and, especially for topical or risk-averse users, optional baseline serum DHT testing to provide context for future changes. 

Side effects, if they occur, should be addressed early with dose reduction, spacing doses, or switching delivery routes rather than abrupt discontinuation, since most are dose-sensitive and reversible. For topical users, repeat serum DHT testing after ~30 days can help confirm that systemic exposure remains low. 

Ongoing monitoring should focus on objective progress via standardized photos every 3–6 months and general symptom awareness rather than day-to-day fluctuations. 

Extra caution is warranted with dutasteride due to its long half-life and accumulation, making conservative dosing and deliberate adjustments especially important. When approached with planned checkpoints and proportional responses, both drugs can be used safely, predictably, and effectively over the long term.

Who Should Use Finasteride or Dutasteride?

Finasteride and dutasteride are among the most effective pharmacologic options for AGA, but they are not one-size-fits-all treatments. Choosing which drug to use depends on hair-loss pattern, rate of progression, prior treatment response, side-effect tolerance, and long-term goals.

Both drugs require consistent, long-term use to maintain results. Candidates should be comfortable with ongoing therapy and realistic timelines, as visible improvements often take 6-12 months, with maximal benefits closer to two years.

Consider Finasteride If…

You’re starting treatment, or your AGA is early-to-moderate. Oral finasteride is the usual baseline because it’s effective for most men and has a long track record. It’s also more forgiving: if you need to adjust dose, frequency, or route due to side effects, finasteride is generally easier to fine-tune.

If you’re risk-averse or simply want the most studied on-label option for hair loss, finasteride is usually the logical starting point, especially if you can commit to consistent use and track progress with photos over months.

Consider Dutasteride If…

Your hair loss is aggressive, or you’re losing ground despite finasteride. Dutasteride’s broader 5AR inhibition often translates into greater average gains in hair counts and thickness in shorter head-to-head trials. Clinically, it’s most often considered when progression is rapid, miniaturization is extensive, or finasteride hasn’t provided adequate stabilization after a consistent trial.

Who Should be Cautious (or Avoid)?

Men without androgenetic alopecia – Finasteride and dutasteride are ineffective for conditions such as alopecia areata, telogen effluvium, traction alopecia, or scarring alopecias. Using them in these contexts adds risk without meaningful benefit.

Those highly risk-averse to hormonal manipulation – While most users tolerate these medications well, anyone uncomfortable with altering systemic hormone levels, even at low risk, may prefer non-hormonal options or topical-only approaches with careful dosing.

Men who experienced significant adverse effects previously – Dutasteride may be more appropriate for men with rapid progression, extensive miniaturization, or those who continue to lose ground despite consistent finasteride use. Its stronger and broader DHT suppression can provide an additional margin of control in these cases.

Men trying to conceive in the near term – Although evidence of fertility harm at hair-loss doses is limited, many clinicians advise avoiding systemic 5AR inhibitors when actively trying to conceive, particularly dutasteride due to its long half-life. This decision should be individualized and discussed with a clinician.

Those unable to maintain consistency – Oral therapies require daily (or structured intermittent) dosing, while topical therapies demand regular application and attention to volume and frequency. If adherence is unlikely, expected benefits drop substantially.

Final Thoughts and Takeaways

Finasteride and dutasteride, in their different formulations, are not competing “good vs bad” options. Instead, they are different tools for different stages and severities of androgenetic alopecia. 

The real decision isn’t which drug suppresses more DHT on paper, but how much suppression you need to control your hair loss, and how much systemic exposure you’re comfortable carrying long term.

Finasteride has the longest safety record, strong long-term efficacy, and a forgiving dose–response curve that allows real-world flexibility. For early-to-moderate AGA, or for men prioritizing reversibility and adjustability, finasteride, either oral or carefully dosed topical, covers the majority of clinical needs.

When hair loss is aggressive, rapidly progressive, or insufficiently controlled on finasteride, dutasteride’s broader 5AR inhibition offers a higher ceiling of protection. Head-to-head trials consistently show greater average gains, and it does not show a clearly higher overall incidence of side effects in controlled studies despite stronger systemic and scalp DHT reduction.

Topical vs oral delivery, total daily exposure, application volume, and frequency often have a larger impact on outcomes and tolerability than the finasteride-vs-dutasteride label alone. Hair loss therapy is a long game. The optimal choice is not the strongest drug you can tolerate for a few months, but the strategy you can follow consistently for years with acceptable trade-offs.

Finasteride is one of the most effective and widely studied treatments for androgenic alopecia (AGA). It works by lowering dihydrotestosterone (DHT) levels at the scalp to slow or halt androgen-driven hair follicle miniaturization. While most men tolerate finasteride well and experience meaningful, long-term hair preservation, side effects can occur in a minority of users and are a legitimate concern for anyone considering or already using the medication.

Importantly, tolerance to finasteride varies from person to person. Factors such as baseline hormone levels, genetics, lifestyle, and overall health can influence how an individual responds. The goal of this article is to outline practical, evidence-informed strategies to help manage or reduce side effects, enabling thoughtful, safe decisions about finasteride use with appropriate medical guidance.

Interested in Topical Finasteride?

Low-dose & full-strength finasteride available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Common Finasteride Side Effects

Sexual side effects, such as decreased libido, erectile dysfunction, and ejaculation disorders, occur in a small minority of users. They are most commonly reported early in treatment and often improve or resolve on their own.^[1]Hirshburg, J. M., Kelsey, P. A., Therrien, C. A., Gavino, A. C., & Reichenberg, J. S. (2016). Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic … Continue reading

Breast tenderness and enlargement (gynecomastia) are sometimes reported. Gynecomastia in particular is well-documented and can persist in a minority of cases even after stopping the drug.^[2]Kaplan, S. A., Chung, D. E., Lee, R. K., Scofield, S., & Te, A. E. (2012). A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has … Continue reading

Some men report cognitive symptoms while taking finasteride, most commonly described as “brain fog” or reduced mental clarity, but these complaints have not been observed at meaningful rates in controlled clinical trials. If such effects occur, they are likely subtle and gradual, which may make them difficult to quantify or consistently attribute to the medication

There is a small number of cases where sexual, cognitive, or mood-related symptoms have persisted, leading to the development of the term post-finasteride syndrome (PFS). 

PFS remains controversial: some clinicians consider it a genuine but extremely rare drug-related condition, while others argue that existing evidence is low quality and heavily confounded by psychological factors, reporting bias, and the high baseline prevalence of sexual dysfunction in men.^[3]Traish, A. M. (2020). Post-finasteride syndrome: a surmountable challenge for clinicians. *Fertility and Sterility.* 113(1). 21–50. Available at: https://doi.org/10.1016/j.fertnstert.2019.11.030,^[4]Trüeb, R. M., Régnier, A., Rezende, H. D., & Dias, M. F. R. G. (2019). Post-finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness?. *Skin … Continue reading

Interested in Topical Finasteride?

Low-dose & full-strength finasteride available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

How common are side effects? 

It’s important to remember that the majority of men who use finasteride experience no noticeable side effects, 

In the original large, randomized, placebo-controlled trial that led to FDA approval for AGA, sexual side effects were reported in about 4.2% of men taking finasteride versus 2.2% on placebo in the first year. This suggests a small absolute risk, and participants in the study who stopped taking finasteride due to side effects reported that they did not persist after the medication was discontinued.^[5]Kaufman, K. D., Olsen, E. A., Whiting, D., Savin, R., DeVillez, R., Bergfeld, W., Price, V. H., et al. (1998). Finasteride in the treatment of men with androgenetic alopecia. *Journal of the American … Continue reading 

In other trials, rates vary widely across studies depending on study design, definitions, and participant expectations.

Higher rates seen in some studies appear to be strongly influenced by the nocebo effect, where awareness of potential side effects increases reporting. More conservative analyses estimate that up to 10-15% of users may experience some form of sexual symptoms, most of which are mild, transient, and reversible.^[6]Traish, A. M., Hassani, J., Guay, A. T., Zitzmann, M., & Hansen, M. L. (2011). Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and … Continue reading

The Most Important Rule: Speak to a Physician

If you get severe side effects, stop and speak to your primary care physician.

Early evaluation helps rule out other medical, hormonal, or psychological contributors, establishes whether symptoms are plausibly related to finasteride, and prevents unnecessary continuation of treatment when modification or discontinuation is appropriate.

Prompt medical guidance also ensures that side effects are documented and managed correctly, rather than being compounded by anxiety, misinformation, or unsupervised dose changes. The strategies outlined below apply only to mild or moderate symptoms, should be considered only under clinician supervision, and are not appropriate for severe, rapidly worsening, or distressing effects, which warrant immediate medical review.

With that in mind, we can now look at ways to reduce the side effects of finasteride.

1. Continue Treatment and Allow Time for Adaptation (When Symptoms Are Mild)

One of the most consistently observed patterns with finasteride and other 5α-Reductase (5AR) inhibitors is that many reported side effects improve or resolve with continued use, particularly when they are mild and occur early in treatment. 

Clinical trials and follow-up data also suggest the side effects are most common in the first 12 months. This pattern supports the idea that early side effects often reflect a transient adjustment phase rather than a permanent intolerance.^[7]Lowe, F. C., McConnell, J. D., Hudson, P. B., Romas, N. A., Boake, R., Lieber, M., Elhilali, M., et al. (2003). Long-term 6-year experience with finasteride in patients with benign prostatic … Continue reading,^[8]Hudson, P. B., Boake, R., Trachtenberg, J., Romas, N. A., Rosenblatt, S., Narayan, P., Geller, J., et al. (1999). Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia … Continue reading

Several biological mechanisms may explain this improvement. Androgen receptors and downstream hormone signaling can adapt to reduced DHT levels, central nervous system sensitivity to hormonal shifts may normalize, and early symptoms may be amplified by anxiety or expectancy effects that lessen with reassurance and time.

2. Reduce the Daily Dose

The standard dose of finasteride for AGA is 1 mg once daily, a regimen supported by large randomized controlled trials showing clear improvements in hair count, hair shaft thickness, and global photographic assessments. 

However, a key pharmacologic feature of finasteride is its non-linear (logarithmic) dose–response curve, meaning that most of its DHT–lowering effect occurs at relatively low doses.

By the time a daily dose of 1 mg is reached, inhibition of 5AR is already near maximal. As a result, lower doses, such as 0.2–0.5 mg daily, can still meaningfully suppress serum and scalp DHT, often preserving much of finasteride’s hair-protective benefit. ^[9]Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W. P., Cotterill, P. C., Thiboutot, D. M., et al. (1999). The effects of finasteride on scalp skin and serum androgen levels in men with … Continue reading

Increasing the dose beyond 1 mg does not produce proportionally greater hair regrowth, but instead primarily increases systemic exposure, which may raise the likelihood of side effects without additional cosmetic gain.

From a practical standpoint, this dose–response relationship allows for flexibility in real-world use. Because finasteride side effects tend to be dose-sensitive rather than all-or-nothing, reducing the daily dose is often an effective first adjustment for improving tolerability while maintaining therapeutic efficacy.

3. Reduce Dosing Frequency

Finasteride’s pharmacology also allows for flexibility in dosing frequency. The drug binds tightly to 5AR, and suppression of DHT persists well beyond the drug’s short plasma half-life.^[10]National Center for Biotechnology Information. (n.d.). Finasteride. *NCBI Bookshelf.* Available at: https://www.ncbi.nlm.nih.gov/books/NBK513329/ (Accessed: November 2025),^[11]Steiner, J. F. (1996). Clinical pharmacokinetics and pharmacodynamics of finasteride. *Clinical Pharmacokinetics.* 30(1). 16–27. Available at: https://doi.org/10.2165/00003088-199630010-00002 In practical terms, this means that daily dosing is not strictly required to maintain meaningful inhibition of scalp DHT once steady-state suppression has been achieved.

Common clinician-guided intermittent regimens include 1 mg three times per week or 0.5 mg every other day, both of which can significantly reduce cumulative drug exposure while preserving much of finasteride’s therapeutic effect. Because DHT levels recover gradually rather than immediately, these schedules often maintain adequate androgen suppression for hair stabilization.

Intermittent dosing may be especially helpful for men who develop mild side effects on daily therapy, those who are particularly sensitive to hormonal changes, or individuals transitioning into a long-term maintenance phase after initial hair loss control.

If you want to understand more about finasteride dosing, you can read our in-depth article here.

4. Switch to Topical Finasteride

Topical finasteride is designed to reduce DHT locally within the scalp while limiting systemic exposure, making it an attractive option for men who experience side effects with oral therapy. By delivering the drug directly to the scalp, topical formulations aim to suppress DHT activity in hair follicles without relying on sustained systemic circulation.

Randomized trials comparing topical and oral finasteride show that topical treatment can produce similar improvements in target-area hair counts and other hair growth parameters, while generally causing less suppression of serum DHT and lower measured systemic drug levels.^[13]Hajheydari, Z., Akbari, J., Saeedi, M., & Shokoohi, L. (2009). Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. *Indian Journal of … Continue reading

One trial demonstrated that topical finasteride reduced DHT in the blood by 34.5%, compared to 55.6% with oral finasteride. They also found that sexual side effects were more associated with oral treatment.^[14]Piraccini, B. M., Blume-Peytavi, U., Scarci, F., Jansat, J. M., Falqués, M., Otero, R., Tamarit, M. L., et al. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic … Continue reading

That said, finasteride’s highly sensitive, logarithmic dose–response curve means that even small amounts entering the bloodstream can suppress DHT. Total systemic exposure depends not only on concentration, but also on application volume, frequency, treated surface area, and formulation vehicle. 

As such, topical treatments also require care when applying, and success with topical finasteride depends on consistent, measured application and adherence to the prescribed regimen.

When used thoughtfully, topical finasteride can preserve much of the hair benefit of oral therapy while reducing the risk of systemic side effects for many men.

Find out more about topical finasteride in our article.

5. Use Ultra–Low-Dose Topical Finasteride

As we’ve already seen, even low doses of finasteride can have a significant impact on hair growth. For men who are particularly sensitive to finasteride or who experience side effects even with standard topical formulations, ultra–low-dose topical finasteride may offer a further risk-reduction strategy.

These formulations typically use very low concentrations (e.g., 0.005%), aiming to provide localized scalp DHT suppression while minimizing systemic exposure as much as possible. Supporting this strategy, a small clinical study of 0.005% alcohol-based topical finasteride found appreciable changes in serum DHT levels, indicating little-to-no systemic absorption. Despite minimal systemic exposure, participants still experienced meaningful hair growth outcomes, suggesting that even ultra-low topical doses can be effective at the scalp level.^[15]Mazzarella, G. F., Loconsole, G. F., Cammisa, G. A., Mastrolonardo, G. M., & Vena, G. A. (1997). Topical finasteride in the treatment of androgenic alopecia: preliminary evaluations after a … Continue reading

Ultra–low-dose topical finasteride has not been studied extensively in large randomized controlled trials. Observationally, many users report improved tolerability and stable hair outcomes, but responses are variable, and efficacy may be more modest than with higher doses.

Interested in Topical Finasteride?

Low-dose & full-strength finasteride available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

6. Use PDE5 Inhibitors to Address Sexual Side Effects

For men who develop erectile dysfunction while using finasteride, PDE5 inhibitors (such as sildenafil or tadalafil) can be an effective symptom-management option. These medications are well studied in urology, including in men treated with 5AR inhibitors for benign prostatic hyperplasia (BPH).^[16]Casabé, A., Roehrborn, C. G., Da Pozzo, L. F., Zepeda, S., Henderson, R. J., Sorsaburu, S., Henneges, C., Wong, D. G., & Viktrup, L. (2014). Efficacy and safety of the coadministration of … Continue reading

In that setting, PDE5 inhibitors have consistently been shown to improve erectile performance and sexual confidence, even when the underlying hormonal environment is altered.

It’s important to be clear about what this strategy does (and doesn’t) do. PDE5 inhibitors do not reverse DHT suppression or directly address libido changes or ejaculatory volume in the same way they may improve erectile rigidity. However, for many men, symptom relief can meaningfully reduce distress and help prevent performance anxiety from amplifying the problem.

Because PDE5 inhibitors are prescription medications with cardiovascular considerations and potential drug interactions, they should be used only under clinician supervision, particularly in men with heart disease, low blood pressure, or those taking nitrates or certain alpha-blockers.^[17]Lui, J. L., Shaw, N. M., Abbasi, B., Hakam, N., & Breyer, B. N. (2023). Adverse reactions of PDE5 inhibitors: an analysis of the World Health Organization pharmacovigilance database. *Andrology.* … Continue reading

7. Optimize Testosterone

Testosterone plays a vital role in sexual health and, like finasteride, is associated with a wide range of symptoms. Reduced libido, erectile changes, fatigue, or low mood overlap significantly with those of hypogonadism, thyroid dysfunction, or other hormonal imbalances.^[18]National Center for Biotechnology Information. (n.d.). Dutasteride. *NCBI Bookshelf.* Available at: https://www.ncbi.nlm.nih.gov/books/NBK532933/ (Accessed: November 2025)

Improving total and free testosterone levels through lifestyle changes or medical treatment when indicated can therefore restore androgen balance and reduce the relative impact of DHT suppression in sensitive individuals.

In select cases, testosterone replacement therapy (TRT) may be considered, but only with careful specialist oversight. TRT can improve sexual function, energy, and quality of life, yet it may also accelerate AGA unless combined thoughtfully with hair-loss treatments.^[19]Zhang, Y., Xu, J., Jing, J., Wu, X., & Lv, Z. (2018). Serum levels of androgen-associated hormones are correlated with curative effect in androgenic alopecia in young men. *Medical Science … Continue reading For these reasons, TRT should never be initiated solely to counter finasteride side effects without a clear medical diagnosis and a comprehensive discussion of risks, benefits, and long-term goals.

8. Review Diet, Lifestyle, and Environmental Factors

While lifestyle changes cannot reverse finasteride’s pharmacologic action on DHT, they can meaningfully improve erectile function, mood, energy levels, sleep quality, and overall androgen balance, all of which overlap with the most commonly reported finasteride-related complaints.

A wide body of evidence shows that diet, exercise, and weight management play a significant role in sexual function. Randomized trials demonstrate that intensive lifestyle programs can significantly improve erectile function, with a meaningful proportion of men regaining normal erectile performance over time.^[20]Esposito, K., Giugliano, F., Di Palo, C., Giugliano, G., Marfella, R., D’Andrea, F., D’Armiento, M., & Giugliano, D. (2004). Effect of lifestyle changes on erectile dysfunction in obese men: … Continue reading,^[21]Hehemann, M. C., & Kashanian, J. A. (2016). Can lifestyle modification affect men’s erectile function?. *Translational Andrology and Urology.* 5(2). 187. Available at: … Continue reading

Environmental and behavioral factors can also be reviewed. Excessive heat exposure (such as frequent sauna use), high alcohol intake, cannabis use, and certain medications (including antidepressants) can independently impair sexual function or mood and may confound the interpretation of finasteride-related symptoms.

Although no studies have looked specifically at lifestyle programs for finasteride side effects, strong evidence shows that improving fitness, diet, sleep, and stress can enhance the same areas (erectile function, mood, energy, and hormone balance) that many men find most affected.

9. Consider Experimental or Adjunctive Supplements (With Caution)

Some men explore supplements marketed for testosterone support or sexual function, such as tongkat ali, in an effort to counter finasteride-related symptoms. Small studies suggest that tongkat ali may modestly increase testosterone or improve libido in certain populations, but the evidence is limited, inconsistent, and highly variable between individuals.^[22]Leisegang, K., Finelli, R., Sikka, S. C., & Selvam, M. K. P. (2022). Eurycoma longifolia (jack) improves serum total testosterone in men: a systematic review and meta-analysis of clinical trials. … Continue reading

It’s critical to remember these supplements are experimental, not first-line solutions. Product quality, dosing, and purity can vary widely, and robust data on long-term safety or interactions with finasteride are lacking. While some individuals report subjective benefit, others notice no effect at all.

For these reasons, supplements should only be considered after established strategies have been explored and ideally discussed with a clinician, rather than relied upon as a primary way to manage side effects.

10. Switch Treatments or Change Strategy Entirely

If side effects persist despite adjustments to dose, frequency, or formulation, it may be appropriate to change strategies altogether. Hair loss treatment is not all-or-nothing, and finasteride, while highly effective, is not the only option.

Many men choose to rely on non-hormonal treatments entirely. Options such as topical or oral minoxidil, microneedling, low-level laser therapy devices, platelet-rich plasma (PRP), or hair transplantation can provide meaningful benefits without altering androgen pathways.

You can read more about alternative treatments in our guides and in-depth articles on minoxidil, microneedling, low-level laser therapy devices, and platelet-rich plasma (PRP).

While these approaches may not match finasteride’s disease-modifying effect on DHT, they can still preserve or improve cosmetic density for many users.

If you’re using topical finasteride, you might consider switching to low-dose topical dutasteride. offer better scalp localization at very low application frequencies due to dutasteride’s stronger and longer-lasting binding to 5AR. When used carefully and infrequently, some patients tolerate topical dutasteride well while maintaining hair stabilization.

Final Thoughts

Finasteride side effects are often manageable with thoughtful adjustments to dose, dosing schedule, formulation, and supporting lifestyle factors. There is no single correct way to use finasteride. Personalization is key, and the right approach depends on individual biology, risk tolerance, and treatment goals.

Health should always come first. Any side effects warrant open discussion with a clinician, and treatment decisions should be made collaboratively rather than in isolation. With informed, flexible planning, many men are able to find a balance that protects both their hair and their overall well-being.

Dutasteride is one of the most powerful pharmacologic treatments for androgenic alopecia (AGA). Initially approved for benign prostatic hyperplasia, dutasteride is now commonly prescribed off-label for hair loss in men and, more recently, has gained attention in topical form to minimize systemic exposure. This has created an important clinical question: how do oral and topical dutasteride compare in terms of effectiveness, safety, and real-world practicality?

This article examines what the current scientific literature reveals about oral versus topical dutasteride, reviewing mechanisms of action, efficacy data, and safety profiles to help you make more informed treatment decisions.

Interested in Topical Dutasteride?

Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Dutasteride Mechanism of Action and Formulations

AGA is driven by increases in dihydrotestosterone (DHT). DHT binds to androgen receptors in hair follicles, triggering miniaturization that leads to thinner, shorter hairs. Dutasteride works by inhibiting an enzyme called 5α-reductase (5AR), which converts testosterone into DHT. Dutasteride is a dual 5AR inhibitor, meaning it blocks both type I and type II 5AR, leading to decreased DHT levels and ultimately halting the progression of AGA and restoring thicker hair.^[1]Gerst, C., Dalko, M., Pichaud, P., Galey, J. B., Buan, B., & Bernard, B. A. (2002). Type-1 steroid 5α-reductase is functionally active in the hair follicle as evidenced by new selective … Continue reading,^[2]Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004). Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by … Continue reading

Interested in Oral Dutasteride?

Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Oral Dutasteride – Mechanism and Formulations

Oral dutasteride is absorbed through the gastrointestinal tract into systemic circulation, leading to significant and sustained reductions in DHT in the blood (serum). This includes reductions in scalp DHT, since less DHT is available systemically to diffuse into hair follicles.^[4]Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004). Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by … Continue reading,^[5]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading

The flip side is that any symptoms tied to systemic DHT suppression, such as sexual side-effects,  are driven by this same mechanism. Given the long half-life and accumulation, systemic exposure persists even if doses are missed or therapy is stopped, and any adverse effects may take weeks to resolve.^[6]Tsai, T.-F., Choi, G. S., Kim, B. J., Kim, M.-B., Ng, C. F., Kochhar, P., Jasper, S., Brotherton, B., Orban, B., & Lulic, Z. (2018). Prospective randomized study of sexual function in men taking … Continue reading

Topical Dutasteride – Mechanism and Formulations

Topical dutasteride treatment might avoid some of these pitfalls: high exposure at the scalp and low exposure elsewhere can target delivery and avoid systemic issues. It is applied directly to the scalp in formulations such as:

• Simple solutions (often alcohol- or glycol-based)
• Gels or lotions
• Liposomal formulations
• Nanoemulsions and nanoemulgels
• Nanocrystalline and other particulate systems

These vehicles are designed to ensure that dutasteride can cross the stratum corneum (the outermost protective layer of the skin) and, ideally, remain localized within the scalp.

What is the Available Evidence for Oral Dutasteride?

The effect of dutasteride on hair loss is well documented: multiple randomized placebo-controlled studies have been conducted over the last 25 years. Dutasteride was first developed as a treatment for benign prostatic hyperplasia and taken as a tablet. Early studies into dutasteride for hair loss therefore used oral formulations, with topical treatments developed later.

Here, we’ll take a look at the evidence supporting the use of oral dutasteride for hair loss. Many studies compare dutasteride with other treatments, most notably finasteride, or use the drug in combination with other therapies. We’ll focus on data showing the effect of dutasteride alone compared to placebo, but will also touch on comparisons with other popular treatments. 

Below is a summary of the findings to date on the safety and efficacy of oral dutasteride:

	Study Design and Population	Treatments and Concentrations (Daily)	Hair Growth Outcomes	Systemic Effects
Study #1[7]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading	Randomized, placebo-controlled, double-blinded trial. 415 men with male pattern hair loss aged 21-45 years old; 24 weeks.	0.05, 0.1, 0.5, or 2.5 mg dutasteride; 5 mg finasteride.	Dose-dependent increase in total hair count vs placebo. Improved hair count vs finasteride.	Serum decrease in DHT level (92% at 0.5 mg).
Study #2[8]Stough, D. (2007). Dutasteride improves male pattern hair loss in a randomized study in identical twins. *Journal of Cosmetic Dermatology.* 6(1). 9–13. Available at: … Continue reading	Randomized, placebo-controlled, double-blinded trial. 17 pairs of identical twin males with AGA; 12 months.	0.5 mg dutasteride.	Significant increase in total hair counts in dutasteride-treated twins.	Not assessed.
Study #3[9]Eun, H. C., Kwon, O. S., Yeon, J. H., Shin, H. S., Kim, B. Y., Ro, B. I., Cho, H. K., et al. (2010). Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male … Continue reading	Randomized, placebo-controlled, double-blinded trial. 153 men with male pattern hair loss aged 18-49; 6 months	0.5 mg dutasteride.	Significant increase in total hair count.	Sexual dysfunction was reported in 4.1% of the treatment group and 2.7% of placebo (not statistically significant).
Study #4[10]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading	Randomized, placebo-controlled, double-blinded trial. 917 men with AGA aged 20-50; 24 weeks.	0.02, 0.1, or 0.5 mg dutasteride; 1 mg  finasteride	Increase in terminal hair count and width vs placebo. Significant increase in hair width vs dutasteride.	No significant changes in reported adverse events.
Study #5[11]Tsunemi, Y., Irisawa, R., Yoshiie, H., Brotherton, B., Ito, H., Tsuboi, R., Kawashima, M., Manyak, M., & ARI114264 Study Group. (2016). Long-term safety and efficacy of dutasteride in the … Continue reading	Open-label, prospective study, no control. 120 men with AGA aged 20-50; 52 weeks.	0.5 mg dutasteride.	Increase in terminal hair count and hair width compared to baseline.	12% of men experienced libido decrease and impotence, of which 50% and 57%, respectively, were not resolved by the end of the study.
Study #6[12]Shanshanwal, S. J., & Dhurat, R. S. (2017). Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled … Continue reading	Open-label, randomized study; no placebo control. 90 men with AGA aged 18-40; 24 weeks.	0.5 mg dutasteride or 1 mg finasteride.	Increase in total hair count and width compared to baseline. Increase in total hair count was significantly higher in dutasteride than finasteride group.	Erectile dysfunction and loss of libido reported in 3 and 4 patients respectively.
Study #7[13]Tsai, T.-F., Choi, G. S., Kim, B. J., Kim, M.-B., Ng, C. F., Kochhar, P., Jasper, S., Brotherton, B., Orban, B., & Lulic, Z. (2018). Prospective randomized study of sexual function in men taking … Continue reading	Randomized, placebo-controlled, double-blinded trial. 117 men with AGA aged 23-50; 24 weeks.	0.5 mg dutasteride.	Not assessed.	Incidence of sexual adverse events was approximately double in the dutasteride group (16% vs 8% in placebo).
Study #8[14]Choi, G.-S., Sim, W.-Y., Kang, H., Huh, C. H., Lee, Y. W., Shantakumar, S., Ho, Y.-F., et al. (2022). Long-term effectiveness and safety of dutasteride versus finasteride in patients with male … Continue reading	Retrospective chart review. 600 men over 18 with AGA.	0.5 mg dutasteride or 1 mg finasteride.	Greater improvements in BASP classifications of AGA compared to baseline were found in dutasteride vs finasteride.	Incidence of adverse events was higher in finasteride group (10.5%) than in dutasteride group (7.6%).

What is the Available Evidence for Topical Dutasteride?

While evidence for the efficacy of oral dutasteride is well established, research into topical dutasteride solutions started relatively recently. Below is an overview of the studies into the efficacy of topical dutasteride:

	Study Design and Population	Treatments and Concentrations (Daily)	Hair Growth Outcomes	Systemic Effects
Study #1[15]Sánchez-Meza, E., Ocampo-Candiani, J., Gómez-Flores, M., Herz-Ruelas, M. E., Ocampo-Garza, J., Orizaga-y-Quiroga, T. L., Martínez-Moreno, A., & Ocampo-Garza, S. S. (2022). Microneedling plus … Continue reading	Randomized, placebo-controlled, double-blinded trial. 34 men with AGA aged 18-65; 20 weeks.	Microneedling with 0.01% dutasteride solution. Placebo was microneedling with saline solution.	Significant improvements in hair thickness, hair density, and vellous: terminal hair ratio.	Not assessed.
Study #2[16]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., Kssvv, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo- and active-controlled phase II study … Continue reading	Randomized, placebo-controlled, double-blinded trial. 135 adult males aged 20-60 with AGA; 24 weeks.	0.01%, 0.02%, or 0.05% topical dutasteride; 1mg oral dutasteride	Dose-dependent increase in total hair count and hair width. 0.05% solution showed significant improvement over finasteride in total hair count.	No change in serum DHT levels observed vs placebo.

How Does Oral and Topical Dutasteride Stack Up Against Each Other?

When comparing oral and topical dutasteride, the most important point to note is that there are currently no published clinical trials directly comparing the two formulations alone head-to-head for AGA. All comparisons must be made indirectly, using separate studies with different designs, populations, timelines, and formulations.

What About the Quality of the Available Evidence?

Despite this limitation, the evidence available for each formulation allows us to evaluate its strength and predictability. The current evidence quality for each formulation is as follows:

• Oral dutasteride — 59/100
• Topical dutasteride — 55/100

By our metrics, this means that both treatments have similar evidence quality overall. Longer-term data support oral dutasteride, while topical dutasteride remains less validated, largely due to fewer studies and limited long-term follow-up.

We’ll take a closer look at the strength of the evidence supporting both formulations.

Oral Dutasteride Studies

Oral dutasteride can reduce serum DHT levels by up to 90% and scalp DHT levels by 51-79%.^[17]Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004). Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by … Continue reading,^[18]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading Randomized controlled trials consistently demonstrate that dutasteride, particularly at the standard 0.5 mg daily dose, suppresses serum and scalp DHT and delivers some of the most robust regrowth outcomes documented for AGA. 

A number of the studies outlined above include large sample sizes, often over 100 participants, with the largest including over 900.^[19]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading Importantly, these cohorts should be large enough to detect changes in the incidence of adverse events, even if they are relatively rare. The replication of results in multiple trials using similar endpoints is a strong indicator of the efficacy of the drug. 

Unfortunately, the longest of these RCTs only lasted 6 months, which may mean that lasting impacts on growth are overlooked. Similarly, side effects associated with long-term use over many years may be missed. 

We can turn to longer studies using finasteride for some indication of how sustained benefits may be, given the similar mechanism of action of the two treatments. A 3-year trials using 1 mg daily doses of finasteride showed sustained improvement in hair growth over the course of the study, while placebo groups saw decreased hair counts.^[20]Price, V. H., Menefee, E., Sanchez, M., & Kaufman, K. D. (2006). Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. … Continue reading

 A 10-year follow-up study concluded that improvements in hair growth, as determined by expert analysis of hair photographs, from finasteride do not worsen over time, and in 21% of cases, hair growth got even better after 5 years of treatment.^[21]Rossi, A., Cantisani, C., Scarnò, M., Trucchia, A., Fortuna, M. C., & Calvieri, S. (2011). Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year … Continue reading

While we can’t draw any firm conclusions about the long-term efficacy of dutasteride from studies using finasteride, these findings can indicate the impact of long-term inhibition of 5AR, which is also seen in dutasteride treatment.

Topical Dutasteride Studies

Evidence for topical dutasteride is promising but remains less mature. Early clinical research indicates that topical formulations can meaningfully improve hair density, hair shaft diameter, and overall investigator-assessed regrowth, with efficacy in trials approaching that of oral therapy. 

One small study with only 34 participants showed significant improvements in hair growth and thickness when combined with microneedling, compared to microneedling alone. Another study combined dutasteride formulations with minoxidil and also found that topical dutasteride delivered via microneedling produced hair density and thickness improvements similar to oral dutasteride, with fewer systemic side effects.^[22]Sánchez-Meza, E., Ocampo-Candiani, J., Gómez-Flores, M., Herz-Ruelas, M. E., Ocampo-Garza, J., Orizaga-y-Quiroga, T. L., Martínez-Moreno, A., & Ocampo-Garza, S. S. (2022). Microneedling plus … Continue reading,^[23]Abu Obeid, M. N., Abdel Fattah, N. S., Elfangary, M. M., & Al Husseni, R. M. (2024). Comparison between topical minoxidil 5% alone versus combined with dutasteride (topical 0.02% through … Continue reading

A recently published Phase II trial, the first to test topical dutasteride without microneedling, reported that all concentrations improved hair growth versus placebo, produced minimal changes in serum DHT, and that 1 ml daily of 0.05% appeared to outperform oral finasteride. However, concerns about unusually high baseline hair counts and inconsistencies in the placement and size of the 1 cm² target areas used for hair measurements raise questions about the reliability of these results.^[24]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., Kssvv, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo- and active-controlled phase II study … Continue reading

Real-world outcomes from low-dose topical dutasteride users (0.01–0.02% applied daily or near-daily) suggest more modest benefits, with good scalp localization and stable serum DHT noted as positives, rather than regrowth exceeding that with oral finasteride.

There have been some concerns raised about the ability of dutasteride to penetrate into the scalp. Dutasteride is a relatively large molecule, with one molecule weighing 528.5 Daltons (Da). There is a commonly cited rule, called the 500 Dalton Rule, that states that molecules should be under 500 Da in order to penetrate the skin. However, dutasteride has been demonstrated to be effective in topical formulations and can measurably lower DHT concentrations. What’s more, a small, unpublished study has also shown that the drug does penetrate into both the scalp and serum, even at low concentrations. As such, in this case, dutasteride does seem to penetrate the skin in the scalp, without the need for microneedling or injection.

How Safe are Dutasteride Formulations?

Because dutasteride produces sustained suppression of DHT, safety considerations, particularly regarding hormonal and sexual side effects, are central to treatment selection. Most clinical trials record adverse events, while some studies are focused specifically on side-effects.^[26]Tsai, T.-F., Choi, G. S., Kim, B. J., Kim, M.-B., Ng, C. F., Kochhar, P., Jasper, S., Brotherton, B., Orban, B., & Lulic, Z. (2018). Prospective randomized study of sexual function in men taking … Continue reading

Oral Dutasteride

Across randomized trials and long-term observational studies, the most consistently reported adverse effects of oral dutasteride involve sexual function, including:

• Decreased libido
• Erectile dysfunction
• Ejaculation disorders
• Gynecomastia and breast tenderness (rare)

Trials report overall total adverse event rates between 4 and 12%, with sexual adverse events such as decreased libido as high as 13%, although this was reported in higher doses (2.5mg daily).^[27]Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., Rittmaster, R. S., & Dutasteride Alopecia Research Team. (2006). The importance of dual 5α-reductase … Continue reading At the standard 0.5mg daily dose, sexual side effects typically occur at a rate of between 1 and 5%. In the context of other popular treatments, comparisons with finasteride show no consistent increase in sexual side effects with dutasteride, despite dutasteride lowering serum DHT by an additional 20-30% beyond finasteride.^[28]Harcha, W. G., Barboza Martínez, J., Tsai, T.-F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study … Continue reading

Most controlled studies show that the majority of sexual side effects resolve either during treatment or after discontinuation. However, due to dutasteride’s long half-life (4-5 weeks) and high tissue binding, systemic effects can persist. At standard 0.5mg daily dosing, serum DHT generally returns to 80% of baseline within 6 months of discontinuation.

Topical Dutasteride

Topical dutasteride is generally well tolerated, and reported adverse events are usually mild and localized, including:

• Scalp irritation
• Erythema
• Contact dermatitis
• Pruritus or dryness

These occur inconsistently and are formulation-dependent, influenced by solvent systems, penetration enhancers, and application volume.

The primary safety advantage of topical dutasteride is reduced systemic exposure. In trials, topical regimens in the 0.01–0.05% range produce minimal or no significant changes in serum DHT or testosterone.^[29]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., Kssvv, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo- and active-controlled phase II study … Continue reading When decreases in serum DHT are observed with topical use, they are generally smaller than those seen with oral dosing.^[30]Abu Obeid, M. N., Abdel Fattah, N. S., Elfangary, M. M., & Al Husseni, R. M. (2024). Comparison between topical minoxidil 5% alone versus combined with dutasteride (topical 0.02% through … Continue reading

Adherence and Practical Considerations

Dutasteride, whether oral or topical, is primarily used for AGA in men, though its use for hair loss remains off-label in the United States. Oral dutasteride is formally FDA-approved only for benign prostatic hyperplasia, while topical formulations exist solely through compounding pharmacies.

Adherence and Route of Application

Oral dutasteride offers the simplest adherence burden: one capsule daily (or a modified intermittent schedule). This ease is a major factor behind its consistent outcomes. Topical dutasteride, while potentially safer from a systemic standpoint, requires regular scalp application and attention to dosing volume. 

The effectiveness of topical formulations is heavily influenced by factors such as vehicle, scalp contact time, treated surface area, and individual skin permeability. These practical considerations can meaningfully shape both efficacy and systemic absorption.

Advanced vehicles such as nanoemulsions or nanoemulgels can increase scalp penetration by up to 1.5-fold compared to conventional solutions.^[31]Ali, M. S., Alam, M. S., Alam, N., & Siddiqui, M. R. (2014). Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. … Continue reading However, this may also increase systemic exposure. Application frequency can be adjusted to balance efficacy and hormonal safety. Because dutasteride binds to 5AR for prolonged periods, daily application is not always necessary.

Time on the scalp also matters. The longer a topical formulation remains in contact with the skin, the more dutasteride can penetrate the follicle. Most protocols recommend allowing at least four hours before washing the hair. Rinsing too soon can reduce efficacy, while prolonged contact increases both potency and the possibility of systemic absorption.

The size of the application area affects systemic exposure. Treating a small region, such as the crown, introduces less drug into circulation than applying the same concentration across the entire scalp. Patients with diffuse thinning often benefit from using lower volumes or concentrations to counterbalance the increased surface area.

As we can see, there is a wide range of factors to consider when making a treatment plan with topical dutasteride, which may make consistent application a challenge.

Use in Women

Off-label use of dutasteride in women is limited and generally reserved for postmenopausal women or women with documented hyperandrogenism or a strong family history of AGA. Due to the systemic androgenic impacts of the drug, it’s typically only used in cases where other therapies (minoxidil, spironolactone) are inadequate.

Clinical Interpretation and Decision-Making

The key trade-off between oral and topical formulations is systemic potency versus localized targeting, balanced against differences in side-effect risk, convenience, and cost. Oral therapy is simpler and less variable; topical therapy requires consistent application but offers greater hormonal safety for risk-averse patients.

Combination therapy, most commonly topical dutasteride with minoxidil, can enhance outcomes through complementary mechanisms. Oral dutasteride may also be paired with topical agents in some cases.

Significant research gaps remain, including the absence of direct head-to-head oral-versus-topical trials, limited long-term safety data for topical dutasteride, and the lack of standardized dosing guidelines for topical formulations.

Final Thoughts

Dutasteride, whether oral or topical, represents one of the most powerful tools currently available for treating AGA. Oral dutasteride offers the most consistent and robust regrowth outcomes, supported by the strongest body of clinical evidence, but with predictable systemic hormonal suppression and long persistence after discontinuation.

Topical dutasteride, while still supported by a smaller and newer evidence base, offers a compelling alternative for patients seeking meaningful scalp-level efficacy with reduced systemic exposure. Its ultimate success depends heavily on formulation quality, dosing strategy, and adherence.

There is no universally “best” option: only the best option for specific circumstances. Treatment selection should be guided by hair-loss severity, prior treatment response, risk tolerance, reproductive plans, and long-term adherence capacity. As research continues to evolve, clinical guidance will become more precise. For now, optimal results come from choosing the formulation that best aligns with your goals and comfort with risk.

Interested in Oral Dutasteride?

Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Minoxidil is a medication that began as a treatment for hypertension (high blood pressure). However, after observing excess hair growth during the testing stages of the drug, minoxidil was repurposed as a treatment for hair loss. Topical minoxidil soon received FDA approval for the treatment of both male and female pattern hair loss, while oral minoxidil is also used as an off-label treatment for hair loss.^[1]Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug design, development and therapy. 2777-2786. Available at: … Continue reading

So, if minoxidil is a treatment for hair loss, why does it cause an increase in hair loss when you start using it? Yes, you did read that right – minoxidil can actually cause an increase in hair loss as part of what is often called the ‘dread shed.’ This phenomenon was demonstrated in a retrospective study of 435 patients with androgenic alopecia (AGA) who were prescribed low-dose oral minoxidil [≤5 mg per day] by the same clinic. Self-reported adverse events were recorded for each of the users and, of the 435 patients, 32% experienced increased hair shedding.^[2]Sanabria, B., de Nardo Vanzela, T., Miot, H. A., & Ramos, P. M. (2021). Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients. Journal of the American Academy of … Continue reading

This is evidently cause for concern – if you have just started minoxidil treatment to prevent hair loss, a sudden increase in hair loss is possibly the last thing you would hope and expect to experience. So what is it about minoxidil that causes this to happen, how long does it usually last, and is it actually a good thing? In this article, we will explore the hair cycle and minoxidil in detail to provide answers to each of these questions.

Interested in Topical Minoxidil?

High-strength topical minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

The Hair Cycle

To understand why minoxidil can increase hair shedding, let’s first take a refresher on the hair cycle. Our hair is constantly going through a cycle of growing (anagen), regression and transition (catagen), resting (telogen), and shedding (exogen), which it repeats continuously. 

Healthy hairs grow for anywhere between 2 and 8 years, and there is a correlation between the length and strength of a hair and the time spent in anagen. Catagen is the transition from anagen to telogen, a period of approximately 2 weeks during which the follicle regresses from the hair shaft and disconnects it from the blood supply, preventing any further growth. Telogen follows and lasts for 2-3 months, with a new hair shaft beginning to develop at the base of the follicle underneath the now resting hair shaft. Exogen then represents the transition from telogen to anagen, with the growing hair shaft pushing out the old hair shaft.^[3]Natarelli, N., Gahoonia, N., & Sivamani, R. K. (2023). Integrative and mechanistic approach to the hair growth cycle and hair loss. Journal of clinical medicine. 12(3). 893. Available at: … Continue reading 

In the healthy scalp, the percentage of hairs in each of the hair cycle stages is thought to remain fairly consistent. At any one time, evidence suggests that approximately 9% of the hairs on a healthy scalp are in the telogen phase (although there are some suggestions that this figure may actually be too high).^[4]Natarelli, N., Gahoonia, N., & Sivamani, R. K. (2023). Integrative and mechanistic approach to the hair growth cycle and hair loss. Journal of clinical medicine. 12(3). 893. Available at: … Continue reading These hairs exist in a largely asynchronous fashion, with hair follicles progressing through the hair cycle according to their own unique pattern. Hair follicles undergo between 10 and 30 full cycles, and it is normal for up to 150 hairs to fall out per day without there being an underlying hair loss problem, as the hairs are constantly being replaced.^[5]Bergfeld, W. (2009). Diffuse hair loss: its triggers and management. Cleve Clin J Med. 76(6). 361-370. Available at: https://doi.org/10.3949/ccjm.76a.08080 This keeps hair fall relatively consistent, preventing periods of significant hair shedding.

What Happens to the Hair Cycle during AGA?

AGA, the hair loss condition for which topical minoxidil is an approved treatment, is caused by damage to the hair follicle that contributes to its miniaturization. This is when individual strands of hair become smaller and smaller over time, eventually becoming vellus hairs that are shorter, thinner, and more white, which makes them difficult to see. We have a previous article that explores AGA-induced hair loss in great detail, but let’s summarize the key characteristics below:

• Perifollicular fibrosis – collagen deposition in the spaces around the hair follicles restricts the room within which hair shafts are able to grow, acting as a physical barrier to hair growth.
• Increased telogen:anagen ratio – healthy scalps typically have 1 telogen hair for every 12 anagen hairs (1:12 telogen:anagen), but people with AGA may exhibit ratios that are as high as 1:4 or even 2:5. The telogen phase also lengthens, with hairs spending longer in a state of non-growth.
• Shortened anagen phase – as previously mentioned, the length of an anagen phase directly corresponds to the length of the eventual hair shaft, and people with AGA typically exhibit anagen phases that become shorter with every hair cycle.

Although the exact mechanisms underlying AGA are yet to be fully understood, it is evident that AGA is a progressive and cumulative process that occurs due to harmful factors damaging the hair follicle and shortening the anagen phase.

How Minoxidil Works

Minoxidil is also yet to be fully understood, but several mechanisms have been suggested that could explain how it reduces hair loss:

• Vasodilation – Minoxidil started out as a treatment for hypertension, so its function as a vasodilator is well documented. Studies have shown that minoxidil increases blood flow by opening potassium channels, reducing high blood pressure. However, an unintended benefit of this function is increased blood flow to the hair follicles, providing them with nutrients and oxygen that help to prolong the anagen phase.^[7]Messenger, A. G., & Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British journal of dermatology. 150(2). 186-194. Available at: … Continue reading
• Prostaglandin mediation – Minoxidil has been shown to increase the production of prostaglandin E2 (PGE2) in cultured human dermal papilla fibroblasts, the specialized cells that sit at the base of the hair follicle. It is thought that PGE2 may protect hair follicles from damage.^[8]Michelet, J. F., Commo, S., Billoni, N., Mahé, Y. F., & Bernard, B. A. (1997). Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair … Continue reading
• Growth factor mediation – Studies have shown that minoxidil has the potential to upregulate the expression of several growth factors that support hair growth, including vascular endothelial growth factor in human dermal papilla cells.^[9]Lachgar, Charveron, Gall, & Bonafe. (1998). Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. British Journal of Dermatology. 138(3). … Continue reading

It is likely that minoxidil reduces hair loss through a combination of several mechanisms, including those noted above and perhaps others that are yet to be discovered.

How Might Minoxidil Cause the Dread Shed?

So, we know the basics of the hair cycle, some of the mechanisms that contribute to pattern hair loss, and some of the mechanisms by which minoxidil may reduce hair loss. But what does all this have to do with the ‘dread shed ’? Fortunately, observing the effects of minoxidil is more straightforward than trying to understand how it works, and there is one key effect which is believed to contribute to the increase in shedding: shortening of the telogen phase.

As we previously discussed, a key characteristic of AGA is lengthening of the telogen phase, which causes an abnormal amount of scalp hair to be in a state of arrested growth at the same time. It is widely believed that minoxidil directly addresses this issue by both shortening the telogen phase and accelerating the telogen to anagen transition. In one study,  application of topical minoxidil to rats caused a dramatic shortening of the telogen phase, falling from 20 days to just 1-2 days.^[10]Mori, O., & Uno, H. (1990). The effect of topical minoxidil on hair follicular cycles of rats. The Journal of dermatology. 17(5). 276-281. Available at: … Continue reading In a separate study that was also conducted in rats, topical minoxidil caused a significant switch from the telogen to anagen phase as quickly as 10 days after beginning treatment (Figure 2).^[11]Shatalebi, M. A., & Rafiei, Y. (2014). Preparation and evaluation of minoxidil foamable emu oil emulsion. Research in pharmaceutical sciences. 9(2). 123-133. Available at: … Continue reading

We could only find one clinical study that has investigated the telogen-anagen shift in humans at an early stage after beginning minoxidil use. They conducted a 24-week trial in which men with AGA either applied topical minoxidil [5%] or topical cetirizine for the first 16 weeks, then stopped use for 8 weeks. Although the results were not statistically significant, they showed that minoxidil caused an increase in the percentage of anagen hair and a decrease in the percentage of telogen hair, supporting the idea that minoxidil rapidly induces shortening of the telogen phase.^[13]Mostafa, D. H., Samadi, A., Niknam, S., Nasrollahi, S. A., Guishard, A., & Firooz, A. (2021). Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia: a … Continue reading

In accelerating the telogen to anagen transition, minoxidil also causes “hair follicle synchronization” or synchronization of the hair cycle. As we highlighted earlier, healthy scalps are somewhat ‘protected’ from significant hair shedding events due to the asynchronous nature of the hairs and their individual hair cycles. However, due to the increased density of telogen follicles in the AGA-affected scalp, minoxidil causes a greater-than-normal percentage of hairs to enter anagen at the same time. This syncing of the hair cycles then results in more hairs being pushed out at the same time.

So, to summarize the process that is believed to be the key factor behind the dread shed:

• In AGA, a greater number of hair follicles are in telogen
• Minoxidil treatment accelerates the transition of these hair follicles from telogen to anagen and causes many follicular units to become synchronized
• The transition leads to initiation of the shedding phase (exogen)
• Increased hair shedding occurs

Is The ‘Dread Shed’ Real?

Until very recently, evidence of minoxidil-induced hair shedding was either anecdotal or provided by studies of minoxidil in which increased hair shedding was noted as an adverse event. However, a newly published study sought to investigate the shedding phase in detail.

In this 2025 study, 49 patients with AGA used topical minoxidil [2% or 5%] for 24 weeks. Total hair shedding was quantified daily by the participants, who self-assessed their hair fall after combing, after washing, and on the pillow after sleeping. This was then averaged every 4 weeks and compared to the level of hair shedding prior to starting treatment. They found that the participants who used 5% minoxidil exhibited increased hair shedding (relative to pre-treatment) for 4-8 weeks, while the participants who used 2% minoxidil exhibited increased shedding for 8-12 weeks (Figure 2).^[14]Bi, L., Kan, H., Wang, J., Ding, Y., Huang, Y., Wang, C., Du, Y., Lu, C., Zhao, M., Sun, W. & Su, T. (2025). Whether the transient hair shedding phase exist after minoxidil treatment and does it … Continue reading 

This study provides definitive evidence that minoxidil does cause an initial shedding phase. However, importantly, hair shedding eventually fell below baseline levels in both groups, indicating that the initial shedding phase is temporary and that minoxidil did begin to reduce hair loss.

Is Initial Hair Loss Actually a Good Sign?

The same authors investigating the minoxidil shedding phase also sought to determine whether the amount of shedding had any association with treatment efficacy. They compared peak relative hair shedding (within the first 12 weeks) to changes in AGA severity using the Basic and Specific classification (BASP), which is a universal hair loss classification system that is used to assess the distribution and severity of hair loss in men and women of all races. They also compared peak relative hair shedding to several trichoscopy measurements, including hair density, hair diameter, and terminal hair proportion.^[16]Bi, L., Kan, H., Wang, J., Ding, Y., Huang, Y., Wang, C., Du, Y., Lu, C., Zhao, M., Sun, W. & Su, T. (2025). Whether the transient hair shedding phase exist after minoxidil treatment and does it … Continue reading

Interestingly, in the 5% minoxidil group, a significant association was found between the amount of initial hair shedding and hair density, hair diameter, and the proportion of terminal hairs. In other words, people who lost more hair in the ‘dread shed’ actually experienced greater outcomes from minoxidil treatment. Furthermore, participants who initially shed the most hair in both the 2% and 5% minoxidil groups demonstrated the greatest improvements in AGA severity by week 24.^[17]Bi, L., Kan, H., Wang, J., Ding, Y., Huang, Y., Wang, C., Du, Y., Lu, C., Zhao, M., Sun, W. & Su, T. (2025). Whether the transient hair shedding phase exist after minoxidil treatment and does it … Continue reading 

These results are very interesting – not only does the initial shedding phase indicate that the minoxidil is working, but more shedding may even predict better treatment outcomes! So, if you’ve just started treatment, don’t fear the shed!

Final Thoughts

Minoxidil is an FDA-approved treatment for AGA but, in some cases, it can cause increased hair shedding in the early stages of use. Known as the ‘dread shed,’ this phase is believed to be caused by minoxidil shortening the telogen phase of the hair cycle, causing old hairs to fall out. This shedding is even more pronounced due to the increased density of telogen hairs present in the scalps of people with AGA. However, this shedding is only temporary, typically lasting between 4 and 8 weeks. Moreover, people who experience more shedding in this initial phase may actually experience greater overall outcomes from their minoxidil treatment. So, if you have just started minoxidil and are noticing increased shedding, don’t panic – it is most likely a sign that the minoxidil is working.